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 NANOPARTICLES AND NANOMEDICINE 
Nanotechnology is a modern research field related to the design, development and 
use of materials at the nanoscale, which involves several scientific areas, including 
biology and chemistry. Nanomaterials have peculiar chemical and physical 
properties, different from those of the corresponding bulk materials, therefore they 
have attracted great interest. As shown in Figure 1.1-1 from ref. 1, the dimensions 
of nanomaterials allow them to easily interact with cells and subcellular elements, 
enabling the action on these biological systems. Therefore, in medicine and life 
science these materials are helpful and innovative tools; in fact, by using them 
new and more powerful strategies and applications can be performed, since they 
can solve several problems related to standard approaches.2 In this context, the 
term “nanomedicine” has been introduced to indicate this branch of 
nanotechnology, dedicated to the development of nanomaterials for medical 
applications. Nanomaterials are suitable for in vitro diagnostics, in vivo imaging 
or therapy; moreover, some nanosystems are able to combine the therapeutic 
application with the diagnostic aspect, improving the quality and the sensitivity of 
imaging techniques, thus resulting promising theranostic tools for several 
pathologies.3,4 
 
Figure 1.1-1: Length scale from 1 nm to 100 μm comparing nanomaterials to cells and subcellular 
elements (from ref. 1). 
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In the wide world of nanomaterials, nanoparticles (NPs) are those presenting all 
three dimensions at the nanoscale.5 As shown in Figure 1.1-2 from ref 6, NPs can 
be distinguished according to the chemical composition, shape, size and 
functionalization of the surface. These parameters can be modulated during the 
synthesis, in order to provide the proper instruments for a specific biomedical 
application.2 For example, liposomes and polymeric NPs are promising tools in 
therapeutic applications, such as drug delivery, but they have some limitations in 
diagnostics. On the other hand, several inorganic NPs can be used for in vitro 
diagnostics or can be exploited as contrast agents in imaging techniques, 
improving the reliability of the diagnosis. 
 
Figure 1.1-2: Schematic representation of nanoparticles used in nanomedicine, differing in chemical 
composition, size, surface functionalization or shape (from ref. 6). 
Concerning therapy, the use of NPs can provide solutions to the intrinsic 
limitations of classic drug administration methods; in fact, the drug loading on 
nanocarriers, especially lipid or polymeric ones, modify the pharmacokinetic 
features of the pharmaceuticals, for instance, improving their water-solubility and 
prolonging plasma half-life.7 In this way, better therapeutic effects can be 
obtained, reducing the administered drug amount and, consequently, the side 
effects on healthy tissues. In this context, several liposomal drugs and polymer-
drug conjugates are already commercially available or in clinical or preclinical 
1. GENERAL INTRODUCTION 
4 
 
trials: for instance AmBisome® (Gilead Sciences, USA), a liposomal formulation 
of amphotericin B, or Prothecan® (Enzon Pharmaceuticals, USA), a PEG–
camptothecin nanoconjugate, for the treatment of fungal and protozoal infections 
or various cancers, respectively.2 
Conversely, inorganic NPs such as those made of Au or iron oxide are exploited 
for in vivo imaging techniques. Their optical or magnetic features make them good 
contrast agents for imaging techniques, providing more spatial and temporal 
information and increasing the sensitivity of the diagnostic tool. Moreover, their 
joining may often enable multimodal imaging combining different techniques. For 
instance, Au NPs can be exploited as contrast agents in X-ray imaging and 
computed tomography (CT) while iron oxide superparamagnetic NPs in magnetic 
resonance imaging (MRI).8-10 
Concerning in vitro diagnostics, inorganic NPs like Au NPs or magnetic NPs are 
the most promising.11 The nanoparticle-based diagnostics can offer advantages for 
the detection of specific markers, opening new frontiers in the diagnosis of  several 
pathologies, including cancer, neurological disorders and infectious diseases.12 
Through adequate surface functionalization with macromolecules, especially 
enzymes and antibodies, interesting bioanalytical applications of NPs can be 
achieved, improving the sensitivity of the analytical methods or innovating them. 
For example, these kinds of NPs have been commonly employed in biosensors 
and immunoassays.13,14 For instance, Au NPs have been used for detecting 
biologically relevant molecules in optical and electrochemical analytical 
methods.15,16 Magnetic NPs, instead, have been utilized preferentially for 
detection and bio-separation of analytes or specific cell populations, like stem 
cells or pathogenic bacteria. In fact, by exploiting their magnetic properties, the 
application of an external magnetic field allows their efficient separation from a 
complex biological matrix.17,18 
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1.1.1 General features of NPs 
NPs show peculiar chemical and physical characteristics which differentiate them 
from the corresponding bulk material. These properties can be divided into three 
groups: the surface-dependent, the dimension-related and those deriving from the 
quantum-size effect.1 
The extended surface in the small volume of NPs leads to high surface-to-volume 
ratio that affects many of their properties. In fact, compared to 3D materials the 
increase in the number of surface atoms, characterized by binding weaker than the 
internal atoms, produces changes in the physicochemical properties, such as 
melting point and chemical reactivity. Other features like magnetic ones change, 
instead, according to the dimensions of the material. For example, ferromagnetic 
and ferrimagnetic materials exhibit superparamagnetic behaviour when their size 
is nanoscale.19 Finally, the size-dependent quantum effects are related to the 
change in the electronic levels of nanomaterials, which become discrete sets 
instead of a continuum as in the bulk counterparts. Variations in the optical 
properties of Au NPs are due to this phenomenon.20,21 
The presence of special intrinsic properties in NPs explains why they have had 
great success in the nanotechnological field and, in particular, in nanomedicine. 
Moreover, the characteristics of NPs can be adapted to obtain more specific 
nanosystems for a selected biomedical application through the surface coating 
with chemically different materials and/or the functionalization with biomolecules 
or pharmaceuticals.22 
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1.1.2 Multitasking NPs 
In the last years, the scientific community is making considerable efforts to design 
and develop multifunctional nanosystems in order to improve and extend the 
applicability of the NPs in a theranostic view. A multitasking NP is defined as a 
system capable of carrying out different functions at the same time; for instance, 
presenting proper functionalities, a single nanoplatform can be suitable for 
diagnostic and therapeutic purposes.23 The introduction of these functionalities 
can be performed during the synthesis of NPs through an appropriate modification 
of their surface with inorganic compounds or organic molecules or 
macromolecules which leads to the combination of the specific physical, 
chemical, biological or pharmaceutical features deriving from each component. 
As shown in Figure 1.1-3 from ref. 24, a general multitasking nanosystem for 
theranostics contains both functionalities for diagnostic and for therapeutic 
purposes. For example, the presence of an inorganic material such as Au or iron 
oxide which have peculiar optical or magnetic properties make the NPs suitable 
in medical imaging techniques (MRI or optical imaging). Otherwise, the 
incorporation of elements or compounds presenting radioactivity or fluorescence, 
such as radionuclides, organic fluorescent probes or lanthanides, can help 
monitoring the nanosystems during in vivo diagnostic applications.25 Often, a 
multimodal imaging using different techniques can also be possible.  
At the same time, the presence of biologically or pharmacologically active 
compounds, for instance drugs or biomolecules, allows the use of the multitasking 
nanosystem as a therapeutic tool. Moreover, the addition of macromolecules or 
small molecules, like antibodies or targeting ligands, able to interact with specific 
biological target, can selectively address NPs into the pathological area.3,24  
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Figure 1.1-3: General representation of a multitasking nanosystem for theranostic applications 
(from ref. 24). The nanocore can be coated by inorganic or organic shells and functionalized with 
molecules or macromolecules acting as targeting, therapeutic or diagnostic agents. 
Concerning in vitro diagnostic, the combination of components with peculiar 
physical properties, like Au NPs or iron-oxide NPs, with molecules or 
macromolecules characterized by high-recognition features, like antibodies or 
specific ligands, can offer advantages in the analytical method. For instance, 
multitasking NPs can improve the analytical features of the technique, like 
sensitivity and specificity; they can allow the performance of multistep procedures 
in easier way, facilitating the sample preparation or reducing the time of the 
analysis.26,27 
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 MAGNETIC NANOPARTICLES 
Among the NPs, the magnetic ones can offer many solutions in nanomedicine, 
facilitating, innovating or integrating standard procedures. Being sensitive to the 
magnetic field, they can be helpful for in vitro and in vivo diagnostic techniques, 
but also in therapeutic applications such as drug delivery and hyperthermia.28,29 
The combination of these NPs with other materials, such as Au NPs, liposomes or 
polymers, or their modification with biologically relevant molecules are the main 
strategies to fulfil the need of efficient medical tools. Engineered magnetic NPs 
can therefore represent promising instruments in diagnostics and theranostics and 
may contribute to approach the personalized medicine.25,26,30 
1.2.1 Magnetite nanoparticles and superparamagnetism 
Among the most interesting magnetic nanoparticles (MNPs), iron oxides NPs are 
the best known and, in particular, those made of magnetite (Fe3O4) are considered 
the most promising for biomedical applications thanks to their special features. 
The crystal structure of Fe3O4, as shown in Figure 1.2-1 from ref. 31, consists in a 
cubic inverse spinel structure in which O atoms form a close-packed cubic lattice 
while the interstitial tetrahedral sites are occupied by Fe3+ ions and the octahedral 
ones by Fe3+ and Fe2+ ions. 
The synthetic strategies commonly used to produce Fe3O4 MNPs are physical 
methods, such as gas-phase deposition and electron beam lithography, or wet 
chemical preparations, for instance sol-gel synthesis or chemical co-
precipitation.32-34 The last one is the simplest and most efficient synthesis method 
to obtain Fe3O4 MNPs. In the absence of surface coatings or functionalization, 
Fe3O4 MNPs are unstable since they tend to oxidize and aggregate. The 
transformation in hematite (α-Fe2O3) or maghemite (ϒ-Fe2O3) or the increase of 
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the particle dimensions produce changes in the magnetic properties of the 
nanomaterials, limiting or compromising their biomedical use. 34 
 
Figure 1.2-1: On the left: schematic representation of the inverse spinel structure of magnetite, 
highlighting Fe and O atoms in red and blue, respectively (from ref. 31). Fe3+ ions occupied the 
interstitial octahedral and tetrahedral sites while Fe2+ ions only the octahedral ones. On the right: 
representation of the magnetization M vs applied field H plot for materials showing different 
magnetic properties (from ref. 28).  
1.2.1.1 Magnetic properties 
The materials can be classified in paramagnetic, diamagnetic or 
ferromagnetic/ferrimagnetic depending on their response to an applied external 
magnetic field (H), and according to the value of the magnetic susceptibility (χ). 
This parameter represents the proportional constant between the magnetization of 
the material (M) and H, according to the equation M= χH. The values of χ > 0 
characterize paramagnetic materials, χ < 0 the diamagnetic ones while χ >> 0 the 
ferro/ferrimagnetic materials.  
Figure 1.2-1 from ref. 28 shows the relation between M and H. From the graph M 
vs H, the parameters saturation magnetization (Msat), remanence (Mr) and 
coercivity (Hc) can be obtained. Msat corresponds to the highest M value 
obtainable during the application of H. Mr represents the M value once H is absent 
while Hc is the intensity of the applied H required to reduce Msat to zero. 
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Among the magnetic properties, ferromagnetism is considered a cooperative 
behaviour, since only a certain number of atoms bound together can display it. 
These materials possess unpaired electrons spins which align spontaneously in the 
same direction (ferromagnetic) or in the opposite one (antiferromagnetic), 
exhibiting magnetization in the absence of a magnetic field. When the number of 
the antiparallel aligned magnetic moments is not equal, an overall magnetization 
is present, and the material is classified as ferrimagnetic. Concerning Fe3O4, its 
ferrimagnetic character derives from the antiferromagnetic coupling between the 
Fe3+ ions which allows the magnetic moments of Fe2+ ions to generate the 
magnetization of the unit cell. Ferromagnetic and ferrimagnetic materials exhibit 
permanent magnetization once H is removed and they are characterized by the 
presence of the hysteresis loop into the M vs H representation. However, when 
the dimensions of the particles decrease up to a particular domain, each particle 
comprises a single magnetic domain and the magnetic behaviour changes from 
ferro/ferrimagnetism to superparamagnetism. For instance, in MNPs a size < 20 
nm is required to have superparamagnetism while 128 nm is the critical dimension 
for forming multi-domain structures in spherical MNPs which leads to the 
decrease in the Hc value.35 The main difference between ferro/ferrimagnetic and 
superparamagnetic material is that the second does not remain magnetized once 
the external magnetic field is removed, like a paramagnetic one. 
Superparamagnetic materials do not show magnetic hysteresis and their value of 
magnetic susceptibility is higher than that of paramagnetic materials and quite 
similar to ferromagnetic ones.19 
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 BIOMEDICAL APPLICATIONS OF MNPs 
The pharmaceutical and biomedical applications of Fe3O4 MNPs cover all the 
medical fields. The general features of NPs and the peculiar magnetic properties, 
biocompatibility and low cytotoxicity of Fe3O4 MNPs make them suitable for 
diagnostic, imaging and/or therapy. For in vivo applications they should have low 
dimensions and narrow size distribution, to avoid the rapid clearance, and high 
magnetization.2,36 In this context, superparamagnetism is fundamental to avoid 
magnetically-driven particle agglomeration, after the removal of the magnetic 
field; in fact, the presence of aggregates can lead to occlusion of capillary vessels 
and dangerous side effects. To improve the chemical stability and 
biocompatibility of Fe3O4 MNPs surface functionalization is often required.37 
Engineered Fe3O4 MNPs are thus innovating standard medical strategies, 
improving their sensitivity and reliability, and are enabling new applications, 
previously unimaginable, especially in therapeutic treatments. 
As depicted in Figure 1.3-1 from ref. 38, Fe3O4 MNPs are providing their benefits 
also in in vitro diagnostics in several bioanalytical methods, like biosensing 
techniques, in the separation and sample-enrichment of analytes or in the 
immobilization of macromolecules.18,26,39 In vivo Fe3O4 MNPs are used as contrast 
agents in MRI, while their high potential as drug delivery systems or in 
hyperthermia has also been studied.29,36 They can be used alone or in combination 
with other nanomaterials, allowing the joining of different properties and the 
widening of their applicability.40,41 The biomedical applications of Fe3O4 MNPs 
are described in more details in the following sections. 
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Figure 1.3-1: Schematic representation of biomedical applications of magnetic nanoparticles (from 
ref. 38). MNPs can be exploited in therapeutic applications like magnetic hyperthermia and drug 
delivery or in in vivo imaging as contrast agents for MRI. Their main uses in in vitro diagnostics 
concern cell labelling and magnetic separation and immobilization of macromolecules.  
1.3.1 In vivo imaging 
A proper and reliable imaging of internal organs is fundamental for allowing the 
further appropriate medical treatments; in this area, MRI is one of the mainly used 
imaging techniques since it produces images with good temporal and spatial 
resolution without performing invasive procedures. In fact, MRI is very helpful in 
discriminating between healthy and affected tissue in case of several pathologies, 
related especially to soft tissues and cartilages. MRI is based on the achievement 
of relaxation signals of proton spins corresponding to water molecules in the 
human body, after the excitation by radiofrequency waves in a strong magnetic 
field.  
Contrast agents, generally based on paramagnetic materials such as Gd, are used 
for clarifying the collected images and promoting a better diagnosis. Fe3O4 MNPs 
1. GENERAL INTRODUCTION 
13 
 
are providing the development of a new generation of contrast agents; in fact, 
thanks to their superparamagnetic behaviour these MNPs are able to generate 
strong contrast effect and consequently excellent sensitivity in T2-weighted 
images (T2= spin-spin relaxation time), improving image resolution.9,39,42 In this 
context, several formulations of polymer-coated/stabilized superparamagnetic 
nanoparticles of iron oxides (SPION) are already commercially available as MRI 
contrast agents, for instance Resovist® (Bayer HealthCare Pharmaceuticals, USA) 
or Feridex I.V.® (AMAG Pharmaceuticals Inc., USA) for liver, spleen and bone 
marrow imaging.42 
1.3.2 Therapy 
Concerning therapeutic applications, Fe3O4 MNPs offer the possibility to achieve 
stimuli-sensitive drug nanocarriers because of the magnetic field responsiveness 
typical of these nanosystems. In fact, by applying an extracorporeal magnetic field 
the remote magnetic focusing of the engineered Fe3O4 MNPs to a desired area can 
be achieved.43 The simultaneous presence of active targeting agents can help 
facilitating the interaction with affected tissue or cell. To develop a good drug 
delivery system, the engineering of Fe3O4 MNPs is generally required; in this way 
high drug loading can be obtained together with the improvement of 
physicochemical and biological features of Fe3O4 MNPs, for instance their 
chemical stability and half-life.38 Drug delivery systems based on engineered 
Fe3O4 MNPs or incorporating them have been developed for magnetically guided 
chemotherapy, radioimmunotherapy, photodynamic therapy or 
magnetofection.40,44,45 Due to the opsonization phenomenon, the intravenous 
administration of these nanosystems limits their applicability since it leads to rapid 
clearance, as happened for several kinds of NPs.46,47 A more recent strategy, 
known as cell-mediated delivery, consists in exploiting immune cells loaded with 
engineered NPs, often functionalized with drugs, for transporting and delivering 
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the nanosystems in the pathological area.48 Moreover, it has been demonstrated 
that cells engulfed with Fe3O4 MNPs acquired magnetic field responsiveness.49 
In cancer therapy, Fe3O4 MNPs can be exploited also for magnetic hyperthermia; 
this therapeutic strategy consists in killing cancer cells by exposing them to high 
temperatures (42-46 °C).41,50 In this case, Fe3O4 MNPs represent the source of heat 
since they can be heated by alternating magnetic field. When Fe3O4 MNPs are 
located in the tumour area, the exposition to an external alternating magnetic field 
generate heat locally in the tumour, thus causing the preferential death of 
malignant cells. The heat production depends on several factors such as the 
physicochemical properties of Fe3O4 MNPs or their functionalization or 
parameters of the magnetic field. Several examples for thermal treatment of 
different kinds of cancer can be found in the literature.29,51,52 
Finally, the combination of drug delivery and hyperthermia results in better 
therapeutic treatments while the matching of one or both of these strategies with 
the use in MRI imaging, make Fe3O4 MNPs highly powerful theranostic 
tools.40,50,53,54 
1.3.3 In vitro diagnostics 
The main applications of Fe3O4 MNPs in in vitro diagnostics concern cell labelling 
and separation, detection of microorganisms or biologically-relevant molecules, 
protein immobilization, bioanalysis and immunoassays.12,55 For instance, the 
selective recognition of a specific kind of cell by Fe3O4 MNPs allows the further 
magnetic separation from a complex matrix; in this way it is possible to prepare 
enriched samples suitable for other analysis.56 For performing the detection or the 
labelling of cells, microorganisms or other molecules, Fe3O4 MNPs have to be 
chemically modified introducing a functionality able to recognize the target. 
Antibodies (Ab) are very commonly used for this purpose thanks to their selective 
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binding capacity. In this context, several Fe3O4 MNPs-Ab have been developed 
for the in vitro recognition and separation of cancer cells, stem cells or pathogenic 
bacteria or biochemicals, such as proteins or small molecules.57-60 
Thanks to the possible easy and quick recovery, Fe3O4 MNPs immobilizing 
enzymes or proteins have been developed without dramatically affecting the 
catalytic activity or the structure of the macromolecules. Moreover, the general 
features of NPs improve the sensitivity of these enzyme-immobilized platforms, 
reducing also the operational costs.61,62 Finally, in medical and clinical diagnostics 
Fe3O4 MNPs can be used as solid support also for the immobilization of 
biomarkers or antibodies able to detect specific ligands. Fe3O4 MNPs-Ab can 
therefore be exploited in immunoassays, such as Enzyme Linked ImmunoSorbent 
Assay (ELISA) or NPs-based bio-barcode assays, or in biosensors for the 
detection and quantification of small molecules or biomolecules in complex 
biological matrices.63-65
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 Objectives and scientific strategy 
The main aim of this thesis has been the development of new multifunctional 
superparamagnetic nanosystems for biomedical applications in the field of therapy 
and in vitro diagnostics. Starting from the favourable features of Fe3O4 MNPs, 
which make them already suitable for several purposes, the design of core-shell 
structured nanosystems has been accomplished to increase the potential 
applicability. In fact, covering the superparamagnetic core with inert and 
biocompatible inorganic materials leads to an increase in the chemical stability of 
the entire nanosystem. Moreover, in this way the surface functionalization can be 
easily carried out according to the chemical features of the external shell.  
Two kinds of core-shell nanosystems have been firstly developed in this research 
work and then engineered depending on the planned end use. In fact, the 
introduction of other functionalities on the MNPs deriving from organic coatings, 
and the loading of bioactive molecules or macromolecules, like proteins or drugs, 
lead to the production of more efficient and specific nanosystems towards the 
biological targets. 
Thus, the specific objectives proposed in this research work are: 
- The development of core-shell nanosystems made of Fe3O4@Cu@Au 
MNPs and Fe3O4@SiO2 MNPs as the starting points for the production of 
engineered multitasking MNPs for different biomedical applications. 
- The achievement of new nanosystems loading chemotherapeutic drugs or 
antimicrobial compounds for therapeutic purposes and the in vitro 
evaluation of their activity on cancer cell lines or microbial cultures.  
- The study of internalization of differently coated MNPs into human 
immune cells for contributing on investigating the therapeutic approach 
based on cell-mediated drug delivery.  
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- The development of innovative immunoassays and immunosensors 
involving MNPs-Ab for in vitro diagnostic purposes. 
 Thesis structure 
After the brief general introduction presented in chapter 1 on MNPs for 
biomedical purposes, the production and physicochemical characterization of the 
two nanosystems Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 MNPs, on which this 
thesis is based, are explained in chapter 3. The several engineered nanosystems 
developed starting from one or both of the basic inorganic nanostructures and their 
in vitro applications are described in the following chapters. 
As shown in Figure 2.2-1 the central sections of this thesis deal with: 
- The development of Fe3O4@Cu@Au nanosystems loading the bioactive 
targeting molecules, folic acid and methotrexate, and the in vitro 
interaction with the human breast cancer cell lines MCF-7 and MDA-MB-
231 (chapter 4). 
- The coating of Fe3O4@Cu@Au MNPs with homo-polypeptides or 
proteins and the evaluation of their uptake by monocyte-differentiated 
macrophages (chapter 5). 
- The functionalization of Fe3O4@SiO2 MNPs with two bacterial secondary 
metabolites, syringomycin E and syringopeptin 22A, and the study of the 
antimicrobial activity on yeast cultures and the internalization into 
monocyte-differentiated macrophages (chapter 6). 
- The evaluation of new immunoreagents for the detection of epinephrine 
by standard ELISA assays and the implementation of the diagnostic 
platforms using MNPs-Ab for the development of magneto-ELISAs and 
amperometric magneto-immunosensors (chapter 7). 
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- Proof-of-concept of the possibility to use MNPs-Ab as catalyst for the in 
vitro detection of epinephrine (annex). 
 
Figure 2.2-1: Structure of this thesis, starting from the synthesis of the basic nanostructures 
Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 MNPs (chapter 3) leading to their surface modification 
for the in vitro biomedical applications (chapters 4-7 and annex). 
Conclusions of this thesis can be found in chapter 9 while the bibliography on 
which this research work has been supported can be found in chapter 11, after 
chapter 10 which includes the acronyms and abbreviations. 
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 INTRODUCTION 
This chapter deals with the development of the nanosystems used in this thesis, 
corresponding to Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 MNPs. The limits of 
using bare Fe3O4 MNPs, deriving from their vulnerability to oxidation and 
spontaneous aggregation process, can be minimized planning a core-shell 
structure. The ideas behind the development of these inorganic nanosystems, in 
addition to the synthetic processes and their physicochemical characterization are 
illustrated in this section.  
3.1.1 Core-shell nanoparticles 
The development of nanosystems with a core-shell structure extends the use of 
the NPs due to the improvement of some of their features.66 This structure is 
characterized by the presence of an internal nucleus (core) and one or more layers 
made of other materials (shell). These kinds of NPs are able to greatly improve 
the chemical stability or biocompatibility of the material constituting the core, 
thus expanding their applicability in the biomedical field. The choice of the shell 
composition generally depends to the end use of the NP.24  
Concerning the core-shell MNPs, Fe3O4 almost always constitutes the core of the 
system and it is enclosed inside one or more shells of organic or inorganic 
materials, as shown in Figure 3.1-1. The advantages 
of a core-shell magnetic nanostructure derive from 
the possibility to combine the properties of the core, 
in this case superparamagnetism, with other 
physicochemical features of the external material.67 
The outer coating preserves Fe3O4 from the 
oxidation of Fe2+ ions, that would alter the structure 
Figure 3.1-1: General scheme 
of a Fe3O4 MNPs with core-
shell structure. 
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and thus the magnetic properties. By modulating the chemical composition of the 
coating, it is possible to improve the stability and dispersibility of Fe3O4 MNPs, 
also minimizing the formation of aggregates. The presence of shells made of 
inorganic compounds can add or enhance the properties of the entire nanosystem, 
such as the optical, the catalytic or the electrical ones.37 Furthermore, by using 
proper coating materials the drug loading capacity or the biocompatibility of the 
nanosystem can be improved, facilitating the more effective interaction with 
biological systems and providing more powerful drug delivery systems.68 
Conversely, the presence of a coating material having peculiar properties, such as 
radioactivity, fluorescence or absorption, makes those nanosystems active in more 
than one medical diagnostic technique.69-71 Among the materials selected for 
covering Fe3O4 MNPs, gold and silica are the most commonly used due to the 
chemical inertia and biocompatibility. These materials provide the stability of the 
MNPs in solution, limiting their spontaneous aggregation, and help to covalently 
bind various molecules or biomolecules suitable for the final biomedical 
applications.38 
3.1.1.1 Silica shell 
The chemical inertness and stability are interesting features of silica (SiO2), 
making it an optimal material for covering Fe3O4 MNPs. Compared to the bare 
magnetite nanosystems, silica-coated magnetite MNPs (Fe3O4@SiO2 MNPs) are 
much more stable in solution since the shell protects them from oxidation and 
limits their aggregation process; in fact, silica coating is able to shield the 
magnetic dipole interactions and increase the surface negative charges on Fe3O4 
MNPs, enhancing their electrostatic repulsion.37  
Although SiO2 NPs, especially those made of mesoporous SiO2 72, are very 
promising materials for drug delivery or generally in nanomedicine, the 
combination with a superparamagnetic core offers advantages in focusing, 
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monitoring and revealing them during in vivo administration.73 Fe3O4@SiO2 
MNPs can be synthesized by different procedures among which the Stöber method 
is the most commonly used for the achievement of an homogeneous silica shell.74 
Furthermore, the presence of a SiO2 layer facilitates the surface modification of 
the Fe3O4@SiO2 MNPs with heterobifunctional molecules exploitable as linkers 
for the conjugation of biologically relevant compounds. In fact, the presence of 
surface silanol groups ensures high reactivity towards alcohols or silane coupling 
agents through hard-hard interactions.75 Using alkoxysilanes, such as those shown 
in Figure 3.1-2, the surface activation of the nanosystems with other functional 
groups, such as amino, thiol or epoxy groups, can be carried out allowing further 
functionalization.38,76  
 
Figure 3.1-2: Chemical structure of the alkoxysilanes APTES, GPTMS and MPTMS. 
3.1.1.2 Gold shell 
Gold is commonly used for the coating of Fe3O4 MNPs since this noble metal is 
characterized by extraordinary optical and electronic properties, in addition to 
high chemical stability and biocompatibility. Thanks to those features, many 
research studies are focused on the applications of gold nanoparticles (Au NPs) in 
nanomedicine, as diagnostic or therapeutic agents for instance in biosensing or 
drug delivery (for more information see ref. 77,78).  
The special optical features of Au NPs are related to the phenomenon known as 
Localized Surface Plasmon Resonance (LSPR) which consists in the collective 
oscillation of the free conduction electrons due to the interaction with an 
3. SYNTHESIS AND PHYSICOCHEMICAL CHARACTERIZATION OF Fe3O4@Cu@Au 
AND Fe3O4@SiO2 NANOSYSTEMS 
 
25 
 
electromagnetic wave. The oscillation frequency normally occurs in the visible 
region and its changes can be monitored following the corresponding strong 
absorption band.20 This phenomenon is very sensitive to the composition, the size, 
the shape and the environment of Au NPs and, for these reasons, it is commonly 
used for detecting and studying surface binding processes.79 Moreover, the optical 
properties of Au are exploited for a promising therapeutic application for cancer 
therapy known as phototherapy, based on the local heating upon excitation of the 
surface plasmon oscillations, which can cause cancer cell death.80 
Thus, the coating of the F3O4 core with an Au layer produces an enhancement of 
the stability and inertness of Fe3O4, preventing its oxidation and maintaining the 
superparamagnetic properties. Moreover, the presence of a Au shell gives the 
possibility to match the magnetic properties of the core with the optical features 
of Au, leading to nanosystems suitable for theranostics; for instance, NPs active 
at the same time in MRI, hyperthermia and photothermal therapy can be 
achieved.80 In addition to the improvement of biocompatibility, the Au shell 
ensures the surface modification of the nanosystem via gold-thiol chemistry.38  
3.1.1.3 Functionalization of gold shell 
The Au shell offers the opportunity to easily functionalize the NPs exploiting soft-
soft interactions, occurring between the soft acid Au and the soft base S.81 This 
interaction leads to stable bonds (binding energy of S-Au bond = 45 kcal/mol) 
ensuring the covalent but quite easily breakable anchorage of different kinds of 
molecules.82 The self-assembled monolayers (SAMs) of thiolate-Au can be 
achieved by using monothiol (RSH), thioether (RSR’) or disulfide (RSSR’) 
molecules containing alkyl or aryl groups, which general structure is reported in 
Figure 3.1-3. SAMs may also be made of two or more linkers with  different 
functional groups, enabling further functionalization with several kinds of 
molecules and biomolecules.83  
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Figure 3.1-3: General structure of the organosulfur compound thiol, thioether, disulfide and cyclic 
disulfide. The general structure of thiol-terminated polyethylene glycol is also reported. 
Thiol-terminated polyethylene glycol (thiol-PEG), which structure is shown in 
Figure 3.1-3, is one of the most commonly used polymeric coating for the 
functionalization of Au shell, since it leads to an increase of the in vitro and in 
vivo stability of the NPs.84 The PEGylation of the nanosystems improves the 
dispersibility and the biocompatibility, avoiding the non-specific binding to 
protein and cells present in the vascular system during the in vivo administration 
of the NPs.85 The use of heterobifunctional PEG molecules containing, on one 
side, the thiol group and, on the other side, another functional group, like amino 
or carboxyl group, enables to form covalent bonds with both the Au surface and 
other biomolecules or bioactive compounds, such as enzymes, antibodies or drugs. 
Mixed SAMs made of heterobifunctional-PEG molecules alternating reactive and 
non-reactive groups, for instance thiol-PEG containing -COOH or -OCH3, can be 
a good option for the further functionalization with proteins; in fact, the reduction 
of the surface charge density may promote the binding of the macromolecule.86  
The functionalization of Au surface can also be performed with short-length thiols 
or sulfides, for instance a heterobifunctional molecule carrying a thiol and a 
carboxylic acid group. In this case, choosing molecules containing a disulfide 
group instead of a thiol can avoid the formation of disordered and unstable 
structures. Moreover, cyclic disulfide can produce a more stable coating compared 
to acyclic disulfides since the anchorage occurs through two S atoms.87  
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3.1.1.4 Fe3O4@Au nanoparticles 
Although several examples of Fe3O4@Au nanosystems can be found in the 
literature, the production of core-shell Fe3O4@Au MNPs with a uniform and 
homogeneous Au layer is not easy.88,89 This problem arises from the fact that Au 
provides a defective and incomplete coating of Fe3O4; in fact, Au reacts with soft 
ligands while the magnetic core exposes the hard -OH groups that have low 
affinity for Au. For these reasons, the Au deposition on the iron oxide surface is 
extremely challenging since the noble metal tends to form separated NPs. The 
direct synthesis of core-shell Fe3O4@Au MNPs has been achieved by a reverse-
micelle approach, which present some limitations due to low yield and poor 
reproducibility.90,91  
An interesting strategy to overcome these problems and obtain a uniform coating 
was developed in the research group in which this thesis was carried out, 
depositing an intermediate Cu shell between the Fe3O4 core and Au layer.  
3.1.1.5 Copper shell 
Cu has high chemical affinity for Au, as proved by their ability to give alloys, that 
may guarantee the deposition of a homogeneous Au layer on Fe3O4 MNPs, and it 
can easily be deposited on magnetite surface by simple redox reactions.92,93 Thus, 
the Cu layer on one hand protects Fe3O4 from oxidation and, on the other hand, 
can be exploited for the Au deposition through a direct redox reaction. Moreover, 
the presence of Cu enhances some physicochemical features of the nanosystems, 
especially in terms of catalytic ability.94  
Therefore, the development of core-shell nanosystems made of Fe3O4@Cu or the 
production of superparamagnetic NPs loading copper ions can provide advantages 
in biomedical applications. In fact, nanosystems able to act as contrast agents in 
both MRI and positron emission tomography (PET) can be achieved using the 
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mixture of 63Cu and the radionuclide 64Cu. The integration of these techniques 
allows to highly improve the diagnosis of pathologies, in pre-clinical and clinical 
applications, since it matches the high resolution of MRI with the sensitivity of 
PET.70,95 
 CHAPTER OBJECTIVES 
Since the central aim of this thesis is the development of new superparamagnetic 
nanosystems for biomedical applications, the synthesis and physicochemical 
characterization of the basic inorganic structures have been the first steps to 
address.  
The nucleus made of Fe3O4 is the central part of two kinds of core-shell 
nanosystems differing in the materials that constitute the external shells. The core-
shell structure has been selected in order to protect Fe3O4 from oxidation, 
maintaining its superparamagnetic features, and to improve the chemical stability 
and biocompatibility of the nanosystems. The choice of producing two kinds of 
nanosystems instead of one derives from the possibility to easily achieve different 
surface functionalization exploiting the specific chemical reactivity of the 
materials constituting the shells. In fact, selecting, from one hand, the noble metal 
Au and, from the other hand, the inert material SiO2, the surface functionalization 
can be based on soft-soft or hard-hard interactions, respectively. In this way it is 
possible to covalently attach molecules bringing completely different functional 
groups, avoiding their derivatization, and also to modulate the strength of the bond 
between MNPs and surface coating depending on the biomedical end use.  
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The core-shell nanostructures designed and synthesized in this research work are 
Fe3O4@Cu@Au MNPs and Fe3O@SiO2 MNPs; the first is characterized by an 
intermediate shell of Cu covered by the external shell of Au while the second 
presents a SiO2 shell, as shown in Figure 3.2-1. 
 
Figure 3.2-1: Schematic representation of the inorganic structure of the nanosystems developed in 
this thesis: core-shell Fe3O4@Cu@Au MNPs (on the left) and Fe3O4@SiO2 MNPs(on the right). 
As previously introduced, concerning Fe3O4@Cu@Au MNPs, the choice of Cu is 
due to its chemical affinity towards the -OH groups on Fe3O4 surface and to its 
redox properties which allow the further uniform deposition of Au through a direct 
reaction. On the other side, the production of a uniform SiO2 shell on Fe3O4 is 
possible thanks to the high compatibility between silicon and iron oxide. In this 
case, the need of an intermediate layer is avoided, producing directly Fe3O4@SiO2 
MNPs.  
The physicochemical characterization of Fe3O4@Cu@Au MNPs and 
Fe3O4@SiO2 MNPs is very important to confirm their chemical nature and 
morphological features and to evaluate their properties. For this reason, different 
spectroscopic and microscopic techniques will be used to collect information 
about the chemical composition, the shape, the dimensions and the internal 
structure of those nanosystems. 
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 RESULTS AND DISCUSSION 
The experimental results concerning the synthetic strategies for the achievement 
of Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 MNPs and their physicochemical 
characterization by means of spectroscopic and microscopic techniques are 
presented and discussed in this section. 
3.3.1 Fe3O4@Cu@Au MNPs 
3.3.1.1 Synthesis of the core: Fe3O4 MNPs 
The magnetic nucleus of the core-shell Fe3O4@Cu@Au MNPs was obtained by a 
modification of the synthetic protocol based on Massart’s procedure.96 As shown 
in Figure 3.3-1, the nucleation of Fe3O4 was carried out by co-precipitation 
method, adding dropwise a solution containing Fe2+/Fe3+, with a molar ratio of 
1:2, to an ammonia solution at room temperature (rt). 
The synthesis was performed in inert conditions to avoid the oxidation of Fe2+ that 
can lead to the formation of maghemite (γ-Fe2O3) instead of magnetite, modifying 
the magnetic properties of the MNPs.97 This synthetic protocol was easy to 
perform, cost effective and quick; in fact, the addition of the iron solution in the 
basic environment rapidly led to the formation of black magnetic NPs. 
  
Figure 3.3-1: Reaction scheme for the synthesis of Fe3O4 MNPs by co-precipitation method. 
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During the synthetic step, the vigorous mechanical stirring 
and the use of high molar excess of the stabilizing agent 
polyvinylpirrolidone (PVP) allow to minimize the 
aggregation process normally occurring among Fe3O4 
MNPs through the formation of μ-oxo bonds. PVP – the 
structure of which is shown in Figure 3.3-2 - is a water 
soluble and biocompatible polymer able to coordinate iron 
through its C=O groups, reducing the average particle 
size.98 After 30 min reacting at rt, the mixture was heated at 80°C, promoting the  
loss of -OH surface groups involved in the aggregation processes, in order to 
facilitate the formation of the crystal structure in Fe3O4 nuclei. 
The superparamagnetic nature of the Fe3O4 MNPs allows the separation from the 
reaction mixture through magnetic collection, carried out by applying external 
permanent magnets, as shown in Figure 3.3-3. Finally, to remove the unreacted 
reagents Fe3O4 MNPs were purified by dialysis against H2O and then dried and 
characterized before undergoing covering steps. 
 
Figure 3.3-3: Magnetic separation of MNPs using external permanent magnets. After few minutes 
from applying magnets the black solution containing MNPs (left) becomes transparent (right). 
  
Figure 3.3-2: 
Chemical structure of 
polyvinylpirrolidone 
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3.3.1.2 Physicochemical characterization of Fe3O4 MNPs 
Since the development and applications of magnetic nanosystems based on 
Fe3O4@Cu@Au MNPs is the central topic of the research group led by Prof. 
Mario Barteri, in which this thesis was carried out, several experimental data on 
the physicochemical characterization of this kind of nanosystem had already been 
collected and/or published.99-101  
The magnetic properties of Fe3O4 MNPs studied by means of vibrating sample 
magnetometer (VSM) were reported in a previous doctoral thesis, confirming the 
superparamagnetic features of these MNPs, since the measured Ms was of 71.6 ± 
0.2 emu/g, comparable to the reference value of  ≈ 80 emu/g.99 The analysis 
performed by means of atomic force microscopy (AFM) demonstrated the 
nanometric dimensions and spherical shape of Fe3O4 MNPs, showing an average 
diameter of 15 nm, but also the presence of larger aggregates.  
The X-ray powder diffraction (XRPD) measurements made it possible to study 
the crystal nature of the Fe3O4 MNPs. As shown in the diffractogram in Figure 
3.3-4, the peaks belonging to Fe3O4 crystals were identified, using reference data 
(JCPDS file No. 88-0315), and the corresponding Miller indices were reported. 
The broadness of the diffraction peaks may be related to the nanometric size of 
the particles while the significant background noise may be due to the presence of 
a not-negligible portion of amorphous materials. 
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Figure 3.3-4: XRPD spectrum of Fe3O4 MNPs including Miller indices corresponding to Fe3O4. 
3.3.1.3 Synthesis of the Cu shell: Fe3O4@Cu MNPs 
Fe3O4 MNPs were exploited as nucleation seeds for the deposition of metallic Cu; 
this layer was produced by a redox reaction between a salt of Cu (II) and the 
reducing agent L-ascorbic acid, as reported in Figure 3.3-5. 
 
L- ascorbic acid,  known as vitamin c, was used as reducing agent thanks to its 
peculiar features: its involvement in many metabolic pathways, both as reducing 
agent and coenzyme, has proven its high biocompatibility and poor cytotoxicity. 
Moreover, it is characterized by low cost and high-water solubility (400 mg/mL 
at T 40°C) and it could act at the same time as reducing agent and stabilizer, 
simplifying the synthetic procedure.102 Ascorbic acid, in fact, could easily reduce 
CuII to Cu0 (E°CuII/Cu0 = 0,34V vs SCE at T 25°C), being oxidized to 
dehydroascorbic acid (E°Dehydroascorbic/ascorbic acid= 0.08V vs SCE at T 25°C). 
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Figure 3.3-5: Scheme of the redox reaction between L-ascorbic acid and copper (II) nitrate for the 
deposition of the copper shell on Fe3O4 MNPs. 
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The reaction was mechanically stirred for 1 h at 50 °C and Fe3O4@Cu MNPs were 
purified by dialysis against H2O and finally dried. The same coating protocol was 
performed twice in order to improve the homogeneity of the Cu layer. 
3.3.1.4 Physicochemical characterization of Fe3O4@Cu MNPs 
The physicochemical characterization of Fe3O4@Cu MNPs was performed by 
means of XRPD in order to confirm the success of the deposition reaction. 
XRPD spectrum, reported in Figure 3.3-6, proved the presence of Cu as Cu0 and 
CuO into the nanosystems, in addition to Fe3O4, as shown by the diffraction peaks 
and the corresponding Miller indices, compared to the reference data present in 
the literature (JCPDS file No. 04-0836 and No. 80-1916). 
 
Figure 3.3-6: XRPD analysis of Fe3O4@Cu MNPs; The Miller indices corresponding to Fe3O4 (in 
black), Cu0 (in blue) and CuO (in green) are indicated. 
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3.3.1.5 Synthesis of the Au shell: Fe3O4@Cu@Au MNPs 
As previously described, the Cu layer in Fe3O4@Cu MNPs allowed the deposition 
of Au through a direct redox reaction between the tetrachloroauric acid, containing 
Au3+ ions, and the Cu0 shell, as reported in Figure 3.3-7. 
The Au3+ is characterized by a strong oxidative power (E° Au3+/Au0 = 1.52 V at T 
25°C) and it can easily react with Cu0, consuming the copper shell and releasing 
Cu2+ in solution. It was important to neutralize the strong acidity of HAuCl4, 
reaching pH 6,5 by adding saturated bicarbonate solution, in order to avoid the 
degradation and solubilization of Fe3O4@Cu MNPs. The reaction mixture was 
mechanically stirred 45 min at 60°C and, after washing with H2O, a second 
coating was carried out to improve the thickness of the layer, reaching to a more 
homogeneous Au shell. 
For the second deposition, L-ascorbic acid was used as the reducing agent thanks 
to its peculiar features previously described. The reaction, reported in Figure 
3.3-8, was stirred for 2 h at 60°C in bicarbonate buffer solution, neutralizing the 
solution as previously performed, and using high excess of vitamin c.103 
 
Figure 3.3-8: Scheme of the redox reaction between L-ascorbic acid and chloroauric acid for the 
second deposition of the gold shell on Fe3O4@Cu MNPs. 
After magnetic separation, the Fe3O4@Cu@Au MNPs were purified by dialysis 
against H2O, dried and characterized by spectroscopic and microscopic 
techniques. 
Figure 3.3-7: Scheme of the direct redox reaction between the copper shell and tetrachloroauric 
acid for the deposition of the Au layer on Fe3O4@Cu MNPs. 
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3.3.1.6 Physicochemical characterization of Fe3O4@Cu@Au MNPs 
Fe3O4@Cu@Au MNPs were characterized by means of XRPD, AFM and 
transmission electron microscopy (TEM). 
The XRPD analysis proved the successful deposition of Au since several peaks in 
the diffractogram, reported in Figure 3.3-9, could be assigned to the noble metal, 
in addition to those belonging to Fe3O4, as confirmed by reference data (JCPDS 
file No. 04-0784). Moreover, the absence of diffraction peaks related to Cu, except 
those of its oxidized compound CuO, suggested the consumption of that shell. 
 
Figure 3.3-9: XRPD analysis of Fe3O4@Cu@Au MNPs; Miller indices belonging to Fe3O4 (in 
black), CuO (in green) and Au (in red) are reported. 
The characterization of Fe3O4@Cu@Au MNPs by means of the microscopic 
technique AFM and TEM confirmed the spherical shape of the nanosystems and 
their nanometer dimensions. In fact, according to the images shown in Figure 
3.3-10, the average diameter of Fe3O4@Cu@Au MNPs was estimated of 20 nm 
and the evidence of a core-shell structure was obtained. Aggregates having 
nanometric and micrometric dimensions were also detected. 
Fe3O4@Cu@Au MNPs
20 30 40 50 60 70 80
0
5.010 3
1.010 4
1.510 4
2.010 4
Fe3O4
CuO
Au
220
111
200
511
440
220
311
111
Diffraction Angle 2  [°]
In
te
n
si
ty
3. SYNTHESIS AND PHYSICOCHEMICAL CHARACTERIZATION OF Fe3O4@Cu@Au 
AND Fe3O4@SiO2 NANOSYSTEMS 
 
37 
 
 
Figure 3.3-10: TEM (on the left) and AFM (on the right) analysis of Fe3O4@Cu@Au MNPs, 
confirming the nanometer dimension and the core-shell structure of the nanosystems. 
3.3.2 Fe3O4@SiO2 MNPs 
In order to produce the other kind of nanosystem, Fe3O4 MNPs were exploited as 
nucleation seeds for the deposition of SiO2 shell. As previously described in 
section 3.1.1.1, SiO2 was selected as the coating agent because of its excellent 
biocompatibility and chemical stability. Moreover, the surface functionalization 
of Fe3O4@SiO2 MNPs could be carried out taking advantages from the strong 
hard-hard interactions among silicon and other compounds, especially silanes; 
using heterobifunctional silanes the conjugation of molecules or biomolecules of 
interest can be achieved.104  
3.3.2.1 Synthesis of silica shell: Fe3O4@SiO2 MNPs 
The deposition of the SiO2 shell on Fe3O4 MNPs was carried out by the sol-gel 
process, known as Stöber method.74 This synthetic strategy concerned the 
polymerization of tetraethoxysilane (TEOS) in alcohol solution using ammonia as 
catalyst, as reported in Figure 3.3-11. 
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Figure 3.3-11: Scheme of the polymerization reaction of TEOS for the deposition of SiO2 shell on 
Fe3O4 MNPs. 
The reaction was performed stirring Fe3O4 MNPs for 3 h at rt in TEOS solution. 
The mechanism consists in the hydrolysis of TEOS in isopropyl alcohol followed 
by the condensation step on the surface of Fe3O4 MNPs, leading to the formation 
of the SiO2 shell. Fe3O4@SiO2 MNPs were separated from the reaction mixtures 
through magnetic collection, washed several times first with alcohol and then with 
H2O and finally dried. Two kinds of Fe3O4@SiO2 MNPs differing in the thickness 
of the shell were synthesized; these MNPs were produced performing the 
reactions with different amounts of TEOS, using three-times the concentration of 
TEOS in one reaction compared to the other.105  
3.3.2.2 Physicochemical characterization of Fe3O4@SiO2 MNPs 
Fe3O4@SiO2 MNPs were characterized by means of spectroscopic and 
microscopic techniques. The chemical characterization was achieved performing 
Fourier-transform infrared spectroscopy (FT-IR) and XRPD analysis while the 
morphological study was carried out by using AFM and TEM. 
The FT-IR spectrum of Fe3O4@SiO2 MNPs, shown in Figure 3.3-12, confirmed 
the presence of silica in the inorganic nanostructure in addition to the iron oxide 
since the typical vibrational bands of SiO2 and Fe3O4 could be clearly recognized. 
In fact, the intense vibrational bands centred at ν ≈ 1067 cm-1 and ν ≈ 587 cm-1 
could be assigned to the stretching vibrations of Si-O-Si and Fe-O bond, 
respectively. The broad band at ν ≈ 3430 cm-1 and that at ν ≈ 1630 cm-1 could, 
instead, be ascribed to the O-H vibrations of adsorbed H2O.   
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Figure 3.3-12: FT-IR spectrum of Fe3O4@SiO2 MNPs, highlighting the typical vibrational bands 
belonging to O-H, Si-O-Si and Fe-O bonds. 
The XRPD spectrum of Fe3O4@SiO2 MNPs, shown in Figure 3.3-13, suggested 
the presence of SiO2 in an amorphous state. This consideration derived from the 
increase in the non-crystalline portion of the material, which caused high 
background at diffraction angles < 30°, and in the contemporary absence of 
diffraction peaks corresponding to SiO2 crystals. The diffraction peaks belonging 
to Fe3O4 were, instead, identified by the corresponding Miller indices. 
 
Figure 3.3-13: XRPD analysis of Fe3O4@SiO2-MNPs; SiO2 was present in an amorphous state 
while the diffraction peaks belonging to Fe3O4 were identified by the corresponding Miller indices. 
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The AFM image, shown in Figure 3.3-14, proved the spherical shape and the 
nanometric dimensions of Fe3O4@SiO2 MNPs; the average diameter was 
estimated of 20 nm but aggregates with larger dimensions were found. 
 
Figure 3.3-14: AFM image of Fe3O4@SiO2 MNPs, confirming the spherical shape and nanometric 
dimensions. 
The analysis of Fe3O4@SiO2 MNPs by means of TEM confirmed these 
morphological features and allowed also to appreciate the internal structure. The 
comparison among the TEM images corresponding to the bare Fe3O4 MNPs (A) 
with those of the coated Fe3O4@SiO2 MNPs synthesized using the lowest (B) or 
the highest (C) quantity of TEOS is reported in Figure 3.3-15. All the samples 
were not well dispersed and presented aggregates. The core diameter was 
estimated around 10-15 nm, in agreement with the AFM analysis. Concerning the 
coating reactions, Fe3O4@SiO2 MNPs sample B, obtained using the less 
concentration of TEOS, had comparable dimensions and similar appearance to 
Fe3O4 MNPs, since the presence of the SiO2 shell was not detected. Conversely, 
the core-shell structure was clearly identifiable in the nanosystems synthesized 
using high amount of TEOS, Fe3O4@SiO2 MNPs sample C; in this sample the 
presence of materials with diverse electron densities producing different contrast 
in the image, such as silicon and iron, was evident. As shown in Figure 3.3-16, 
the thickness of the SiO2 shell in these MNPs was estimated of 8 nm.  
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Figure 3.3-15: TEM images corresponding to Fe3O4 MNPs (A) and Fe3O4@SiO2 MNPs synthesized 
using the lowest (B) or the highest (C) quantity of TEOS. Samples A and B were comparable while 
the core-shell structure was detectable in sample C. 
 
Figure 3.3-16: TEM image of Fe3O4@SiO2 MNPs sample C reporting the experimental measures 
of the silica shell thickness. 
Since the experimental data highlighted the core-shell structure in the sample 
corresponding to Fe3O4@SiO2 MNPs synthesized with the high concentration of 
TEOS, only these nanosystems were selected for the further functionalization and 
biomedical applications. 
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 CHAPTER CONTRIBUTIONS 
- Core-shell superparamagnetic Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 
MNPs were synthesized and characterized by means of different 
spectroscopic and microscopic techniques. The chemical composition and 
the crystal structure were confirmed by XRPD and/or FT-IR analysis 
while data about the nanometric dimensions, shape and internal structure 
were collected by AFM and TEM analysis. 
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 MATERIALS AND METHODS 
Reagents, materials and equipment: All the chemical reagents were purchased by 
Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and used without further 
purification. Permanent magnets made of Neodymium-Iron-Boron alloy, having 
a magnetic field of 0.3 T, were used for magnetic separations. Sonication was 
performed with UNISET-AC characterized by 45 W power and 38 KHz maximum 
frequency. The diffractometer RIGAKU-MINIFLEX II, with a θ-2θ Bragg-
Brentano geometry and Cu anti-cathode (Cu Kα1 λ= 1.5405 Å), was used for 
XRPD analysis on solid MNPs. Infrared spectra were recorded from 200 to 4000 
cm-1 using the spectrometer VARIAN 660-IR FT-IR and preparing the IR tablets 
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mixing 1 mg of sample with 200 mg of anhydrous KBr. AFM analysis were 
performed using the microscope MULTIMODE VEECO equipped with the 
software Nanoscope IIIa; the topographical images of the sample, deposited as 
diluted aqueous solution on Si slices, were collected in tapping mode using a 
RTESP Bruker tip (nominal parameters r = 8mm, f = 300 kHz, k = 40 N/m) and 
recorded with a 512x512 pixel resolution, corrected by polynomial background 
filters using the software Gwyddion 2.31. TEM images were collected with the 
microscope Philips ECM-200 KV. 
Synthesis of the magnetite core - Fe3O4 MNPs: 200 mL of an aqueous solution 
containing (NH4)2Fe(SO4)2*6H2O (3.8 mmol), Fe2(SO4)3 (3.8 mmol) and PVP 
(MW 10 000, 19.1 mmol) were added dropwise in argon atmosphere to 600 mL 
of NH4OH (0.7 M) dissolving the same amount of PVP. After 30 min reacting at 
rt under mechanical stirring, the mixture was heated at 80°C and stirred 30 min. 
Once cooled, Fe3O4 MNPs were magnetically separated from the mixture and 
dialyzed 24 h against bi-distilled H2O. After drying under vacuum, about 700 mg 
of Fe3O4 MNPs were obtained. 
Synthesis of the Cu shell - Fe3O4@Cu MNPs: 100 mg of Fe3O4 MNPs (0.43 mmol) 
were dispersed in 48 mL of bi-distilled H2O and sonicated 10 min. The molar ratio 
between Fe3O4 : CuII used was 1.5:1. 10 mL of an aqueous solution of Cu(NO3)2 
(0.29 mmol) and, after 5 min, 2 mL of an aqueous solution of L-ascorbic acid (0.58 
mmol) were added dropwise to the dispersion. The reaction was mechanically 
stirred for 1 h at 50°C. Fe3O4@Cu MNPs were magnetically separated, washed 
with bi-distilled H2O and then used for the second covering. 
The second covering reaction was performed as the previous one, using the same 
amount of L-ascorbic acid and changing the molar ratio between Fe3O4 and CuII 
to 4:1. After 1 h stirring at 50°C, the product Fe3O4@Cu MNPs was washed with 
saturated NaCl solution and then dialysed 24 h against bi-distilled H2O and finally 
dried in the stove overnight at 120°C.  
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Synthesis of the Au shell - Fe3O4@Cu@Au MNPs: 100 mg of Fe3O4@Cu MNPs 
(0.82 mmol of Cu) were dispersed in 45 mL of bi-distilled H2O. 5 mL of a aqueous 
solution of HAuCl4*3H2O (0.21 mmol), neutralized to pH 6.5 with saturated 
NaHCO3 solution, were added dropwise to the dispersion. The mixture was 
mechanically stirred for 45 min at 60°C. Fe3O4@Cu@Au MNPs were 
magnetically separated from the mixture, washed with saturated NaHCO3 solution 
and then bi-distilled H2O and finally covered with the second Au shell. 
For the second gold deposition reaction, Fe3O4@Cu@Au MNPs achieved from 
the first covering reaction were dispersed in 43 mL of bi-distilled H2O and 5 mL 
of a neutralized aqueous solution of HAuCl4*3H2O (0.10 mmol, pH 6.5) were 
added to the dispersion. After adding 2 mL of an aqueous solution of L-ascorbic 
acid (0.50 mmol) the mixture was mechanically stirred at 60°C for 2 h. 
Fe3O4@Cu@Au MNPs were collected by magnetic separation, washed with 
EDTA solution (1 mM; pH 7) and then dialysed 24 h against bi-distilled H2O. 
Fe3O4@Cu@Au MNPs were desiccated overnight in the stove at 120°C. 
Synthesis of the SiO2 shell - Fe3O4@SiO2 MNPs: 100 mg of Fe3O4 MNPs were 
dispersed in 6 mL of bi-distilled H2O and sonicated for 15 min. Under mechanical 
stirring, 20 mL of a solution of TEOS in isopropyl alcohol (at the concentration 
of 1 mg/mL or 2,5 mg/mL) and 1 mL of NH4OH (0.7 M) were added slowly to 
the dispersion. After reacting 3h at rt, Fe3O4@SiO2 MNPs were magnetically 
separated from the solution, washed with isopropyl alcohol and bi-distilled H2O 
and then dried overnight under vacuum. 
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 INTRODUCTION 
The development of new nanosystems suitable for theranostic applications in 
cancer treatment is the focus of the research work presented in this chapter. The 
basic metallic structure of Fe3O4@Cu@Au MNPs has been used for the 
conjugation of bioactive molecules also known to be active targeting ligands, like 
the vitamin folic acid and the chemotherapeutic drug methotrexate. To reach this 
goal, the preliminary activation of the Au surface with molecules suitable for the 
further modification has been carried out. To evaluate the therapeutic effect of the 
synthesized nanosystems, biological studies on breast cancer cell lines have been 
performed in collaboration with the research group led by Prof. Laura Masuelli at 
the Department of Experimental Medicine - Sapienza University of Rome. 
4.1.1 Tumour targeting using nanosystems 
Since the spread of cancer is rapidly increasing, causing millions of deaths 
worldwide, the development of new therapeutic strategies based on NPs and the 
improvement of the imaging techniques can contribute to early diagnosis and 
more efficient treatments, preventing the lethal outcomes of cancer.106-108 Several 
kinds of nanoparticles, especially liposomes and polymeric nanoparticles, have 
already been approved or submitted to clinical trials for the treatment of several 
primary tumours and/or metastasis: for instance Myocet® (Sopherion 
Therapeutics Inc., USA), non-PEGylated liposomes loading Doxorubicin, or 
NK105, PEG-poly(aspartic acid) carriers loading Paclitaxel (Phase III)109 have 
been proposed for the treatment of breast cancer.107  
Fe3O4 MNPs can also be useful for cancer therapy and imaging, as previously 
described in section 1.3. In addition to their exploitation as contrast agents in MRI 
or in hyperthermia, Fe3O4 MNPs can be functionalized in order to carry proper 
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molecules with pharmaceutical or targeting activity, such as anti-cancer drugs or 
proteins. A great advantage of engineered Fe3O4 MNPs, compared to other 
modified NPs, comes from the magnetic core which offers the possibility to 
remotely focusing them in the pathological area by using external magnetic 
fields.110 
Generally in cancer therapy two different strategies can be used to increase the 
accumulation of nanocarriers into tumours.111 They are known as passive and 
active targeting and their general mechanism is shown in Figure 4.1-1 from ref 112.  
 
Figure 4.1-1: Schematic representation of passive and active targeting strategies for accumulating 
nanoparticles in tumours (from ref. 112). The passive targeting consists in exploiting the enhanced 
permeability and retention effect of the tumoural mass due to ineffective lymphatic drainage and 
fenestrations in blood vessels of the affected tissue. The active targeting involves the use of active 
targeting ligands or specific antibodies which can address the nanosystems preferentially to 
malignant cells.  
Since the tumoral mass needs oxygen and other nutrients to support its intense 
growth, the generation of new vasculature structures rapidly occurs. The speed of 
this process, defined as angiogenesis, leads to the formation of imperfect and 
irregular blood vessels which are characterized by a reduced density of endothelial 
cells and large gaps among them. In addition to the poor and defective lymphatic 
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drainage of the tumoral area, these fenestrations allow the passive diffusion of 
nanomaterials into the pathological area. This phenomenon is known as Enhanced 
Permeation and Retention effect (EPR) and is commonly exploited for improving 
accumulation of nanocarriers into tumoral tissue, providing an increase in the 
local distribution of drugs.111,113 However, EPR cannot be exploited for all kinds 
of tumours since it depends on several features, such as the position and the size 
of the tumour or the pore dimensions of the fenestrations; for instance, tumours 
presenting necrotic areas characterized by hypoxic environment cannot be reached 
by exploiting this passive accumulation phenomenon and, moreover, EPR is often 
compromised by the increased intratumor pressure.114  
The use of specific ligands for cancer cell which can act as targeting molecules 
can help overcoming the limitations of the passive drug-delivery strategy.115 The 
active targeting compounds include specific antibodies, proteins, nucleic acids, 
peptides or other small molecules such as vitamins. They can actively interact 
with some elements, such as surface molecules or receptors, present in the affected 
organ, tissue or cell. Thanks to this specific interaction, the drug delivery 
nanosystems loading active targeting ligands are preferentially directed to the 
pathological tissues, enabling a more efficient therapeutic activity. Furthermore, 
if the active targeting concerns a membrane receptor able to trigger the 
internalization process and that is overexpressed in cancer cells, the uptake of the 
functionalized nanosystem can be facilitated.116 Some examples of active 
targeting molecules are antibodies or their fragments consisting in the 
hypervariable region, proteins such as transferrin, peptides with RGD sequence 
(arginine-glycine-aspartic acid) or vitamins like folic acid.117,118  
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4.1.2 Folic acid and methotrexate 
Folic acid (FA) is an essential vitamin belonging to 
the B group (vitamin B9). As shown in Figure 4.1-2, 
a pteridine ring (in black), a p-aminobenzoic acid 
moiety (PABA, in red) and a γ- glutamic acid residue 
(γ-Glu, in blue) compose its chemical structure. In 
nature it can be found in several forms differing in the 
oxidation state of the pteridine ring, or in the N(5) or 
N(10) substituents or in the number of glutamate 
residues; all these compounds belong to the folate 
family. Folates are converted by the enzyme dihydrofolate reductase (DHFR) in 
the active form tetrahydrofolate (THF), using NADPH as cofactor. THF acts as 
coenzyme in many biochemical processes concerning the one-carbon transfer at 
different oxidation state, for example in the metabolism of purine, pyrimidines 
and some AA. Due to its biological importance, a deficiency of FA is correlated 
to pathologies affecting especially nervous system, such as spina bifida.119 
Due to the involvement of DHFR in cell growth, several chemotherapeutic drugs 
have this enzyme as their biological target. Among those, methotrexate (MTX) is 
a folate structural analogue since -NH2 group is present in the pteridine ring 
instead of -OH and -CH3 instead of -H in the PABA 
moiety, as shown in Figure 4.1-3. These structural 
differences allow MTX to act as antagonist of FA 
(antifolate), binding to the active site of DHFR and 
inhibiting it.120 This process leads to a leakage of 
THF, blocking the nucleic acid synthesis and causing 
cell death. Due to its cytotoxic activity, MTX is 
commonly used for the treatment of several kinds of 
cancer, especially lung and breast cancer.121,122  
Figure 4.1-2: Chemical 
structure of folic acid; the 
pteridine ring, the p-
aminobenzoic acid and the ϒ-
glutamic acid residue are 
highlighted respectively in 
black, red and blue. 
Figure 4.1-3: Chemical 
structure of methotrexate; the 
pteridine ring, PABA and γ-Glu 
are highlighted in black, red 
and blue respectively, while the 
substituents differing from FA 
are circled. 
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4.1.3 Folate receptors and cancer cells 
The need of FA occurs particularly in rapidly dividing cells, including cancer 
cells, and for this reason the antifolates are of great interest in cancer therapy. In 
this context, the sensitivity of some cancer cell lines to antifolate drugs derives 
from the overexpression of folate receptors on their cellular membranes, needed 
for allowing high uptake of FA to support their rapid growth.123  
The absorption of folates occurs in the intestinal villi thanks to specific folate 
transporters: folate receptors (FRs), reduced folate carriers (RFC) and proton 
coupled folate transporters are involved in this mechanism.124 Folate receptors are 
trans-membrane proteins anchored by glycosylphosphatidylinositol molecules, 
existing in different isoforms and showing nanomolar binding affinity for FA. The 
α isoform of FRs (α-FR) has become an important tumoral marker since it is 
overexpressed in many tumours affecting especially brain, liver, ovary and 
breast.125 Although it is mainly present in macrophages, it is almost absent or 
hardly accessible in healthy organs, such as liver, lung and placenta. Moreover, 
the amount of folate receptors seems to increase during the worsening of the stage 
of the cancer.126 This protein is thus becoming an interesting biological target for 
the selective treatment of some tumours.123 Because of the high structural 
similarity between FA and MTX, this drug is able to bind to RFC and FR with 
lower affinity than FA but entering into the binding site with the identical 
geometry and orientation of FA.127 
Once bound FA or an antifolate, the folate receptors transport the ligand in 
intracellular environment by a receptor-mediated endocytosis. As shown in Figure 
4.1-4  from ref. 128, after the receptor-ligand complex formation the internalization 
occurs through the intracellular compartment called endosome. The endosome 
acidification produces the detachment of the folate from the protein, since the 
binding is pH dependent and, consequently, its release in the cytoplasmic 
environment together with the recycling of the receptor.128  
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Figure 4.1-4: Mechanism of the folate receptor-mediated endocytosis exploited as active targeting 
strategy in cancer treatment (from ref. 128). The interaction between the folate-loaded system and the 
membrane folate receptors triggers the internalization process which starts with the production of 
the endosomes. Once reached the cytoplasm, the acidification of the endosome causes the 
intracellular release of the folate-functionalized system and the recycling of the folate receptors.  
However, some cancer cells often show resistance to antifolate drug since they are 
able to develop a defence mechanism, such as the amplification of the gene 
encoding for DHFR or the decrease in the receptor-mediated transport 
mechanism.129 To better exploit the promising features of folate active targeting, 
the conjugation of FA or antifolates to nanocarriers seems to be a good strategy; 
in fact, combining the peculiar features of NPs with those of folates the 
accumulation of the nanosystems in targeted tissues can be improved together 
with the internalization into malignant cells.118 In this way, the nanosystems can 
be able to perform a more selective cytotoxic action limiting the side effects on 
healthy tissues. Several metal and polymeric nanosystems have been synthesized 
loading FA for targeting cancer cells 130,131 or loading MTX and using it both as 
targeting and therapeutic agent.127,132 Examples of MNPs functionalized with FA 
or MTX for cancer theranostics can be found in the literature, generally exploiting 
the magnetic core for MRI or performing multimodal strategies.54,133 
The design and development of new nanosystems able to overcome the cellular 
defence strategies, exploiting the active targeting ability of FA or MTX and being 
effective in cancer treatment remain interesting research topics. 
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 CHAPTER OBJECTIVES 
Due to the interesting features of the bioactive molecules FA and MTX in 
directing a nanosystem preferentially to cancer cells, the development of 
Fe3O4@Cu@Au MNPs loading those molecules is the topic of this chapter. This 
section represents a continuation of a previous research work reported in ref. 99, 
carried out in the same research group, demonstrating the internalization of  the 
same nanosystems into human granulocytes and human breast cancer cell lines. 
The optimization of the synthetic protocol, the quantification of the loaded 
bioactive molecule and the evaluation of the cytotoxic effects on the cancer cell 
lines remained unsolved topics which have to be investigated.  
To engineer Fe3O4@Cu@Au MNPs, the activation of the Au surface by soft-soft 
interactions with the vitamin lipoic acid can be a good strategy to allow the further 
binding of the cationic homopolymer poly-L-Lys; in this way the conjugation of 
the vitamin or the drug can be easily achieved. The synthesis and physicochemical 
characterization of the nanosystems, shown in Figure 4.2-1, are the main 
objectives of this work. These nanoplatforms can represent multitasking 
nanosystems suitable for theranostic application due to the contemporary presence 
of different functionalities; in addition to the magnetic core, active in focusing and 
revealing the nanosystems by magnetic-based techniques, the specific features of 
the bioactive molecules can allow their use as drug delivery systems, targeting 
cancer cells in a more selective way.  
 
Figure 4.2-1: Schematic representation of Fe3O4@Cu@Au MNPs loading the bioactive molecules 
folic acid or methotrexate thanks to the activation of their surface with lipoic acid and poly-L-lysine. 
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Moreover, the performance of biological experiments on cancer cell lines can help 
understanding the real applicability of those nanosystems; for this reason, in vitro 
experiments on the human breast cancer cell lines MCF-7 and MDA-MB-231, 
shown in Figure 4.2-2, can give information concerning the cytotoxic effects of 
the developed nanosystems.  
 
Figure 4.2-2: Images of the breast cancer cell lines MCF-7 and MDA-MB-231 (from ATCC) 
selected for the in vitro biological experiments. 
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 RESULTS AND DISCUSSION 
In this section the development of Fe3O4@Cu@Au nanosystems functionalized 
with FA or MTX is described, including the intermediate activation steps with the 
vitamin lipoic acid, and the homopolymer poly-L-lysine. The study of the 
interactions among the synthesized nanosystems and the breast cancer cell lines, 
MCF-7 and MDA-MB-231, is also reported and discussed. 
4.3.1 Functionalization with lipoic acid 
In order to achieve nanosystems active in theranostics, the Fe3O4@Cu@Au MNPs 
were activated with a heterobifunctional compound able to bind the surface of the 
nanoplatforms and allow the further conjugation of molecules or biomolecules.  
Lipoic acid (LA) was selected to play this 
role of linker thanks to its chemical and 
biological features. As shown in Figure 
4.3-1, the disulfide bond could interact with 
the Au surface, according to the Au-S 
chemistry, while the -COOH group could be 
exploited for the further conjugation of other molecules. Moreover, LA showed 
high biocompatibility since it is involved in many biochemical pathways 
concerning the transfer of acyl group. It acts as cofactor of important enzymes, 
such as the pyruvate dehydrogenase multi-enzyme complex, and it plays an 
antioxidant role by contrasting reactive oxygen species and chelating heavy 
metals.134  
Figure 4.3-1: Chemical structure of lipoic 
acid in which the disulfide bond and the 
carboxyl group are highlighted. 
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4.3.1.1 Esterification of lipoic acid 
LA was previously derivatized in a more reactive form by an esterification 
reaction on the -COOH group, as shown in Figure 4.3-2, introducing a good 
leaving group for the subsequent reactions. After reacting 24h at rt with N,N’-
Dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS) in DCM, 
the reaction mixture was filtered to remove the coproduct dicyclohexylurea. The 
NHS-lipoate was purified by crystallization using the mixture ethyl acetate : 
hexane – 1:1, as reported in the literature 135, and obtaining the product with 61% 
yield as yellow crystals needles-shaped.  
 
Figure 4.3-2: Scheme of the esterification reaction of lipoic acid using DCC and NHS. 
4.3.1.2 Anchorage on Fe3O4@Cu@Au MNPs: MNPs-LA-NHS 
The NHS-lipoate was used for the anchorage on Fe3O4@Cu@Au MNPs, 
mechanically stirring overnight the nanosystems in the ester solution in ethyl 
acetate, as reported in Figure 4.3-3. 
 
Figure 4.3-3: Reaction scheme of the anchorage of NHS-lipoate on Fe3O4@Cu@Au MNPs. 
The reaction was monitored by UV-Vis spectroscopy, comparing the spectra 
recorded before (start - dashed line) and after (stop - solid line) the reaction with 
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Fe3O4@Cu@Au MNPs, that were magnetically separated from the reaction 
mixture. As shown in Figure 4.3-4, the decrease in the intensity of the absorption 
band centred at λ 334 nm, corresponding to lipoate, after the reaction with MNPs 
confirmed the anchorage of NHS-LA on Au surface. 
 
Figure 4.3-4: UV-Vis spectra recorded before (start, dashed line) and after (stop, solid line) the 
reaction between NHS-lipoate and Fe3O4@Cu@Au MNPs, confirming the anchorage of the linker. 
The nanosystems Fe3O4@Cu@Au-Lipoate-NHS MNPs, referred to as MNPs-LA-
NHS, were washed, dried and used for the further conjugation reactions.  
4.3.2 Functionalization with poly-L-lysine 
The homopolymer poly-L-lysine (PLL), which 
structure is shown in Figure 4.3-5, was selected for the 
binding of FA and MTX due to the presence of several 
amine groups exploitable for the drug conjugation. 
Moreover, these groups were suitable for the 
anchorage on nanosystems, through the reaction with 
NHS-lipoate, or for the labelling with a fluorescent 
probe. Furthermore, the hydrophilic and cationic 
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Figure 4.3-5: Chemical 
structure of poly-L-lysine. 
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nature of PLL can enhance the dispersibility of nanoparticles in aqueous 
solution.136 The presence of the polymer on nanosystems or in simple drug-PLL 
conjugates can improve the interactions with cell membranes and the absorption 
of the bound drug.137,138  
4.3.2.1 Anchorage on MNPs-LA-NHS: MNPs-PLL 
The activated carboxyl groups of LA on MNPs-LA-NHS were used for the 
reaction with the nucleophilic -NH2 groups of PLL, leading to the formation of 
amide bonds. As shown in Figure 4.3-6, the reaction was performed in bicarbonate 
buffer since the slightly basic pH was selected as a compromise among 
deprotonating the amine groups and minimizing the hydrolysis of the active ester.  
 
Figure 4.3-6: Reaction scheme of the functionalization of MNPs-LA-NHS with PLL. 
The reaction was monitored by UV-Vis spectroscopy to confirm the conjugation 
(data not shown). UV-Vis spectra were recorded before and after the reaction 
between MNPs-LA-NHS and PLL; the increase in the absorption band at λmax 270 
nm and the decrease in that at λmax 220 nm, belonging to NHS and PLL, in the 
sample corresponding to the supernatant after the reaction with the nanosystems 
proved the PLL anchorage. MNPs-PLL were magnetically separated, washed 
several times with H2O and used for the binding of the bioactive molecules. 
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4.3.3 Functionalization with FA or MTX 
The bioactive molecules FA and MTX were first activated by an esterification 
reaction and then conjugated to the free amine groups of PLL bound to the 
nanosystems.  
4.3.3.1 Esterification of FA and MTX 
The activation of the -COOH groups of the two molecules was achieved by an 
esterification reaction with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) and NHS, in order to obtain the isolable esters NHS-AF and NHS-MTX. 
The reactions, shown in Figure 4.3-7, were performed in anhydrous DMSO to 
dissolve the bioactive molecules, using triethylamine (Et3N) as the catalyst. They 
were carried out overnight at rt in closed systems to avoid the evaporation Et3N 
and protected from light due to the photosensitivity of FA and MTX.  
 
Figure 4.3-7: Scheme of the esterification reaction of FA or MTX using EDC and NHS. 
The NHS-esters were purified by precipitation adding ethyl ether to the 
concentrated DMSO solutions.139 The yellow-orange precipitates were filtered, 
washed with ACN to remove the DMSO and dried under vacuum. Unfortunately, 
this purification method did not remove completely the unreacted FA and MTX 
which remained in significant amount in the final product (from 1H NMR analysis 
NHS-FA:FA ratio 1:1, NHS-MTX:MTX ratio 2:1). However, the conjugation on 
PLL was performed without further purification.  
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The first idea was to try binding NHS-FA and NHS-MTX directly on free PLL to 
allow a better quantification of the loaded drug. This strategy was assessed using 
NHS-FA, since it was more easily available. The reactions were performed 
solubilizing the reagents in DMSO and using different concentrations of FA (FA 
moles at 1.5%, 5%, 10% and 20% of PLL moles, 
calculated on Lys monomers). The solutions were 
stirred overnight at rt and protected from light to avoid 
FA photodegradation. Unfortunately, after drying the 
reaction mixture, the solubilization with H2O of all the 
conjugates PLL-FA led to completely insoluble 
orange compounds with macroscopic tubular shape, 
as those shown in in Figure 4.3-8.  
Further investigation by 1D and 2D 1H and 13C NMR, like DOSY, TOCSY and 
NOESY were performed dispersing PLL-FA conjugates in H2O:D2O mixture at 
90:10 ratio (data not shown). From DOSY experiments DMSO and H2O 
molecules resulted involved in the formation of the secondary structure of the 
PLL-FA conjugate but remaining unstructured since they had logD values < logD 
of PLL and FA (logD = -8.92 for DMSO, -8.56 for H2O, -10,1 for PLL and -9.7 
for FA). From TOCSY analysis two spin systems for the PABA moiety of FA 
were found, justifiable by the presence of a fraction of FA covalently bound to 
PLL and another interacting only by stacking. NOESY experiments did not show 
dipolar correlations among 1H of FA and PLL. All these studies suggested a 
complex secondary structure based on β-sheets, but  the structural complexity of 
the PLL-FA conjugates needed further investigation by solid state techniques.  
However, the insolubility of PLL-FA in all the solvent mixtures tried, differing in 
polarity, pH or ionic strength, drastically limited their use. For this reason, NHS-
FA and NHS-MTX were conjugated on PLL already bound to the nanosystems, 
avoiding the solubilization problems.  
Figure 4.3-8: Photo of tubular 
structures corresponding to 
PLL-FA conjugate, achieved 
using 10% of FA. 
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4.3.3.2 Conjugation on nanoparticles: MNPs-PLL-FA and MNPs-
PLL-MTX 
The free amine groups of PLL, anchored on the nanosystems, were used for the 
reaction with the NHS-esters of FA or MTX. The reactions, reported in Figure 
4.3-9, were performed dispersing MNPs-PLL in a solution of NHS-AF or NHS-
MTX in DMSO, stirring the mixture overnight at rt and protected from light.  
 
Figure 4.3-9: Reaction scheme of the functionalization of MNPs-PLL with NHS-FA or NHS-MTX. 
Since UV-Vis spectroscopy was used for monitoring the reaction and quantify the 
drug loading, Et3N was needed to maintain stable the protonation degree of the 
pteridine moiety of the bioactive molecules during the reaction; in this way it was 
possible to avoid shifts and profile changes in the absorption bands of FA and 
MTX in the UV-Vis spectra.140 The UV-Vis spectra, shown in Figure 4.3-10, 
demonstrated the conjugation of the bioactive molecules on MNPs-PLL. In fact, 
the significant decrease in the absorption bands corresponding to FA or MTX in 
the spectra recorded after the reaction with MNPs-PLL (stop - solid line) 
compared to the starting solutions of NHS-AF or NHS-MTX (start - dashed line) 
proved the functionalization of the nanosystems. The loading was therefore 
estimated in 0.8 mg FA or 0.6 mg of MTX on 50 mg of MNPs, using ε values 
obtained by calibration curves of NHS-FA and NHS-MTX solutions, dissolved in 
the same solvent of the reaction. 
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Figure 4.3-10: UV Vis spectra recorded before (start, dashed line) and after (stop, solid line) the 
reactions between MNPs-PLL and NHS-esters of folic acid (left) or methotrexate (right) which 
confirmed the binding of the bioactive molecules due to the decrease in their absorption bands. 
After magnetic separation and washings, the MNPs-PLL-FA and MNPs-PLL-
MTX nanosystems were characterized by several spectroscopic techniques. FT-
IR and fluorescence spectra of the MNPs, reported in Figure 4.3-11, confirmed 
the conjugation of the bioactive molecules; in the FT-IR spectra, in fact, 
characteristic vibrational bands belonging to FA, MTX and PLL, especially those 
assigned to amide bonds and pteridine moiety, were detected and the 
corresponding frequencies were indicated. The strong vibrational band around ν 
570 cm-1 belonged to Fe-O-Fe bond of the magnetite core.  
Furthermore, the fluorescence spectra of MNPs-PLL-AF and MNPs-PLL-MTX, 
recorded using λexc at 278 nm, showed the emission bands corresponding to the 
PABA and pteridine moieties of the bioactive molecules, at λmax at 350 nm and 
λmax at 440-460 nm, respectively.141 
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Figure 4.3-11: Top: FT-IR spectra corresponding to MNPs-PLL-FA (left) and MNPs-PLL-MTX 
(right). The peaks of the vibrational bands belonging to the bioactive molecules were indicated. 
Bottom: fluorescence spectra, recorded using λexc at 278 nm, of to MNPs-PLL-FA (left) and MNPs-
PLL-MTX (right). The emission bands correspond to the PABA and pteridine moieties of FA and 
MTX. 
4.3.4 In vitro experiments on human breast cancer cell lines 
Once achieved the MNPs-PLL-FA and MNPs-PLL-MTX, in vitro biological 
experiments on cancer cell lines were performed. As introduced previously in 
section 4.1.3, FA or MTX are considered active targeting ligands for nanosystems 
due to the overexpression of folate receptors in many cancer cells; in fact, they 
might help in directing the functionalized nanoplatforms towards cancer cells, 
accumulating inside them and preserving the healthy ones. 
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The stabilized human breast cancer cell lines MCF-7 and MDA-MB-231 were 
selected for the in vitro studies on the biological effects of the nanosystems. Both 
those cell lines correspond to breast adenocarcinoma and literature data confirm 
their upregulation of α-FR expression.142 According to previous results, achieved 
in the same research group in which this thesis was developed, these cell lines 
were sensitive to MTX, especially MDA-MB-231, as demonstrated by cell 
viability assay. Moreover, the internalization of those nanosystems was 
qualitatively confirmed by fluorescence microscopy experiments since the 
nanosystems loading FA and MTX, labelled with the fluorescent probe Texas Red 
(TR), were located in intracellular environment compared to the nanosystems 
functionalized with PLL-TR only.99 Starting from those experimental data, in vitro 
biological experiments on these cell lines were carried out in order to evaluate the 
cytotoxic effects of functionalized MNPs by performing cell proliferation assays. 
MCF-7 and MDA-MB-231 were incubated with MNPs-PLL-MTX, MNPs-PLL-
AF or MNPs-PLL upon different experimental conditions, such as cell amount, 
incubation time, culture medium and nanoparticles-administration method, and 
Sulforhodamine B proliferation assays were performed.143 Cells incubated with 
free MTX and FA were used as controls, in addition to the negative control 
consisting of not treated cells. According to the loading quantification of MTX on 
MNPs, the comparable amount of free MTX, corresponding to 2 μg/mL, was 
selected for the assays.  
The proliferation assays were performed plating 10 000 cells/well or 25 000 
cells/well in DMEM and, the next day, incubating them for 24 h or 48 h with the 
nanosystems. Cells were treated with different amounts of functionalized 
nanoparticles dispersed in medium, both filtered or not filtered on 0.45 μm filters. 
A medium without folate, RPMI w/o FA, was selected to remove the presence of 
basal FA and facilitate the internalization process of MNPs-PLL-FA or MNPs-
PLL-MTX due to the vitamin cell need.133 Since cells might suffered for the 
absence of FA, the complete RPMI medium was also used. The cell incubation 
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with MNPs dispersed in PBS was selected as other experimental condition. Serum 
percentage was also assessed from 0.1% to 10%; low FBS concentration 
minimized the interactions among nanoparticles and proteins while the high one 
corresponded to the standard concentration ensuring a good cell viability. 
The experiments carried out without filtrating the MNPs presented many 
problems due to early cell death; in fact, the nanometric and micrometric 
aggregates had deadly effects on cells, causing their disruption, as shown in Figure 
4.3-12. For this reason, the filtration of the MNPs solutions was necessary; 
however, although this process ensured cell viability, enabling the performance of 
the proliferation assay, it led to low and unknown drug concentrations in the 
samples of MNPs, hindering the comparison with free drug. 
 
Figure 4.3-12: Images of MCF-7 and MDA-MB-231 before (left) and after (right) the treatment 
with not-filtered solutions of MNPs. 
The best, but not promising, results achieved from these in vitro experiments are 
reported in Figure 4.3-13. These results corresponded to Sulforhodamine B assays 
performed on MCF-7 and MDA-MB-231 after 24 h of treatment in three 
experimental conditions. Cells were incubated with different volumes of filtrated 
solutions of MNPs-PLL or MNPs-PLL-MTX (50 μL or 100 μL) in three media: 
in PBS, replacing the medium with DMEM complemented with 10% FBS after 
incubating for 3h, or in RPMI w/o folate + 0.1% FBS or in complete RPMI (w/o 
the pH indicator phenol red) + 1% FBS. Untreated cells and samples incubated 
with MTX 2 μg/mL or FA 0.2 μg/mL were used as controls. According to the 
experimental results, a slight cytotoxic effect of MNPs was detected on both cell 
lines but without significant differences among cell samples treated with MNPs-
PLL and those incubated with MNPs-PLL-MTX. Unfortunately, also free MTX 
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for 24 h in the same medium was not effective in causing cell death at the 
concentration of 2 μg/mL since cell viabilities were comparable to those achieved 
in samples treated with FA 0.2 μg/mL. These data suggested that drug amount in 
filtered samples was indeed too low to produce cytotoxic effects. These not 
promising results suggested the need of finding a strategy to reduce the 
aggregation process of MNPs, to avoid filtration, since it affected the successful 
performance of the in vitro experiments. 
 
Figure 4.3-13: Results of the 24 h Sulforhodamine B proliferation assays on MCF-7 (top) and 
MDA-MB-231 (bottom). The experimental conditions corresponded to untreated cells (ctr) and 
cells incubated with free MTX, FA or MNPs-PLL and MNPs-PLL-MTX at two concentrations in 
volume. The treatments were performed in PBS, replacing after 3 h the medium with DMEM + 10% 
FBS, or in RPMI w/o folic acid (RPMI w/o FA + 0.1% FBS) or w/o phenol red (RPMI w/o PhR + 
1% FBS).  
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4.3.5 Ball milling process 
Several methods were tried in order to minimize the dimensions of the aggregates 
of MNPs, increasing their dispersibility in solution. The use of surfactants such as 
cetrimonium bromide or polysaccharides, like xanthan gum, were not helpful. 
Sonication processes might success in this purpose, but it led to the breaking of S-
Au bond, producing coating release in solution, monitored by UV-Vis 
spectroscopy. Filtration was a good strategy to remove aggregates, but it caused 
high loss of nanomaterial, and consequently of drug amount, as previously 
described. 
Since the previous strategies were not resolutive, mechanical breaking of MNPs 
using ball milling technique was tried. This process consists in grinding materials, 
in this case nanoparticles, by steel balls that moved during the rotation and 
vibration of the entire mill, as illustrated in Figure 4.3-14.  
 
Figure 4.3-14: Scheme of the ball milling process; during the rotations and vibrations of the mill 
steel balls grind MNPs.  
Ball milling was carried out on bare Fe3O4 MNPs, setting up the system in inert 
atmosphere to avoid the oxidation of the magnetite. The effects of this treatment 
were evaluated by means of AFM analysis. As reported in Figure 4.3-15, the 
average diameter of Fe3O4 MNPs after mechanical grinding was estimated of 12-
14 nm. The same analysis was performed after covering the Fe3O4 MNPs with Cu 
and Au shells; AFM images of Fe3O4@Cu@Au MNPs and the related statistical 
analysis suggested the maintenance of the average diameter around 12-14 nm, and 
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the decrease in the presence of aggregates compared to the same nanosystems not 
subjected to ball milling (Figure 3.3-10). Moreover, the enhance of the 
dispersibility of the nanosystems in aqueous solutions was detected.  
 
Figure 4.3-15: AFM analysis of Fe3O4 MNPs subjected to ball milling before (top) and after the 
deposition of copper and gold shells (Fe3O4@Cu@Au MNPs - bottom). AFM images of the samples 
are reported on the left while the corresponding statistical analysis on the right.  
According to these results, the mechanical grinding by ball milling could be a 
good option to minimize the amount of aggregates of MNPs in the sample and 
avoid the filtration of the corresponding solutions. In this way, in vitro biological 
experiments might be performed using functionalized MNPs samples with a 
known drug concentration and enabling the comparison on cytotoxic effects with 
the free drug.  
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 CHAPTER CONTRIBUTIONS 
- The Fe3O4@Cu@Au MNPs were used for the development of 
nanosystems carrying the active targeting molecules FA or MTX; to 
enable the binding of the bioactive molecules, the previous activation of 
the Au surface with LA and the conjugation of PLL were performed. The 
drug loading quantification was carried out by means of UV-Vis 
spectroscopy while the physicochemical characterization of the 
nanosystems was achieved by FT-IR and fluorescence techniques. 
- Since MTX is commonly used as chemotherapeutic drug, the cytotoxic 
effects of functionalized nanosystems were evaluated on the breast cancer 
cell lines MCF-7 and MDA-MB-231. Sulforhodamine B proliferation 
assays suggested a slight cytotoxicity of MNPs, regardless of the presence 
of the drug. The experimental evidences could be explained as the drug 
amount was too low to produce toxic effects due to the necessary filtration 
of the MNPs dispersions. Aggregates, in fact, dramatically affected the 
success of the experiments, causing early cell death.  
- To minimize the presence of big aggregates in the samples, ball milling 
treatment may be a solution.  
4.4.1 Future perspectives 
- Functionalize the Fe3O4@Cu@Au MNPs, subjected to ball milling 
process, with the bioactive molecules FA and MTX and try to improve 
the drug loading, optimizing the reaction conditions.  
- Perform the in vitro experiments without filtrating the MNPs samples thus 
knowing the drug concentration and comparing the effects with free drug.  
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 MATERIALS AND METHODS  
Reagents, materials and equipment: All the chemical reagents were purchased by 
Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and used without further 
purification. All the material used in in vitro biological experiments were 
purchased from Corning (Corning, USA). Permanent magnets made of 
Neodymium-Iron-Boron alloy, having a magnetic field of 0.3 T, were used for 
magnetic separations. Sonication was performed with UNISET-AC characterized 
by 45 W power and 38 KHz maximum frequency. Infrared spectra were recorded 
from 200 to 4000 cm-1 by the spectrometer VARIAN 660-IR FT-IR, preparing the 
IR tablets mixing 1 mg of sample with 200 mg of anhydrous KBr. Steady-state 
fluorescence spectra were collected by Varian Cary Eclypse spectrofluorometer, 
equipped with the Xe lamp using Suprasil® Quartz cuvette. NMR analysis were 
performed by means of the BRUKER AVANCE 400 MHz spectrometer, using 
TSP (stock solution in D2O at 20 mM) as the chemical shift reference. AFM 
analysis were performed using the microscope MULTIMODE VEECO equipped 
with the software Nanoscope IIIa; the topographical images of the sample, 
deposited on Si slice, were collected working in tapping mode using a RTESP 
Bruker tip (nominal parameters r = 8mm, f = 300 kHz, k = 40 N/m) and recorded 
with a 512x512 pixel resolution, corrected by polynomial background filters using 
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the software Gwyddion 2.31. A Vibromulino MM400 (Retsch, Haan, Germany) 
was used for the ball milling process. 
Esterification of Lipoic Acid: NHS-Lipoate: Lipoic acid (4.9 mM) and N-
hydroxysuccinimide (NHS 2 eq, 9.8 mM) were dissolved at rt in 50 mL of 
anhydrous DCM and N,N’-Dicyclohexylcarbodiimide (DCC 2 eq, 9.8 mM) 
was added after cooling the mixture at 4°C. After stirring 6 h at rt, 1 eq of NHS 
and 1 eq DCC were added to the solution. After 24 h reacting, the 
dicyclohexylurea was removed filtered the solution and the work up with a 
Na2CO3 (x3) and NaCl saturated solution (x1) was performed. The organic 
phase was dried and the crystallization with a mixture of ethyl acetate : hexane 
- 1:1 was carried out. The final product NHS-Lipoate was achieved as yellow 
crystals needles-shaped with 61% yield. 1H NMR (300 MHz, CDCl3, 25°C): 
δ=3.47 (m, 1H, H-3), δ=3.04 (m, 2H, H-1), δ=2.72 (s, 4H, H-8, H-9), δ=2.52 (t, 
2H, H-7), δ=2.35 (m, 1H, H-2), δ=1.82 (m, 1H, H-2), δ=1.64 (m, 4H, H-4, H-5), 
δ=1.44 (m, 2H, H-6). 
 
Functionalization with NHS-Lipoate: MNPs-LA-NHS: 100 mg of Fe3O4@Cu@Au 
MNPs were dispersed in 10 mL of NHS-Lipoate in EtAc at 1 mg/mL. After 
reacting overnight at rt, MNPs-LA-NHS were magnetically collected. UV-Vis 
spectra of the solutions corresponding to the reaction supernatant, centrifuged 10 
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min at 10 000 rpm, and to an aliquot of NHS-Lipoate starting solution, maintained 
in the same reaction conditions, were recorded. MNPs-LA-NHS were washed 
with EtAc and then dried under vacuum.  
 Functionalization with poly-L-Lysine: MNPs-PLL: 100 mg of MNPs-LA-NHS 
were dispersed in 10 mL of a solution of PLL*HBr at 1 mg/mL in HCO3- buffer 
(0.1 M, pH 8.3, filtered on 0.2 μm). After mechanical stirring 2 h 30 min at 4°C, 
MNPs-PLL were magnetically collected, washed several times with bi-distilled 
H2O and dried under vacuum. 
Esterification of FA and MTX: NHS-FA and NHS-MTX 
EDC (3 eq, 0.6 mmol) and NHS (3 eq, 0.6 mmol) were added to a solution of 
MTX or FA (0.2 mmol) dissolved in 5 mL of anhydrous DMSO containing 4% 
Et3N. The reaction was stirred overnight at rt protected from light. After 
concentrating the solution under vacuum heating at 40°C, ethyl ether was added 
dropwise to the solution under stirring, in order to precipitate the NHS-ester. The 
solution was then filtered under vacuum washing the precipitate with CH3CN 
(ACN) and finally drying under vacuum, achieving orange-yellow products. 1H 
NMR (400 MHz, d6 DMSO, 25°C) spectra of NHS-FA and NHS-MTX were 
compared to those of FA and MTX monitoring the shifts of the reference doublets 
corresponding to 1H of PABA moieties, at δ 7.73 ppm (2H) and δ 6.73 ppm (2H) 
for FA and at δ 7.62 ppm (2H) and δ 6.76 ppm (2H) for MTX. 
Functionalization with NHS-FA or NHS-MTX: MNPs-PLL-FA and MNPs-PLL-
MTX: 5 mL of a solution of NHS-MTX or NHS-FA at 1 mg/mL in anhydrous 
DMSO containing 4% Et3N were added to 5 mL containing 50 mg of MNPs-PLL 
in the same solvent. The reaction was carried out at rt overnight in systems closed 
and protected from light. The next day, MNPs-PLL-FA or MNPs-PLL-MTX were 
magnetically collected and UV-Vis spectra of the solutions corresponding to the 
reaction supernatants, centrifuged 10 min at 10000 rpm, and to the aliquot of the 
NHS-MTX or NHS-FA starting solution, maintained in the reaction conditions, 
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were recorded. The drug loading was calculated as the average Δc corresponding 
to A values at λ 269 nm, 300 nm and 386 nm for MTX and λ 288 nm and 326 nm 
for FA. The ε at the same λ were obtained using calibration curves of NHS-MTX 
and NHS-FA dissolved in the DMSO + 4% Et3N. For NHS-FA ε288=4.04 mg-1 mL 
cm-1 and ε360=1.83 mg-1 mL cm-1 while for NHS-MTX ε269=4.28 mg-1 mL cm-1, 
ε300=3.48 mg-1 mL cm-1 and ε386=1.35 mg-1 mL cm-1 were used. The estimated 
loading was 0.6 mg MTX on 50 mg MNPs-PLL-MTX and 0.8 mg of FA on 50 
mg MNPs-PLL-FA. MNPs-PLL-MTX and MNPs-PLL-FA were washed several 
times with bi-distilled H2O and dried under vacuum. 
In vitro experiments on MCF-7 and MDA-MB-231 - Sulforhodamine B 
proliferation assays: 25 000 cells/well in DMEM supplemented with 10% FBS 
and 1% pen strep were plated in 96-wells plate for 24 h. MNPs-PLL and MNPs-
PLL-MTX were dispersed at 2 mg/mL in sterile PBS buffer, in RPMI 1640 w/o 
folate + 0.1 % FBS or in RPMI 1640 w/o Phenol Red + 1% FBS. The MNPs 
dispersions were filtered on 0.45 μm filters and 200 μL of the 1:2 or 1:4 dilutions 
in the corresponding medium were added to the plate. FA at 0.2 μg/mL and MTX 
at 2 μg/mL solutions in the same RPMI media or in DMEM + 10% FBS were used 
as controls, in addition to untreated cells in the four media. Cells were incubated 
at 37°C and 5% CO2; only in the sample treated with MNPs in PBS the buffer was 
replaced by DMEM + 10% FBS after 3 h incubating. After 24 h of treatment, 
Sulforhodamine B proliferation assay was performed as described in the standard 
protocol143 and the A values at λ=492 nm and 620 nm were measured. The 
corresponding ΔA is related to cell viability, considering 100% the ctr sample.  
Ball Milling Process: Fe3O4 MNPs were subjected to ball milling treatment, 
assembling the system in a glove box in inert atmosphere. 1,44 g of Fe3O4 MNPs 
and 3 steel balls, with a total weigh of 12.5g were mixed. 8 grinding cycles, lasting 
1 h each, were performed working at ν 25 Hz. 
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 INTRODUCTION 
Cell-based delivery of nanosystems using immune cells is becoming a very 
interesting strategy to transport and release engineered NPs inside the body.48 The 
design of nanosystems which can be efficiently internalized leading to a good 
percentage of engulfed cells is already a challenge in this field. The development 
of nanosystems coated with different macromolecules for the engulfment of 
macrophages is the topic of this research work. 
5.1.1 Transferrin 
Transferrin (Tf) has gained great interest for 
biomedical applications involving 
nanosystems thanks to its physiological 
importance in transporting and regulating the 
iron concentration in biological environment 
and its specific intracellular uptake. The 
glycoprotein Tf, which structure is shown in 
Figure 5.1-1 from ref 144, is characterized by a 
Mw of ≈80 KDa and it is divided in two lobes 
linked by a short spacer. Each lobe presents two domains interacting together to 
form the deep hydrophilic iron binding site; there, four amino acids (Asp 63, Tyr 
95, Tyr 188 and His 249), arranged in a distorted octahedral geometry, coordinate 
Fe3+ with an affinity constant of Kass 1020 M-1 at physiological pH. During this 
process the synergistic collaboration of two O atoms of a carbonate anion occurs. 
The efficient uptake mechanism of iron-loaded Tf by endocytosis is mediated by 
the specific transferrin membrane receptors (TfR).145 The transferrin binding 
protein TfR1 is expressed in almost all cells of the body, especially in blood cells 
Figure 5.1-1: Structure of the Diferric 
bound human serum transferrin (from 
PDB 3QYT). 
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such as macrophages, and it is often upregulated in rapidly proliferating cells, 
including in cancer cells.146 For this reason, Tf-drug conjugates or nanosystems 
functionalized with Tf can more easily reach and enter into their biological targets 
thanks to the active targeting ability of Tf.147 Several examples of nanosystems 
including transferrin can be found in the literature. For instance, polymeric or lipid 
nanosystems loading drugs, DNA or radioisotopes, complexed or conjugated to 
Tf, can be actively directed to the pathological area for therapeutic applications 
while metal nanoparticles loading Tf can be used for targeting and imaging brain 
tumours, such as glioma.117,148,149 
5.1.2 Streptavidin 
Streptavidin (Stv) is a protein commonly used 
in biological and biotechnological applications 
due to its high affinity for biotinylated 
molecules. In fact, together with Avidin, Stv is 
classified as a biotin-binding protein.150 
Produced by the bacterium Streptomices 
avidinii, Stv is a homo-tetramer able to bind 
with high affinity four molecules of biotin, also 
known as vitamin H, per mole of protein. This 
binding occurs by the strongest non-covalent interaction known in nature, leading 
to the formation of Stv-biotin complex characterized by Kd value of ≈10-15 M. As 
shown in Figure 5.1-2 from ref 151, the secondary structure of Stv is characterized 
by high amount of β-sheets, involved in the formation of the biotin binding site. 
Due to this extraordinary affinity, Stv has been therefore exploited in many 
biotechnological and nanobiotechnological applications based on the binding of 
biotinylated molecules and macromolecules;152,153 Stv-biotin complexes are 
commonly used in several bioanalytical techniques, especially immunoassays and 
Figure 5.1-2: Structure of Streptavidin 
complexed with the peptide FSHPQNT 
(from PDB 1VWA). 
5. Fe3O4@Cu@Au NANOPARTICLES COATED WITH MACROMOLECULES FOR THE 
ENGULFMENT OF HUMAN IMMUNE CELLS 
76 
 
biosensors.154-156 Moreover, the derivatization of drugs or proteins, especially 
enzymes or antibody, with biotin can ensure the strong binding to Stv-coated 
nanosystems which can be employed for diagnostic or therapeutic purposes.157-159 
5.1.3 Cell-mediated delivery: Trojan Horse Approach 
Cell-mediated delivery of nanoparticles is a new and promising option in addition 
to the standard passive and active targeting strategies, already described in section 
4.1.1. It is based on the exploitation of immune cells, especially neutrophils, 
monocytes and macrophages, for the transport and delivery of engineered 
nanoplatforms inside the body.160,161 In this way, the overcoming of several limits 
of the other drug delivery strategies especially reaching deep affected tissues, can 
be achieved. In fact, in addition to their high innate biocompatibility and stealth 
features, immune cells are naturally able to reach all the tissues in the organism, 
also crossing hardly permeable barriers, such as the brain-blood barrier.162 They 
are involved in many fundamental physiological processes: in fact, the organism 
surveillance and defence against external pathogens, such as bacteria and viruses, 
and the elimination of cellular debris and dead cells depend on them. Since many 
of these cells are also directly involved in accelerating or contrasting several 
pathological processes, especially cancer, infections and inflammations, their use 
as carriers of medicated nanosystems can be a good strategy to achieve a more 
efficient in loco drug delivery.163-165 
Generally, the loading of nanosystems on cells can be achieved by covalent 
modification or non-covalent interactions among cell membrane and NPs or by 
exploiting the phagocytic activity of some kinds of immune cells that leads to the 
internalization of the nanosystems.166 The internalization of engineered 
nanoparticles in ex vivo cells, especially monocytes and neutrophils, extracted 
from the patient and incubated with the medicated nanoparticles, produce MNPs-
loaded cells. These cells can act as Trojan Horses once reintroduced in the patient, 
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migrating to the pathological focus thanks to innate chemoattraction, reaching for 
instance the hypoxic areas of tumours.167 Once there, they can release their cargo 
by physiological or external inputs.168 This promising strategy reported in Figure 
5.1-3, is known as Trojan Horse approach and it can help improving the 
effectiveness of therapeutic treatments based on nanotechnological approaches.167 
Macrophages, albeit adherent cells, can also be selected as Trojan horses thanks 
to their high phagocytic activity. 
 
Figure 5.1-3: General scheme of the Trojan Horse approach based on the ex vivo incubation of 
immune cells with engineered nanoparticles and their migration into pathological area by natural 
chemoattraction mechanism once reintroduced in the patient. 
Notwithstanding the great advantages, this technique presents some limits; for 
instance, the need of loading high number of cells in order to achieve a huge 
population of cells migrating to the pathological focus. Moreover, the drug must 
remain active inside the immune cell, without undergoing degradation, and be 
released once reached the target.160 
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5.1.3.1 Macrophages 
Macrophages, together with neutrophils and monocytes, may be suitable for 
internalizing engineered nanosystems as they possess innate phagocytic capability 
that they use for their physiological actions.169 Macrophages are located in almost 
all tissues and they derive from monocytes. Monocytes, instead, are circulating 
cells which can differentiate into macrophages once crossed the endothelial 
barrier and penetrated deeply in the organs. Two phenotypes of macrophages can 
be distinguished depending on their metabolism: the activated pro-inflammatory 
(M1) and the activated anti-inflammatory (M2) macrophages. These cells are 
involved in several diseases, especially cancer and inflammation disorders, 
playing different roles depending on their polarization; in fact, M1 can exhibit 
tumoricidal activities while M2 tumorigenic ones. 
Due to their physiological and/or pathogenic roles and their phagocytic ability, 
macrophages have been selected for imaging and therapeutic applications using 
nanoparticles.170,171 Several engineered nanoparticles have been incorporated into 
macrophages via phagocytosis, thus exploiting these engulfed cells as Trojan 
Horses. For instance, Au nanoshells, NPs or liposomes loading doxorubicin were 
successfully internalized in macrophages or monocyte-differentiated 
macrophages for in vitro or in vivo applications for cancer treatments.172,173 
Moreover, in this context the accumulation of macrophages carrying 
functionalized MNPs into deep tumour sites by applying pulsed magnetic field 
has been demonstrated, since the cells acquired magnetic field responsiveness.174 
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 CHAPTER OBJECTIVES 
Since macrophages are involved in the organism defence and are infiltrated in 
affected organs, they can be exploited as Trojan Horses for cell-mediated delivery 
of engineered nanosystems. Their phagocytic ability can be useful for facilitating 
the internalization of the nanosystems which can be transported and released also 
in hardly accessible areas of the body through natural chemoattraction 
mechanisms. 
A study of the internalization of differently coated nanosystems could help to 
understand the coating features needed for the achievement of high percentage of 
NPs-loaded cells, since this is the main limit to the real applicability of this 
strategy. For this reason, the evaluation of the intracellular uptake of  
Fe3O4@Cu@Au MNPs functionalized with three macromolecules is the aim of 
this work. In this study, transferrin, streptavidin and poly-L-lysine are selected for 
coating the activated MNPs-LA-NHS thanks to their biological and/or chemical 
properties. The protein labelling with the red fluorescent probe Texas Red and the 
physicochemical characterization of the conjugates are the first objectives of this 
research. As shown in Figure 5.2-1, after the synthesis of the engineered 
nanosystems, in vitro experiments incubating them with macrophages, achieved 
by a differentiation process of human leukemic monocytic cells (THP-1 cell line), 
can allow to select the most promising nanosystem for biomedical applications 
based on Trojan Horse method. 
 
Figure 5.2-1: Scheme of the aim of this research work concerning the internalization of differently 
coated nanoparticles in macrophages, achieved by differentiation of monocytic THP-1 cell line. 
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 RESULTS AND DISCUSSION 
The internalization studies on human immune cells of Fe3O4@Cu@Au 
nanosystems functionalized with PLL, Tf or Stv are presented and discussed in 
this section. The synthesis and characterization of the engineered nanoparticles 
have been firstly addressed. 
5.3.1 Functionalization of MNPs-LA-NHS with 
macromolecules 
Three different macromolecules were selected for the coating of MNPs-LA-NHS; 
the two proteins Tf and Stv were chosen due to the active targeting ability and the 
possibility of further binding of biotinylated molecules, respectively. PLL, 
instead, was selected as synthetic polymer model according to its chemical 
features and biocompatibility. In order to reveal the nanosystems during biological 
experiments, the macromolecules needed to be labelled. The red fluorescent dye 
Texas Red (TR) was selected for the labelling of PLL and Tf, while Stv was 
bought already conjugated to the same probe. 
5.3.1.1 Labelling of PLL and Tf with TR  
The labelling of PLL and Tf with TR was needed for monitoring the nanosystems 
during the in vitro experiments with macrophages, thus the functionalized MNPs 
displayed red fluorescent and could be detected by fluorescence microscopy. TR 
is the Sulforhodamine 101 chloride, a more reactive derivative of the rhodamine 
due to the presence of the -SO2Cl group. The nucleophilic -NH2 groups of Lys 
residues of the macromolecules, in fact, could easily react with the -SO2Cl 
functionality of the dye, as shown in Figure 5.3-1, leading to covalent sulfonamide 
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bonds. The reactions were performed mechanically stirring the solutions for 1 h 
in HCO3-/CO32- buffer at pH 9 in order to improve the deprotonation of -NH2 
groups. The T was maintained at 0°C to slow down the spontaneous hydrolysis of 
the -SO2Cl group to sulfonate while the reaction system was protected from light 
to avoid the dye photobleaching. 
 
Figure 5.3-1: Scheme of the labelling of poly-L-lysine and Transferrin with the dye Texas Red.  
The PLL-TR and Tf-TR conjugates were purified by gel permeation 
chromatography, as shown on the left in Figure 5.3-2, eluting the solutions on the 
Sephadex® stationary phase with H2O and selecting by UV-Vis spectroscopy the 
fractions containing the conjugate. Once purified, the conjugates PLL-TR and Tf-
TR were lyophilized obtaining spongy pink-purple compounds which were 
characterized by fluorescence spectroscopy. As shown on the right in Figure 
5.3-2, in the fluorescence spectra, recorded using λexc at 588 nm, the emission 
bands at λ= 604 nm and λ= 611 nm for PLL-TR and Tf-TR conjugates, 
respectively, belonged to the fluorescent probe. The blue-shift of the bands 
comparing to free TR (λ=615 nm) was probably related to the change in the local 
environment of the dye due to the presence of the macromolecules and it 
confirmed the success of the conjugation process.175 
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Figure 5.3-2: Left: PLL-TR purification by gel permeation chromatography. Right: Fluorescence 
spectra, recorded using λexc at 588 nm, corresponding to PLL-TR (solid line) and Tf-TR (dashed 
line) aqueous solution. The emission bands belong to the TR bound to the macromolecules.  
5.3.1.2 Anchorage on MNPs-LA-NHS 
The labelled macromolecules PLL-TR, Tf-TR and Stv-TR were conjugated on 
MNPs-LA-NHS. As shown in Figure 5.3-3, the formation of the covalent amide 
bonds was achieved by the reaction among the free deprotonated -NH2 groups of 
the Lys residues of the macromolecules and the NHS moiety of the lipoate 
anchored on the nanosystems. 
 
Figure 5.3-3: Reaction scheme of the functionalization of MNPs-LA-NHS with the labelled 
macromolecule PLL-TR, Tf-TR or Stv-TR. 
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The monitoring of the functionalization reaction of MNPs-LA-NHS was 
performed recording UV-Vis spectra of the reaction solutions before and after the 
reactions with the nanosystems, magnetically separated from the mixture. As 
shown in Figure 5.3-4 only for the reaction between MNPs-LA-NHS and PLL-
TR on representative purposes, the functionalization was confirmed; in fact, 
comparing the absorption spectra before (start - dashed line) and after (stop - solid 
line) the reaction with MNPs-LA-NHS, the decrease of the absorption band at 
λ≈590 nm, belonging to TR bound to the macromolecule, and the contemporary 
increase of that at λ=280 nm, corresponding to the free NHS released during the 
reaction, proved the conjugation.  
MNPs-PLL-TR, MNPs-Tf-TR and MNPs-Stv-TR were magnetically collected, 
washed and characterized by fluorescence spectroscopy after drying under 
vacuum. Emission bands, centred around λ=600-612 nm, were achieved for all the 
nanosystems (data not shown). 
 
 
Figure 5.3-4: UV-Vis spectra collected before (start - dashed line) and after (stop - solid line) the 
reaction between MNPs-LA-NHS and PLL-TR. The decrease in the absorption band at λ≈590 nm 
and the increase in that at λ=280 nm, belonging to TR and NHS respectively, confirmed the 
functionalization.  
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5.3.2 In vitro biological experiments on human immune cells 
In vitro biological experiments on monocyte-differentiated macrophages were 
performed in order to study the internalization of the differently functionalized 
nanosystems; the principal aim of this work was to identify the coating leading to 
the highest number of MNPs-loading cells. The achievement of a high percentage 
of MNPs-engulfed cells, in fact, is the main challenging topic in Trojan Horse 
approach since it limits the real applicability. 
5.3.2.1 THP-1 cell line: monocyte-differentiated macrophages 
Macrophages were achieved by differentiation from THP-1 cell line, derived from 
a human monocytic leukaemia.176 This cell line was selected since it can be 
considered a model of native monocyte/macrophages system and it is commonly 
used for NPs-uptake studies.177 
The differentiation was induced incubating for 48 h the monocytic cells with 
Phorbol 12-myristate 13-acetate (PMA) at nanomolar concentration in culture 
medium. As shown in Figure 5.3-5, the significant changes from the round-shaped 
monocytes to the ramified and adherent macrophages confirmed the successful of 
the differentiation. After 24 h resting, macrophages were ready to be used in 
MNPs uptake studies. 
 
Figure 5.3-5: Images of the PMA-induced differentiation of THP-1 monocytes to macrophages. 
Adherent ramified cells (right) were achieved from suspension round-shaped cells (left). 
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5.3.2.2 MNPs-internalization experiments 
Macrophages were incubated with MNPs-PLL-TR, MNPs-Tf-TR or MNPs-Stv-
TR assessing several parameters such as incubation time, culture medium and 
mood of administration of nanosystems. The incubation times were varied from 
15 min to 6 h, to obtain uptake information on short and long time. Good results 
were achieved incubating cells for 2 h, since shorter times led to low uptake while 
longer time to the worsening of cell conditions. One or several administrations of 
MNPs-macromolecules were performed; the repeated administrations slightly 
enhanced the MNPs internalization but causing higher cell stress, revealed by cell 
detachment. Incubation medium was also assessed; MNPs-macromolecules were 
dispersed in PBS buffer or in RPMI w/o PhR, complemented with 1% FBS only 
for long incubation times. The culture medium was finally preferred to maintain 
a good cell viability. Nanoparticles were administered to the cells as unfiltered or 
filtered dispersions, achieving better results in the second case; the filtration on 3 
μm filters allowed to maintain a high concentration of nanosystems removing the 
bigger aggregates which affected cell viability. 
The best results confirming the internalization of the MNPs-macromolecules were 
achieved incubating monocyte-differentiated macrophages for 2 h at 37°C in 5% 
CO2, administering the filtered dispersion of nanosystems only once. Untreated 
cells, incubated in the same conditions as the treated ones, were used as negative 
controls. Different methods or techniques were employed for the characterization 
of MNPs-engulfed macrophages. 
A simple, quick and reliable evidence of the MNPs internalization was achieved 
by Prussian Blue Staining. In this way it was possible to highlight the presence of 
iron deposits inside cells. In fact, as shown in Figure 5.3-6 for macrophages 
incubated with MNPs-Tf-TR, intracellular blue spots, absent in the control 
sample, demonstrated the presence of the nanosystems inside the cells, which 
were identified by nuclear staining with neutral red. The ferric ions of Fe3O4 core, 
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reacted with potassium ferrocyanide forming a deeply blue coloured complex 
ferric ferrocyanide known as Prussian Blue. This staining could work regardless 
of MNPs coating, since the positivity derived from the magnetic core of the 
nanosystems. 
 
Figure 5.3-6: Prussian Blue staining of monocyte-derived cells untreated (ctr on left) or incubated 
with MNPs-Tf-TR (on right). Intracellular blue spots, corresponding to ferric ferrocyanide complex, 
proved the presence of iron deposits produced by internalized nanoparticles. 
A qualitative evidence, not reported, was achieved by applying an external 
permanent magnet under the cell plates after incubating macrophages with MNPs-
macromolecules and removing the not internalized nanoparticles by several 
washings. During this experiment, some cells moved following the magnetic field 
and accumulating around the magnet. This phenomenon could be explained by the 
presence of magnetic materials inside the macrophages, corresponding to 
internalized MNPs, which acquired magnetic field responsiveness.49 
By confocal fluorescent microscopy the evidence of MNPs-macromolecules 
uptake was achieved. Fluorescence images of fixed samples of untreated cells or 
cells incubated with the differently coated nanosystems are shown in Figure 5.3-7. 
Z-stack acquisitions were performed on each sample, virtually sectioning the 
entire cell volume in planes and collecting fluorescent images from each plane. 
Here, the images corresponding to a central plane (23-27/40 planes) were 
reported. 
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The red fluorescence spots in intracellular compartments of macrophages, 
corresponding to cell samples incubated with MNPs-macromolecules, derived 
from TR conjugated to the nanosystems. Blue fluorescence, instead, derived from 
cell nuclei stained with Hoechst. According to these experimental evidences, the 
uptake of MNPs-Tf-TR, MNPs-PLL-TR and MNPs-Stv-TR was achieved, and 
the internalization occurred for all nanosystems regardless from coating. 
However, the percentage of MNPs-engulfed cells was not high, since many cells 
did not show any intracellular red-fluorescent spots. 
 
Figure 5.3-7: Fluorescence images of monocyte-differentiated macrophages incubated 2h without 
(ctr – top left) MNPs or with filtered dispersions of MNPs-Tf-TR (top right), MNPs-PLL-TR 
(bottom left) or MNPs-Stv-TR (bottom right). Cell nuclei were stained with Hoechst while the 
internalized nanoparticles were identified by red spots due to the Texas Red labelling. Images were 
collected by means of a confocal fluorescence microscope with a 100 X immersion objective. The 
images correspond to central planes (23-27/40 planes) of the z-stack acquisitions.  
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Quantitative information about the internalization process were achieved by flow 
cytometry analysis. After 2 h incubation, monocyte-differentiated macrophages 
were detached and fixed with paraformaldehyde solution at 4%, without 
performing the nuclear staining. The samples were analyzed monitoring the red-
fluorescence emission and the quantification of the MNPs-engulfed cells was 
performed comparing the data with the control cell sample. As shown in Figure 
5.3-8, the % of macrophages producing red fluorescent signals, due to internalized 
nanosystems, was estimated of 12%, 9% and 33% for MNPs-PLL-TR, MNPs-
Stv-TR and MNPs-Tf-TR, respectively. These data suggested a preferential 
uptake of MNPs-Tf-TR, although the degree of internalization for all samples was 
not very high. The preference of Tf-coated nanoparticles might be explained as 
the transferrin receptors are usually widely present on macrophage membranes, 
thus facilitating the internalization of that kind of nanosystems by receptor-
mediated endocytosis.178 The low general uptake could instead derive from 
experimental conditions that might be optimized. 
 
Figure 5.3-8: Flow cytometry analysis of monocyte-differentiated macrophages incubated 2h with 
MNPs-PLL-TR (top right), MNPs-Stv-TR (bottom left) or MNPs-Tf-TR (bottom right). The 
percentage of red-fluorescent cells, due to MNPs uptake, was quantified compared to untreated cell 
sample (CTR – top left). 
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 CHAPTER CONTRIBUTIONS 
- A study on the preferential uptake of differently coated nanosystems by 
phagocytic cells was performed by in vitro experiments incubating 
monocyte-differentiated macrophages, achieved THP-1 cell line, with 
Fe3O4@Cu@Au MNPs functionalized with the macromolecules PLL, Tf 
and Stv. By labelling the macromolecules with TR, the internalization of 
the nanosystems was confirmed by fluorescence microscopy, in addition 
to the Prussian Blue Staining used for revealing iron intracellular deposits. 
The MNPs-uptake was successfully achieved, preferentially for MNPs-
Tf-TR, leading to 33% of engulfed cells as measured by flow cytometry. 
- MNPs-Tf-TR might be promising nanosystems for cell-mediated drug 
delivery purposes based on Trojan Horse method. 
5.4.1 Future perspectives 
- Optimize the experimental conditions in order to enhance the loading and 
assess the stability, cytotoxicity and degradation of the internalized 
nanosystems. 
- Try to internalize the nanosystems into other cell lines, including native 
phagocytic cells and evaluate the response of MNPs-engulfed cells to 
external magnetic fields in order to exploit magnets for their collection 
and focusing. 
- Functionalize the MNPs-Tf nanosystems with drugs or explore other 
molecules or macromolecules more specific for activated macrophages 
and evaluate the real applicability of monocytes-derived macrophages as 
Trojan Horses for the delivery of bioactive compounds to malignant cells 
in vitro and in vivo. 
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 MATERIALS AND METHODS 
Reagents, materials and equipment: All the chemical reagents were purchased by 
Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and used without further 
purification. All the material used in in vitro biological experiments were 
purchased from Corning (Corning, USA). Sephadex G-25 fine was used as 
stationary phase in gel permeation chromatography. Permanent magnets made of 
Neodymium-Iron-Boron alloy, having a magnetic field of 0.3 T, were used for 
magnetic separations. Sonication was performed with UNISET-AC characterized 
by 45 W power and 38 KHz maximum frequency. Fluorescence spectra were 
collected by Varian Cary Eclypse spectrofluorometer, equipped with the Xe lamp. 
Prussian Blue staining images were collected by Olympus BX53 equipped with 
an 100x oil immersion objectives lens. The fluorescence confocal microscopy and 
the flow cytometer were at the Centre for Life Nanoscience IIT@Sapienza. The 
fluorescence images were collected z-stack mode acquiring 40 planes, 0.2 μm 
distant one from each other, by means of the inverted microscope Olympus X73 
equipped with 100x oil immersion objectives lens. The flow cytometer BD 
LSRFortessa® with a green laser at  532 nm (600 LP) was used for the 
quantification of the MNPs-loaded macrophages, counting ≈17000 events for 
each sample. 
5. Fe3O4@Cu@Au NANOPARTICLES COATED WITH MACROMOLECULES FOR THE 
ENGULFMENT OF HUMAN IMMUNE CELLS 
91 
 
Labelling of poly-L-Lysine and Transferrin: PLL-TR and TF-TR: 20 mg of PLL   
or Human Apo-Transferrin dissolved at the concentration of 0.1 mg/mL in 
carbonate buffer (0.1 M, pH 9) were mixed with 1 mg of TR dissolved in 50 μL 
of ACN. After 1 h stirring the reactions in dark at 0°C, the purification was 
performed by gel permeation chromatography on Sephadex® G 25-fine stationary 
phase eluting the solutions with bi-distilled H2O. Fractions containing PLL-TR or 
TF-TR, selected by UV-Vis spectra, were collected and lyophilized. Pink-purple 
products were achieved with 67 and 72% yield.  
Conjugation of the macromolecules on MNPs-LA-NHS:MNPs-PLL-TR, MNPs-
Tf-TR and MNPs-Stv-TR: 100 mg of MNPs-LA-NHS were dispersed in 10 mL of 
PLL-TR, TF-TR or STV-TR solutions at 0.5 mg/mL in bicarbonate buffer (0.1 M, 
pH 8.3). After 2h 30 min mechanically stirring the solutions at 4°C protecting 
from light, MNPs were magnetically separated and UV-Vis spectra of the 
supernatants before and after the reactions were collected. MNPs-PLL-TR, 
MNPs-Tf-TR and MNPs-Stv-TR were washed several times with bi-distilled H2O 
and dried under vacuum. 
PMA-induced differentiation of THP-1 cell line: Monocyte-differentiated 
macrophages: 106 monocytes/well of THP-1 cell line in RPMI 1640 w/o PhR, 
supplemented with 10% FBS and 1% Pen Strep, were plated in 6-wells plate and 
treated with PMA 100 ng/mL (2mL/well). After 48h incubating at 37°C and 5% 
CO2, cells were washed with PBS (3x 1mL/well) and incubated in complete RMPI 
w/o PMA. After 24h resting monocyte-differentiated macrophages were used for 
internalization experiments. 
MNPs internalization: Monocyte-differentiated macrophages were incubated with 
MNPs-PLL-TR, MNPs-Tf-TR or MNPs-Stv-TR dispersions in RPMI w/o PhR 
and w/o FBS (2 mL/well), at starting concentrations of 1 mg/mL, filtered on 3 μm 
filters. Cells incubated in the same condition w/o MNPs were used as negative 
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controls. After 2h incubating, not internalized MNPs were removed by three 
washings with PBS. 
Confocal Fluorescence Microscopy analysis: Cells were fixed for 10 min at rt 
with paraformaldehyde and sucrose solution at 4% in PBS (1mL/well). After 3 
washings with PBS, cells were treated 10 min with glycine aqueous solution (200 
mM, 1 mL/well) and, after washings with PBS, the cell nuclei were stained with 
Hoechst solution (5 μg/mL in bi-distilled H2O) for 5 min at rt. Coverslips, 
contained in each well, were mounted on slides with a glycerol solution at 90% in 
PBS and confocal fluorescence analysis were performed.  
Prussian Blue staining: After fixing cells in cooled MeOH, 2 mL of an aqueous 
solution containing potassium ferrocyanide (4%) and HCl solution (4%) were 
added to each well (1mL/well). After 15 min, three washings with bi-distilled H2O 
were performed and cell nuclei were stained for 2 min with Nuclear Red aqueous 
solution at 2%. After washings with bi-distilled H2O, coverslips were mounted on 
slides using Entellan® mounting medium and microscopic images were collected. 
Quantification of MNPs-engulfed macrophages by flow cytometry: 2 mL of 
Accutase® solution were added to each well. After incubating 20 min, detached 
cells were moved to falcon tubes and centrifuged 10 min at 1200 rpm. Pellets were 
dispersed in 200 μL of paraformaldehyde solution at 4% in PBS and flow 
cytometry analysis were performed. 
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 INTRODUCTION 
This research work is focused on the development of new nanosystems for the 
treatment of infectious diseases. The introduction of bioactive compounds, 
deriving from bacterial secondary metabolism, on the magnetite-based 
nanoparticles can lead to the achievement of multifunctional tools for fighting 
pathogenic microorganisms. Two molecules belonging to the lipodepsipeptides 
family, syringomycin E and syringopeptin 22A, have been selected as the 
antimicrobial compounds for the development of these nanosystems. This work 
has been carried out in collaboration with the research group led by Prof. Ingeborg 
Grgurina at the Department of Biochemical Sciences - Sapienza University of 
Rome. 
6.1.1 Lipodepsipeptides from Pseudomonas syringae pv. 
syringae  
Lipodepsipeptides represent a class of phytotoxic secondary metabolites produced 
by some bacteria, including the phytopathogenic Gram-negative bacteria 
Pseudomonas syringae pv syringae. These compounds act as virulence factors for 
the bacteria since they increase the disease severity in the affected plants, inducing 
cell necrosis.179 These molecules are synthesized via the non-ribosomal 
mechanism of peptide synthesis.180 A lipid tail linked to a peptide moiety is the 
general feature of a lipopeptide. The presence of a macrocycle, composed of a 
variable number of residues, closed with an ester bond characterizes the structure 
of the cyclic lipodepsipeptides produced by P.s pv. syringae.181 The peptide 
moiety contains amino acids differing from the canonical ones, modified either in 
the side chain or in the stereochemistry or both. According to the number of 
residues composing the peptide moiety, two subgroups can be distinguished. 
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Lipodepsinonapeptides present nine residues involved in the formation of the 
lactone macrocycle; they include syringomycins (SRs), syringotoxin, 
syringostatin and pseudomycin. The other group is characterized by a peptide 
moiety of 19 to 25 residues and includes syringopeptins (SPs). Most of the AA 
have hydrophobic features and the lactone macrocycle is composed of eight 
residues.180,181 
Lipodepsipeptides have attracted great interest for medical applications due to 
their high biological activity against several pathogenic and non-pathogenic 
microorganisms; particularly, these compounds have shown fungicidal and 
bactericidal activity.182 The peculiar amphiphilic character of the 
lipodepsipeptides is the basis of the antimicrobial activity since it allows the 
interaction with cell membranes; the insertion of lipopeptides into the lipid bilayer 
causes pore formation, leading consequently to membrane depolarization and cell 
death.183 The haemolytic activity of red blood cells of some of these compounds, 
especially SRs, limits the in vivo applicability; however, this phenomenon 
probably does not represent a serious health risk due to the enzymatic degradation 
of SRs during the digestive process which reduces their bloodstream 
circulation.184 
6.1.1.1 Syringomycin E 
Syringomycins belong to the cyclic lipodepsinonapeptide class since they are 
composed of a lactone macrocycle, containing nine amino acids, bound to a 
hydrophobic 3-hydoxy fatty acid. The length of the lipid tail differentiates three 
forms of SRs, named SRA1, SRE and SRG; SRE represents the most abundant 
one and it is characterized by the 3-hydroxydodecanoyl side chain bound to the 
N-terminal L-Ser residue. This AA is also involved in the macrocycle formation 
since it is linked by an ester bond with the C-terminal L-Thr(4-Cl) residue, which 
plays an important role in the biological activity, but it is sensitive to hydrolysis. 
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As shown in the SRE structure depicted in Figure 6.1-1, several D-residues and 
modified amino acids form the peptide moiety, such as the 2,4-diaminobutyric 
acid (Dab), 2,3-dehydroaminobutyric acid (z-Dhb) and L-3-hydroxyaspartic acid 
(L-Asp (3-OH)). 
 
Figure 6.1-1: Chemical structure of syringomycin E, highlighting in red the lactone. 
The antimicrobial activity of syringomycin is due to its insertion into the cell 
membrane which causes the formation of cell pores, freely permeable to 
monovalent and bivalent cations. Particularly, an increased flux of K+, H+ and Ca2+ 
has been demonstrated. This process produces both the collapse of the pH gradient 
through cell membrane and the activation of intracellular signalling pathways, 
consequently leading to cell death.185 The ion-pore forming properties of SRE are 
influenced by the amount and the type of sterols in the target membrane and they 
are triggered by the aggregation process of SRE monomers in six-membered self-
assembled structures which form the membrane channels.186 
Concerning the antimicrobial activity, SRE has shown high antifungal activity 
towards filamentous fungi, such as Geotrichum candidum, and yeasts, such as 
Rhodotorula pilimanae; it also causes growth-inhibitory effects against the 
clinically important fungi Candida spp and Aspergillus spp.187 
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6.1.1.2 Syringopeptin 22A 
Syringopeptins are characterized by a peptide moiety made up of 22 (SP22) or 25 
(SP25) amino acids, predominantly Val and Ala. The lipid tail of 3-hydroxylated 
fatty acid chain, containing 10 or 12 carbon atoms, differentiates the two forms of 
SP22, respectively referred to as A and B. In SP22A, whose structure is shown in 
Figure 6.1-2, the N-terminal residue z-Dhb is acylated by the 3-hydroxydecanoic 
acid while the C-terminal Tyr residue is involved in the formation of the eight-
membered lactone ring with a D-allo-threonine (D-a-Thr) residue. 
 
Figure 6.1-2: Structure of syringopeptin 22A highlighting the lactone in the macrocycle. 
The basic mechanism of the biological activity of SP22A is similar to that of SRE: 
the amphiphilic character of SP22A allows the insertion into the cell membrane, 
forming pores and promoting the transmembrane ionic flux, especially Ca2+, 
which causes cell death.188 SP22A displays antibiotic activity against several 
Gram-positive bacteria and fungi, for instance Bacillus megaterium and Botrytis 
cinerea, presenting some differences in the antimicrobial spectrum as compared 
to SRE. Actually, SP22A is a very interesting bioactive compound since it shows 
antimycobacterial properties inhibiting the growth of Mycobacterium smegmatis, 
which is a non-pathogenic surrogate of Mycobacterium tuberculosis.188,189 
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 CHAPTER OBJECTIVES 
The development of new tools with antimicrobial effects is always a challenge in 
the perspective of fighting pathogenic and resistant microorganisms. Due to their 
biological activities, lipodepsipeptides can be interesting compounds for this 
purpose.182 However, their chemical lability, due to the presence of the lactone 
macrocyclic moiety, and their haemolytic action have limited their medical 
applications. The immobilization of these compounds on nanoparticles could help 
to protect them and increase their stability. Moreover, the conjugation to 
nanoparticles could enhance the biological activity of antimicrobial drugs thanks 
to the physicochemical properties of nanomaterials, as already demonstrated for 
other bacterial antimicrobial peptides.190 Thus, a lower concentration of the 
bioactive molecules can be utilized, consequently reducing the side effects. 
Furthermore, the peculiar properties of MNPs make them interesting carriers of 
the antimicrobial compounds for the achievement of multitasking nanosystems. 
For instance, these nanoparticles can be used in vitro for targeting and separating 
the microorganisms while in vivo they might allow the magnetic focusing into the 
infected area, enabling the imaging and the treatment of the infection. 
For these reasons, the development of new nanosystems based on Fe3O4@SiO2 
MNPs functionalized with the two compounds, SRE and SP22A is the main aim 
of this research work. Moreover, there are no examples in the literature concerning 
the conjugation of these compounds on nanosystems, despite their interesting and 
promising biological activity. 
To perform the conjugation of SRE and SP22A exploiting their peptide moiety, 
Fe3O4@SiO2 MNPs can be first activated with the amino silane APTES and the 
polyelectrolyte poly-L-aspartic acid. The antimicrobial activity of the 
functionalized nanosystems can be estimated by preliminary in vitro growth 
inhibition assays on yeast cultures of Rhodotorula pilimanae. 
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At the same time, the internalization of the engineered nanosystems into human 
immune cells might be an interesting objective. In fact, although immune cells are 
involved in defending the organism, destroying the pathogens by engulfing them, 
several microorganisms can survive inside those cells.191 Hidden into the immune 
cells, pathogens become hard to treat by using standard therapy. The uptake of 
medicated nanoparticles inside the infected immune cells can facilitate the 
therapeutic applications, resulting a good strategy for fighting pathogens.192 In this 
context, preliminary internalization experiments on monocyte-differentiated 
macrophages of MNPs-lipopeptides can help paving the way for treating 
pathogens directly inside the cells where they are hidden. 
Figure 6.2-1 shows a schematic representation of the aims of this research work. 
 
Figure 6.2-1: Representation of the nanoparticles Fe3O4@SiO2 MNPs activated with APTES and 
poly-L-aspartic acid, functionalized with syringomycin E and syringopeptin 22A and used for in 
vitro experiments on R. pilimanae cell culture and monocyte-differentiated macrophages. 
 RESULTS AND DISCUSSION 
The design and development of new promising nanosystems based on 
Fe3O4@SiO2 MNPs for therapeutic applications towards fungal infections are 
illustrated in this section. The production of the nanosystems loading two 
bioactive molecules belonging to the lipodepsipeptide family represented the 
starting point of this research work. The in vitro biological experiments on fungal 
cell cultures and monocyte-differentiated macrophages allowed to evaluate the 
antimicrobial activity and the potential applicability of the nanosystems. 
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6.3.1 Surface activation of Fe3O4@SiO2 MNPs with APTES 
The surface of Fe3O4@SiO2 MNPs was activated with the heterobifunctional 
compound 3-aminopropyltriethoxysilane (APTES) exploiting the hard-hard 
interactions between silica shell and silicon, as already explained in section 
3.1.1.1. As shown in Figure 6.3-1, nanosystems were stirred overnight at rt in an 
aqueous-alcohol solution containing APTES using ammonia as catalyst.193 In this 
way, primary amino groups were introduced on the Fe3O4@SiO2 MNPs enabling 
the further functionalization with a polymer exploiting APTES as the linker. After 
washing with EtOH, MNPs-APTES were dried and characterized. 
 
Figure 6.3-1: Scheme of the functionalization of Fe3O4@SiO2 MNPs with APTES. 
According to the FT-IR spectrum of MNPs-APTES shown in Figure 6.3-2, 
compared to that of bare Fe3O4@SiO2 MNPs reported in Figure 3.3-12, the 
increase in the band at ν ≈ 1180 cm-1 and the presence of that at ν ≈ 660 cm-1 
confirmed the conjugation of APTES on Fe3O4@SiO2 MNPs. In fact, these 
vibrational bands were assigned to the stretching vibrations of Si-O and Si-C 
bonds, respectively. 
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Figure 6.3-2: FT-IR spectrum of MNPs-APTES in which the vibrational bands were assigned to Si-
O, Si-C and Fe-O bonds. 
6.3.2 Functionalization with poly-L-aspartic acid 
After the surface activation, MNPs-APTES were functionalized with the 
polyelectrolyte poly-L-aspartic acid (PLA). By introducing anionic groups, the 
colloidal features of the nanoparticles could be increased, enhancing their water 
dispersibility and minimizing the aggregation process among nanoparticles. 
Moreover, PLA could improve the biocompatibility and biodegradability of the 
entire nanosystem, being a low cytotoxic polymer.194,195 Compared to the 
modification with single carboxylic acid molecules, the presence of several -
COOH groups increased the numbers of suitable binding sites for the modification 
of MNPs with the bioactive molecules. The carboxyl groups could, therefore, be 
exploited for both the anchorage on nanoparticles and the functionalization with 
the lipodepsipeptides. Moreover PLA resulted an interesting polymer for 
biomedical application both as metal chelator and drug carrier, alone or in 
combination with other polymers like PEG and poly-ethylene oxide.196-198 
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As shown in Figure 6.3-3, the reaction was performed stirring the MNPs-APTES 
in PLA solution overnight at rt. The activation of the -COOH groups of PLA with 
EDC/NHS was carried out in PBS solution at slightly basic pH to improve the 
deprotonation of APTES ammine groups, thus facilitating amide bonds formation. 
 
Figure 6.3-3: Reaction scheme of the functionalization of MNPs-APTES with PLA activating the -
COOH with EDC/NHS. 
The physicochemical characterization of the MNPs-PLA was performed by means 
of FT-IR. Analysing the spectrum shown in Figure 6.3-4, in addition to the 
vibrational bands belonging to the inorganic structure of the nanosystems, those 
at ν 3270 cm-1, 1739 cm-1 and 1515 cm-1 could be assigned to the -OH and C=O 
groups of the free carboxylic groups and of the amide bonds, confirming the 
conjugation of the polymer. 
 
Figure 6.3-4: FT-IR spectrum of poly-L-aspartic acid, addressing the vibrational bands to the 
corresponding bonds. 
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6.3.3 Conjugation of syringomycin E or syringopeptin 22A 
SRE and SP22A were selected for the modification of the nanoparticles due to 
their antibiotic activities; in fact, these lipodepsipeptides could act as therapeutic 
agents for the treatment of bacterial or fungal infections. Combining these 
properties with the diagnostic tool represented by the magnetic core of the 
Fe3O4@SiO2 MNPs, multifunctional nanosystems could therefore be developed. 
SRE and SP22A were supplied by the group of Prof. Grgurina. 
The peptide moieties of both lipodepsipeptides contained basic Dab residues, that 
could be exploited for the conjugation on MNPs-PLA. Since the functionalization 
reaction should be performed at basic pH, preliminary studies were planned to 
evaluate the stability of the compounds in these experimental conditions. In fact, 
the hydrolysis of the macrocyclic lactone and/or of the L-Thr (4-Cl) residue at 
basic pH could occur, compromising the antimicrobial activity of SRE and 
SP22A.181 
6.3.3.1 Evaluation of SRE and SP22A chemical stability 
The maintenance of the cyclic structure of SRE and SP22A in conditions similar 
to the experimental ones (120 min, pH 8, T 0°C), was evaluated by means of 
circular dichroism (CD) technique. In fact, a variation of the conformation of these 
compounds, derived from the lactone hydrolysis, could cause modifications in the 
CD spectrum due to the change in the intramolecular conformational constrains. 
CD spectrum, recorded in the far-UV region, of SP22A aqueous solution 
maintained at 4°C is shown in Figure 6.3-5; it is characterized by optical bands at 
λmin 213 nm and λmax 233 nm. CD spectrum of SP22A - start (black line) 
corresponded to the starting aqueous solution of SP22A at pH 6.5. After increasing 
the pH to 8, CD spectra were recorded at times ranging from 0 min to 3 days. 
Analysing the experimental results, no significant differences could be found in 
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the CD spectra corresponding to SP22A solutions until 24h at pH 8. This result 
shows that the native conformation of SP22A in solution was maintained. Slight 
modification of the curve profile could be seen comparing the samples before 
(SP22A – start) and after (SP22A – 0 min) the pH increase; these modifications 
could be related to the change in the ionic strength 199 or to the beginning of the 
formation of tiny amounts of the open form of the peptide, confirmed by 
microbiological assays. After three days at pH 8, the CD spectrum of SP22A 
changed significantly, suggesting the opening of the lactone ring. 
 
Figure 6.3-5: CD spectra of a SP22A solution maintained at 4°C recorded before (black line) and 
after increasing the pH. Blue line corresponded to SP22A – 0 min, acquired upon the addition of the 
buffer. The other CD spectra were recorded at 30 min (green line), 60 min (red line), 90 min (purple 
line), 120 min (orange line), 24 h (light blue line) and 3 days (light green line). The slight 
modifications in the CD spectrum of SP22A at 0 min compared to the start sample were due to the 
change of solvent while the variation of the curve profile in the CD spectrum of SP22A – 3 days 
was related to the lactone hydrolysis. 
Conformational changes of SRE were evaluated in a similar way by means of CD 
spectra recorded in the far-UV region, maintaining the SRE solution at 4°C and 
increasing the pH to 8. The spectra, shown in Figure 6.3-6, were characterized by 
a broad negative band centered at λmin 230 nm, in agreement with data reported in 
the literature.200 The starting solution (pH 6.5) corresponding to sample SRE start 
produced a slightly different curve compared to those obtained after adding PBS 
buffer, due to the change of the solvent, as already reported in the literature for 
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other antimicrobial peptides.199 Until 120 min from pH modification, the CD 
spectra were all comparable, suggesting the maintenance of the native 
conformation in these experimental conditions. The SRE solution was then heated 
at 37°C to facilitate the macrocycle opening; the CD spectrum recorded after 90 
min presented significant differences in terms of intensity and λmin shift 
attributable to conformational changes caused by lactone hydrolysis. 
 
Figure 6.3-6: CD spectra of SRE solution maintained at 4°C recorded before (red line) and after 
increasing the pH. Blue line corresponded to SRE – 0 min, acquired upon the addition of the buffer. 
The other CD spectra were recorded at 60 min (green line) and 120 min (black line). The pink line 
corresponded to the SRE solution heated 90 min at 37°C (pink line). The slight modifications in the 
CD spectrum of SRE at 0 min compared to the start sample were due to the change of solvent while 
the variation of the curve profile in the CD spectrum of SRE – 90 min at 37°C was related to the 
lactone hydrolysis.   
These experimental results suggested the maintenance of the conformational 
structure of SRE and SP22A in the conditions corresponding to 120 min at pH 8 
and 0°C, planned for the conjugation reactions. However, in SRE at basic pH the 
hydrolysis of L-Thr (4-Cl) could also occur; this process could not be detected by 
CD analysis, but it could be evaluated by microbiological assays since it affected 
the antimicrobial activity of SRE, together with the lactone hydrolysis. 
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For these reasons, the further confirmation of the stability of SRE and SP22A was 
achieved by evaluating the antimicrobial effect of the solutions, used for CD 
analysis, by biological in vitro experiments on yeast cultures of R. pilimanae. 
6.3.3.2 Functionalization of nanosystems with SRE and SP22A 
The functionalization of the nanosystems was therefore carried out in a one-step 
reaction, stirring the MNPs-PLA with EDC/NHS solution, for the activation of -
COOH groups, and SRE or SP22A solution, as shown in Figure 6.3-7. The 
reactions were performed in PBS solution at pH 8, maintaining the T at 0°C for 2 
h, to allow the formation of amide bonds. The covalent bonds were formed in 
addition to the spontaneous ionic interactions occurring among negatively charged 
MNPs-PLA and positively charged lipodepsipeptides. 
 
Figure 6.3-7: Scheme of the functionalization of MNPs-PLA with SRE or SP22A activating the -
COOH groups with EDC and NHS. 
After separating the nanosystems, the solutions corresponding to the supernatants 
and the following three washings with H2O were used for the further 
quantification of the loading. The products MNPs-SRE and MNPs-SP22A were 
finally dried under vacuum. The quantification of the immobilization yields, by 
evaluating the residual amount of the lipodepsipeptides in the supernatants was 
performed by the group of Prof. Grgurina. Briefly, the supernatants were applied 
on a Sep-Pak C₁₈ Cartridge conditioned according to the manufacturer’s 
instructions. EDC and NHS were removed eluting with the mixture MeOH:H2O 
5:95 containing 0.1% TFA while the SP22A and SRE were eluted with the mixture 
acetonitrile:isopropyl alcohol 80:20 containing 0.1% TFA. Their amounts were 
estimated by means of UV-Vis spectroscopy using ε280=1280 M-1 cm-1 and 
ε240=9940 M-1 cm-1 for SP22A and SRE, respectively. The immobilization yields 
F
e
3O
4
S
iO
2
F
e
3O
4
S
iO
2
6. Fe3O4@SiO2-LIPODEPSIPEPTIDE NANOSYSTEMS WITH ANTIMICROBIAL 
ACTIVITY 
107 
 
resulted in 36.5% for MNPs-SP22A and 55% MNPs-SRE, corresponding to 36 
μg SP22A/mg of MNPs-SP22A and 18 μg SRE/mg of MNPs-SRE. 
6.3.3.3 Evaluation of the covalently and ionically bound SRE and 
SP22A 
To study the nature of the binding among the lipodepsipeptides and the 
nanosystems, MNPs-SRE and MNPs-SP22A were treated with KCl 0.2 M. In this 
way, the estimation of the amount of covalently bound and electrostatically 
interacting lipodepsipeptides can be achieved; in fact, the fraction of SRE and 
SP22A bound by ionic interactions could be detached using the high ionic strength 
solution. After the treatment, MNPs-SRE and MNPs-SP22A were separated and 
the lipodepsipeptides present in the supernatants were quantified by UV-Vis 
spectroscopy, as previously described. The ionically bound amount was estimated 
of 1% and 25% for SP22A and SRE respectively. 
6.3.4 In vitro growth inhibition assays on R. pilimanae 
The antimicrobial effects of MNPs-SRE and MNPs-SP22A were evaluated by in 
vitro growth inhibition assays on R. pilimanae cell cultures. This yeast is 
commonly used to assess the antifungal activity of the compounds since it is a 
non-pathogenic microorganism easily to growth. The experiments, performed by 
the group of Prof. Grgurina, were carried out plating the yeast in Petri dishes 
covered by PDA medium. The plates were treated with serial 1:1 dilutions of SRE 
or SP22A, free or bound to the nanosystems, or of MNPs-PLA and the yeast 
cultures were growth for 48 h at 25°C. For the assays, concentrations of free 
antibiotic compounds comparable to those of SRE and SP22A bound to the 
nanosystems, quantified as described in section 6.3.3.2, were used. Moreover, 
calibration curves correlating the diameter of the inhibition halos with the 
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concentration of free SRE and SP22A were used for estimating the antibiotic 
activity of the nanosystems.  
The results of the growth inhibition assays on R. pilimanae are shown in Figure 
6.3-8. The bare nanoparticles MNPs-PLA did not produce any antimicrobial effect 
on yeast growth, proving the biocompatibility of these nanosystems. The dilutions 
of free SRE and free SP22A caused growth inhibition and also MNPs-SRE and 
MNPs-SP22A inhibited yeast growth, especially the first nanosystem. In fact, 
around the deposition points of free compounds or nanoparticles, yeast colonies 
were not able to growth, as demonstrated by the presence of inhibition halos. Since 
the absence of antimicrobial effects of MNPs-PLA, the antibiotic activity of 
MNPs-SRE and MNPs-SP22A could only be derived from the bound 
lipodepsipeptides. These experimental evidences, on one hand, confirmed the 
success of the functionalization process of the nanosystems and, on the other hand, 
proved their antifungal activity.  
Comparing the inhibition halos produced by MNPs-SRE with those of free SRE, 
an improvement in the antifungal activity was achieved after immobilization; in 
fact, serial dilutions of MNPs-SRE, up to the ninth one, caused growth inhibition 
while the free SRE displayed antimicrobial activity up to the seventh serial 
dilution. Once bound to the nanoparticles the antibiotic activity of SRE was three 
times increased. This evidence agreed with the already reported in vitro 
enhancement of the biological effects for other bacterial antimicrobial peptides 
after conjugation on nanoparticles, for instance vancomycin.190 In fact, the 
extended surface area of NPs allowed to concentrate the bioactive molecules, 
increasing its local amount, which could act in a more effective way, resulting in 
the enhancement of the antimicrobial activity compared to the free compound. 
Concerning MNPs-SP22A, the antimicrobial activity on R. pilimanae was not so 
evident as for MNPs-SRE, since only the most concentrated solution, deposited 
on the point M in the plate, produced growth inhibition effects. Compared to free 
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SP22A, the immobilization did not improve the antimicrobial activity of the 
lipodepsipeptide. However, preliminary results on liquid cultures of Candida 
albicans confirmed good antifungal activity of MNPs-SP22A; in fact, the 
estimated minimum inhibitory concentration (MIC) values were 8 μM and 32 μM 
for MNPs-SP22A and SP22A respectively.  
 
Figure 6.3-8: Growth inhibition assays on R. pilimanae. Free SRE and SP22A and the nanosystems 
MNPs-PLA, MNPs-SRE and MNPs-SP22A were tested, incubating the plates for 48 h at 25°C. The 
numbered points correspond to serial dilutions of the free or MNPs-bound compounds (decreasing 
concentration from 1 to 10 for SRE or from M to IV for SP22A). Inhibition halos were clearly visible 
in the plates treated with SRE, SP22A and MNPs-SRE. For MNPs-SP22A only the most 
concentrated solution (M) had growth-inhibitory effects while MNPs-PLA were not cytotoxic. 
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Supernatants and washings, collected during the functionalization reactions, were 
also assessed by microbiological assays on R. pilimanae. The results confirmed 
the presence of unreacted bioactive molecules in the reaction supernatants and 
their absence in the washing solutions; in fact, the first produced yeast growth 
inhibition, while the second did not show antimicrobial effects.  
The antifungal activity of MNPs-SRE could derive from lipodepsipeptide both 
ionically interacting and covalently bound to MNPs-PLA. After the detachment 
of the ionically bound SRE treating the nanosystems with KCl solution, the 
MNPs-SRE were still active. Even if covalent functionalization ensured higher 
stability to the nanosystems, avoiding the undesired release of the bioactive 
molecules in physiological environment, the ionically interacting fraction could 
be more easily accessible; this binding, in fact, could provide the compound 
readily available for the interactions with membranes, allowing a more effective 
performance of the antimicrobial activity. 
Therefore, MNPs-SRE and MNPs-SP22A showed interesting antimicrobial 
activity paving the way to new promising nanosystems for the treatment of fungal 
infections. According to the biological effects of SRE and SP22A against other 
microorganisms, in addition to the imaging properties of the magnetite core, those 
nanosystems might be suitable for both diagnosis and treatment of other kinds of 
infection diseases, involving for instance bacteria or mycobacteria. 
6.3.5 In vitro internalization in human immune cells 
Considering that MNPs-SP22A displayed antifungal activity it was reasonable to 
hypothesize that the applicability of these bioactive nanosystems could be 
extended to other microorganisms, including pathogenic ones. Since some 
microorganisms, once phagocyted by immune cells like macrophages, are able to 
survive inside them in a latent state, the internalization of medicated nanoparticles 
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into the infected cells could allow in loco therapeutic treatments.191,201 The uptake 
of the nanosystems loading antimicrobial drugs by immune cells might, in fact, 
lead to the intracellular co-localization of the therapeutic tool and the pathogens, 
enabling their treatment where they are safely hidden. In this context, some studies 
on medicated nanoparticles performing a therapeutic action into infected immune 
cells can be found in the literature; particularly, the examples concern 
nanosystems functionalized with commercially available antimycobacterial drugs 
internalized into M. tuberculosis-infected macrophages.192,202 
For these reasons, studies on the internalization of the MNPs-SP22A nanosystems 
into human immune cells were performed. These internalization experiments were 
carried out on monocyte-differentiated macrophages starting from THP-1 cell 
line, using the differentiation protocol already reported in 5.3.2.1. To reveal the 
nanoparticles during the in vitro experiments, the labelling with a fluorescent 
probe was first accomplished.  
6.3.5.1 Labelling of MNPs-PLA with Texas Red-cadaverine 
The polyelectrolyte PLA was labelled with a derivative compound of TR 
presenting a cadaverine moiety which enabled the formation of covalent amide 
bonds. The reaction, shown in Figure 6.3-9, was carried out for 1 h at rt, stirring 
the MNPs-PLA in a fluorescent probe solution using the carbodiimide chemistry. 
The conjugation of the dye to the nanoparticles conferred them red fluorescence, 
as confirmed by the spectrofluorometric analysis of MNPs-PLA-TR which 
exhibited an emission band centred at λ=608 nm. 
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Figure 6.3-9: Reaction scheme of the labelling of MNPs-PLA with Texas Red-cadaverine. 
After the labelling, SP22A was conjugated on MNPs-PLA-TR following the 
protocol previously described in section 6.3.3.2. SP22A was selected instead of 
SRE for its well-known cytotoxic effect towards M. smegmatis, belonging to 
Mycobacteriaceae family. This group contains several pathogens hard to treat, 
particularly M. tuberculosis which is able to hide and survive inside macrophages. 
6.3.5.2 Internalization in monocyte-differentiated macrophages 
In vitro biological experiments were performed to demonstrate the uptake of 
MNPs-PLA-TR and MNPs-SP22A-TR by monocyte-differentiated macrophages. 
THP-1 cell line was first differentiated treating the monocytes with PMA, as 
described in section 5.3.2.1. The macrophages were then incubated for 2 h at 37°C 
with dispersions of MNPs-PLA-TR or MNPs-PLA-SP22A-TR, filtered on 3 μm 
filters. The filtration was performed in order to remove big aggregates of 
nanosystems which can endanger cell vitality. Untreated cells, maintained in the 
same experimental conditions, were used as negative control. After incubation, 
cells were washed several times with buffer solution and fixed with 
paraformaldehyde solution. After staining cell nuclei, cells were analysed by 
confocal fluorescence microscopy.  
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The fluorescence images of cell samples are shown in Figure 6.3-10. Cells were 
identified by the nuclear blue staining with Hoechst, while nanosystems by the 
red spots deriving from TR conjugated to PLA. Comparing the images with 
control sample, it was possible to confirm that macrophages internalized MNPs-
PLA-TR and MNPs-PLA-SP22A-TR since in both cell samples red fluorescent 
spots were detected. The intracellular localization of the nanosystems was 
confirmed by z-stack acquisition. According to the experimental evidences, the 
cells treated with MNPs-PLA-SP22A-TR showed red-fluorescence emission 
higher than macrophages incubated with MNPs-PLA-TR; several explanations 
could justify this result. For instance, a higher internalization of the 
lipodepsipeptide-functionalized MNPs could have happened, facilitated by the 
interactions between cell membrane and SP22A. Otherwise, the presence of the 
bioactive molecule could have increased the basal autofluorescence emission of 
the immune cells, triggering some metabolic pathways. However, the phenomena 
explaining this significant fluorescent enhancement need to be further 
investigated, evaluating the effect of free SP22A on the same cells. 
 
Figure 6.3-10: Fluorescence images of monocyte-differentiated macrophages untreated (CTR, left) 
and treated with MNPs-PLA-TR (center) or MNPs-PLA-SP22A-TR (right) for 2 h at 37°C. Blue 
spots corresponded to cell nuclei stained with Hoechst, while intracellular red spots derived from 
TR of internalized MNPs. Images were collected by means of a confocal fluorescence microscope 
with a 100x oil immersion objectives lens. The images correspond to central planes (20-25/40 
planes) of the z-stack acquisitions. 
The successful internalization of nanosystems loading the antimicrobial 
compound SP22A into human immune cells could help developing new and 
efficient strategies for the in loco treatment of pathogens.   
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 CHAPTER CONTRIBUTIONS 
- Nanosystems loading the lipodepsipeptide SRE and SP22A were 
developed for the first time, conjugating the bioactive molecules to 
Fe3O4@SiO2 MNPs activated with APTES and PLA.  
- The immobilization of SRE and SP22A did not cause the loss of their 
biological activity since the MNPs-SRE and MNPs-SP22A produced 
growth inhibitory effects on R. pilimanae cell cultures; actually, the 
immobilization of SRE on MNPs-PLA increased three-times the 
antimicrobial activity, compared to free SRE.  
- MNPs- SP22A labelled with the fluorescent probe TR-cadaverine were 
internalized by monocyte-differentiated macrophages, paving the way to 
promising treatments with medicated nanoparticles against pathogens 
directly inside cells. 
6.4.1 Future perspectives  
- Evaluate the antimicrobial activity of MNPs-SRE and MNPs-SP22A 
against other microorganisms, such as pathogenic bacteria, to extend the 
applicability of these novel nanosystems. Estimate the MIC values by 
microbiological assays in liquid batch cultures. 
- Perform internalization experiments of MNPs-SP22A and free SP22A by 
monocyte-differentiated macrophages to understand the internalization 
mechanisms and evaluate the release/degradation of the nanosystems 
inside the cells.  
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 MATERIALS AND METHODS 
Reagents, materials and equipment: All the chemical reagents were purchased by 
Sigma-Aldrich (Merck KGaA, Germany) and used without further purification. 
All the material used during in vitro biological experiments were purchased from 
Corning (Corning, USA). Permanent magnets made of Neodymium-Iron-Boron 
alloy, having a magnetic field of 0.3 T, were used for magnetic separations. The 
spectropolarimeter Jasco J715 was utilized for the circular dichroism experiments, 
using Suprasil® quartz cell for kinetic measurement and acquiring the spectra with 
Spectra ManagerTM software. Steady-state fluorescence spectra were collected by 
Cary Eclypse (Varian) spectrofluorometer, equipped with the Xe lamp using 
Suprasil® quartz cell. Sep-Pak C₁₈ Cartridge  was supplied by Waters (USA). The 
experimental data were elaborated with the software Kaleidagraph (Synergy 
Software, USA). The fluorescence confocal analysis was performed at the Centre 
for Life Nanoscience IIT@Sapienza by means of the inverted microscope 
Olympus X73 equipped with 100X oil immersion objectives lens. The 
fluorescence images were collected by z-stack mode acquiring 40 planes divided 
by 0.2 μm, and were elaborated by ImageJ software. 
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Surface activation with APTES: MNPs-APTES: 400 mg of Fe3O4@SiO2 MNPs 
were dispersed in 16 mL of bi-distilled H2O and 40 mL of EtOH dissolving 4 mL 
of APTES (17 mmol) and 40 μL of NH4OH were added to the dispersion. The 
mixture was mechanically stirred overnight at rt. MNPs-APTES were 
magnetically separated, washed with EtOH and H2O and dried under vacuum. 
Conjugation of PLA:MNPs-PLA: 400 mg of MNPs-APTES were dispersed in 20 
mL of PBS (0.1 M pH 8). 20 mg of PLA were dissolved in NaOH and diluted to 
10 mL with PBS  (0.1 M pH 6) containing EDC (0.3 mmol) and NHS (0.3 mmol). 
The reaction was mechanically stirred overnight at rt. MNPs-PLA were 
magnetically separated, washed with H2O and dried under vacuum. 
CD studies on SRE and SP22A: CD spectrum of 1 mL of an aqueous solution of 
SP22A (0.36 mg/mL in bi-distilled H2O) at 4°C. After mixing with 1 mL of PBS 
(0.2 M pH 8) CD spectra were recorded in the far-UV range at time ranging from 
0 min to 3 days maintaining the solution at 4°C.  
CD analysis of 1 mL of an aqueous solution of SRE (0.125 mg/mL in bi-distilled 
H2O) at 4°C was performed. After the dilution with 1 mL of PBS (0.2 M pH 8) 
CD spectra were recorded in the far-UV range at time ranging from 0 min to 2 h 
maintaining the solution at 4°C. The solution was then heated at 37°C and after 
90 min a CD spectrum was recorded.  
Conjugation of SRE or SP22A: MNPs-SRE and MNPs-SP22A: 40 mg of MNPs-
PLA were dispersed in 2.4 mL of PBS (0.2 M pH 8) dissolving EDC (4.6* 10-5 
mol) and NHS (4.6* 10-5 mol). 2.4 mL of an aqueous solution of SRE (1.2 mg) 
were added to the dispersion and the mixture was mechanically stirred for 2 h at 
0°C. After magnetic separation, 3 washings with bi-distilled H2O were performed 
(1 mL each) and the MNPs-PLA-SRE were finally dried under vacuum.  
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The same protocol was used for the conjugation of SP22A, dispersing the MNPs-
PLA in 1.5 mL of PBS containing EDC/NHS and adding 1.5 mL of the SP22A (4 
mg) aqueous solution. 
Quantification of SRE or SP22A on MNPs-SRE and MNPs-SP22A: Sep-Pak C₁₈ 
Cartridge was used for the chromatographic purification of the supernatants of the 
functionalization reaction of MNPs-PLA with SRE or SP22A. The cartridge was 
conditioned with MeOH:H2O 90:10 containing 0.1% TFA (9 mL) and then 
equilibrated with H2O + 0.1% TFA solution (3x6 mL). The supernatants (3 
aliquots of 1mL) were eluted with the desalting solution (MeOH:H2O 5:95 
containing 0.1% TFA, 3x3 mL) to remove EDC and NHS while the 
lipodepsipeptides were eluted with the solvent mixture ACN:isopropanol 80:20 
containing 0.1% TFA (3x3 mL). The quantification of the lipodepsipeptides 
present in the eluted fractions was performed by UV-Vis spectroscopy using 
ε280=1280 M-1 cm-1 and ε240=9940 M-1 cm-1 for SP22A and SRE, respectively. 
Treatment with KCl solution: 11 mg of MNPs-SP22A or MNPs-SRE were treated 
for 5 min with 800 μL of KCl 0.2 M and centrifuged for 15 min at 14 000 rpm at 
4°C, repeating three times the procedure. The ionically bound SP22A or SRE were 
quantified in the supernatants by UV-Vis spectroscopy using ε280=1280 M-1 cm-1 
and ε240=9940 M-1 cm-1 for SP22A and SRE, respectively. 
Labelling with Texas Red-cadaverine: MNPs-PLA-TR: 100 mg of MNPs-PLA 
were stirred for 30 min at rt in 5 mL of PBS (0.1 M pH 6) dissolving EDC (8.7* 
10-5 mol) and NHS (8.7* 10-5 mol). After magnetic separation the supernatant was 
removed and replaced by 5 mL of PBS (0.1 M, pH 8) containing TR-cadaverine 
(7.2*10-7 mol in 100 μL ACN). After 1h stirring at rt in dark, the MNPs-PLA-TR 
were magnetically collected, washed first with DMF and then several times with 
bi-distilled H2O and dried under vacuum.  
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PMA-induced differentiation of THP-1 cell line: the same protocol reported in 
section 5.6 was used to obtain adherent macrophages. 
MNPs internalization: Monocyte-differentiated macrophages were incubated with 
MNPs-PLA-TR and MNPs-PLA-SP22A-TR dispersions in PBS at starting 
concentrations of 1 mg/mL, filtered on 3 μm filters. Cells incubated in the same 
condition w/o MNPs were used as negative controls. After incubating 2 h at 37°C, 
not internalized MNPs were removed by three washings with PBS. Cells were 
fixed for 10 min at rt with paraformaldehyde and sucrose solution at 4% in PBS 
(500 μL/well). After 3 washings with PBS, cells were treated 10 min with glycine 
aqueous solution (200 mM, 500 μL/well) and, after washings with PBS, cell nuclei 
were stained with Hoechst solution (5 μg/mL in bi-distilled H2O) for 5 min at rt. 
Coverslips, present in each well, were mounted on slides with a glycerol solution 
(90% in PBS) and confocal fluorescence analysis was performed. 
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 INTRODUCTION 
This chapter is focused on the development of in vitro diagnostic applications of  
magnetic nanosystems based on Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 MNPs 
for the detection of epinephrine. This research work was carried out in the 
Nanobiotechnology for Diagnostics group (Nb4D) at IQAC-CSIC in Barcelona, 
led by Prof. M.-Pilar Marco. 
7.1.1 Epinephrine 
Epinephrine (EPI), also known as (-)-epinephrine or adrenaline, is a 
neurohormone that belongs to the catecholamine family, including also other 
important neurotransmitters such as dopamine and norepinephrine (NorEPI). 
Structurally, EPI presents a catechol moiety and a N-methylaminoethanol system, 
as shown in  Figure 7.1-1. 
 
Figure 7.1-1: Chemical structure of epinephrine, highlighting the catechol moiety. 
EPI is considered both a hormone and a neurotransmitter since it is a biogenic 
monoamine produced by the neuroendocrine cells in the adrenal medulla - 
chromaffin cells - and by certain neurons of the central nervous system, that have 
a primary role in the sympathetic nervous system.203 Only the natural L-isomer is 
biologically fully active. Concerning its physicochemical properties, EPI is 
sensitive to light, high pH and heat; in fact, the first parameters causes its oxidation 
and degradation while high temperature produces racemization.204  
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The biosynthesis of EPI, as shown in Figure 7.1-2, starts from L-tyrosine and 
involves a series of enzymatic reactions and cofactors, that leads to the formation 
of the intermediate products L-DOPA, dopamine and NorEPI. The first step 
concerns the insertion of an -OH group into the aromatic ring to generate the 
catechol moiety and it is catalysed by the enzyme tyrosine hydroxylase. This 
reaction represents the rate limiting step because TH can be regulated by 
phosphorylation and by a feedback inhibition process of the final catecholamines.  
 
Figure 7.1-2: Epinephrine biosynthetic pathway. 
Once EPI has been synthesized, it is stored in special granular structures in the 
chromaffin cells containing high amount of ATP or in dense core vesicles in nerve 
terminals and it is released after many physiological stimulations. EPI acts as a 
cellular messenger, circulating in the blood in free state, conjugated as sulphate or 
glucuronide or combined with albumin, and causes a wide variety of biological 
effects. Binding to its specific adrenergic receptors, situated in almost all body 
tissues and classified as α- and β- receptors depending on their localization, EPI 
can affect many metabolic pathways, particularly those related to lipid and 
glycogen. It can also act on blood pressure, smooth and skeletal muscle, peripheral 
nerves and hormone release. Moreover, its release controls the physiological 
reaction known as “fight-or-flight” response. EPI has a half-life of few minutes 
and it is metabolized by methylation or deamination through two major pathways 
involving the enzymes monoamine oxidase or catechol-O-methyltransferase. Its 
metabolites, vanillylmandelic acid, metadrenaline and vanillic acid, are excreted 
in urine and are often used as markers of alterations in catecholamine production 
caused by some pathologies.203,205 
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7.1.1.1 Clinical importance of epinephrine 
Many diseases and altered physiological conditions are associated with elevated 
excretion of catecholamines, including EPI. It is known that the production of EPI 
increases in stressful conditions and, for this reason, it has been termed as an 
“emergency” hormone and it can be used for monitoring the stress level of a 
patient.  
Several important diseases are correlated with alterations in EPI levels in 
biological fluids; the normal endogenous levels of EPI for healthy people are very 
low, <0.5 nM (100 pg/mL) in plasma and <190 nmol/day in 24h-urine.206-208 
Variations in its concentrations are caused by many factors such as, for instance, 
stress, exercise, smoking, pain and hypertension. The measurement of adrenaline 
levels is very helpful for the diagnosis of some pathologies, particularly 
catecholamine-secreting tumours. In fact, pheochromocytoma, paraganglioma, 
ganglioneuroma and neuroblastoma are tumours of the adrenal medulla normally 
associated with hyperproduction and excess of catecholamines in plasma and 
urine, including EPI and its metabolites. Some of these tumours are malignant and 
can lead to death, especially neuroblastoma for childhood.209 The determination 
of biological levels of catecholamines, including EPI, is also important for the 
diagnosis of some neurodegenerative diseases, particularly Parkinson’s disease, 
or mental disorders. Moreover, elevated excretion of EPI is associated with 
cardiovascular disease, for instance hypertension that can be related to the 
presence of pheochromocytoma. EPI has also an important role as drug; in fact, it 
is normally used to treat anaphylaxis and cardiac arrest.207 
Since EPI triggers a variety of biological effects on all the body tissues and is 
involved in some important pathologies, its quantitative determination in 
biological fluids, such as plasma and urine, has become very important for clinical 
diagnosis. 
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7.1.1.2 Detection methods for EPI in the literature 
Due to the low concentration of EPI in biological fluids, very sensitive analytical 
methods are required for its detection. Chromatographic techniques are the most 
sensitive techniques since high-performance liquid chromatography (HPLC) with 
electrochemical or fluorescence detection or HPLC coupled to tandem mass 
spectrometry (LC-MS/MS) can reach limit of detection (LOD) values ranging 
from pM to nM.207,210,211 Electrochemical methods are mainly used for the 
detection of EPI thanks to the possibility of exploiting the electroactive behaviour 
of the catecholamine at certain potentials.212 One limitation of this kind of readout 
is the presence of other compounds interfering during the detection process, 
especially ascorbic acid or drugs, such as paracetamol. Modifications of the 
electrode can improve the sensitivity of the electrochemical detection achieving 
LOD values ranging from nM to μM.213 
For these reasons, sample pre-treatments, pre-concentration or derivatization are 
often needed. Liquid-liquid or solid-phase extractions with C18 column or 
Sephadex® G-10, cation-exchange resin and alumina are some of the techniques 
used for non-selective preparation of the sample.207,214 More selective strategies 
concern the use of boronated gels or other platforms immobilizing boronic acid 
since this compound is able to form a stable complex with the catechol moiety of 
the catecholamines, allowing their almost selective extraction. Biosensors, 
especially based on amperometric detection, are also used for the detection of EPI; 
the immobilization of one or more enzymes able to oxidize the analyte - such as 
Horseradish Peroxidase (HRP) - and amplify the signal are used for the 
quantification of the analyte, leading to LOD values of few μM.215 
Improvements in pre-treatment steps or in the detection methods are coming from 
nanotechnology. Some examples have been reported in the literature. 
Derivatization or modification of common measurement electrodes with 
nanomaterials, like noble metal nanoparticles or carbon nanotubes, are improving 
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the sensitivity of electrochemical detection, leading to LOD around 2-5 µM.216,217 
The use of functionalized nanoparticles for rapid and more selective extraction of 
the analyte has also been studied; for instance, MNPs modified with boronic acid 
derivatives are interesting tools to help the selective extraction process, achieving 
LOD around few ng/mL.218,219 A more recent example concerns the use of 
magnetic nanoparticles functionalized with supramolecular molecules that could 
be used for loading EPI.220 Also fluorescence detection of EPI can be more easily 
achieved using nanosystems; for instance, the quantification can be carried out 
monitoring the inhibition of the Fe3O4 nanoparticle-mediated production of a 
fluorescent compound in the presence of the analyte, leading to LOD values of 
few nM.221 
7.1.2 Immunoassays and immunosensors 
An immunochemical technique is based on the specific recognition phenomena 
between an antibody and an epitope, due to high chemical affinity that leads to the 
binding process. Usually, labels are needed in order to detect and monitor the 
immunochemical interaction, except for some label-free biosensors based on 
surface plasmon resonance (SPR) or impedance.222,223 Chemiluminescent, 
fluorescent or enzymatic labels, like HRP or alkaline phosphatase, are the most 
common tools for revealing the antibody-epitope affinity. Among these 
bioanalytical methods, the ELISA and the immunosensors are widely used.  
Concerning immunosensors, they are compact analytical devices in which the 
immunochemical interaction is detected and converted to an electrical signal by 
means of a transducer.224 According to the sensing principle, the immunosensors 
can be distinguished in electrochemical, optical or piezoelectrical ones. In fact, 
the antibody-epitope binding can produce electroactive species or changes in the 
optical properties or in the total mass of the system; by means of a proper 
transducer, all these signals are finally converted in electric ones.  
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Among the electrochemical immunosensors, the amperometric ones are based on 
the measurements of current generated by electrochemical reaction and are 
promising tools for the detection and quantification of several kinds of 
analytes.225,226 A common kind of amperometric immunosensor is based on an 
ELISA approach and utilizes screen-printed electrodes as the electrochemical 
system; the Ab is generally immobilized on the electrode or on another platform 
but maintained in intimate contact with the electrode. Due to the immunochemical 
reaction, electroactive species are produced, and the electric signal can be 
measured by amperometry.227 Among the optical immunosensors, instead, those 
based on the SPR phenomenon are considered sensitive and powerful devices.228  
Both label-free and labelled immunochemical methods usually rely on different 
formats depending on the molecular weight of the target. The most common 
configurations for ELISAs or other immunochemical techniques, such as 
electrochemical or optical immunosensors, are shown in Figure 7.1-3 from ref. 229. 
The final measurable signal can be detected by different methods.  
 
Figure 7.1-3 Schematic representation of the most common ELISA formats. Competitive indirect 
assay: the antigen, immobilized on the assay plate, competes with the free analyte for the binding 
site of the antibody. Adding the labelled secondary antibody, the spectrophotometric or 
electrochemical signal can be measured. Competitive direct assay: the immobilized antibody can 
recognize and bind the analyte or the enzymatic tracer competitor, which can catalyse the reaction 
of the substrate, giving the measurable signal. Sandwich assay: the analyte, presenting at least two 
epitopes, can be detected by a couple of antibodies, the capture one and the detection one, which 
produces the measurable signal 229. 
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Kinds of immunochemical assay: 
1. For high molecular weight analytes, like proteins or whole bacteria, sandwich 
ELISA format is the most commonly used. Since the analyte presents at least two 
different epitopes and its dimensions are quite big, the detection can be achieved 
using a couple of antibodies: the capture antibody that is immobilized on the plate, 
and the detection antibody, that is added free in solution and produces the 
measurable signal proportional to the amount of the analyte, allowing its 
quantification.  
2. For low molecular weight analytes, such as EPI, the sandwich format cannot be 
used. The detection can be achieved only using another molecule bigger than the 
analyte, that competes with it for the binding site of the antibody. Due to the 
presence of the competitor (generally named antigen (Ag)), that is usually a 
bioconjugate formed by a hapten and a protein, these immunochemical assays are 
referred to as competitive assays. Generally, a hapten can be defined as a small 
and not immunogenic molecule, with physicochemical properties similar to the 
target analyte, which can be bound to a different carrier protein according to the 
purpose.  For the immunization step, highly immunogenic proteins like Keyhole 
Limpet hemocyanin (KLH) or Horseshoe Crab hemocyanin (HCH) are selected, 
while for the development of the immunochemical assays, other macromolecules 
such as proteins, polymers and enzymes are generally used.  
The competitive immunoassays can be divided in direct and indirect formats. In 
the first one the competitor is a hapten covalently attached to a label, referred to 
as tracer, able to produce the signal. The indirect competitive assay requires the 
addition of a labelled secondary antibody, specific for the constant fraction of the 
primary antibody that produces the measurable signal.  
Therefore, in the direct format the signal derives from the tracer while in the 
indirect one it is produced by the labelled secondary antibody. For these reasons, 
in both direct and indirect competitive immunochemical assays, the signal is 
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inversely proportional to the concentration of the analyte. This occurs because the 
analyte and the antigen compete for the binding site of the antibody, depending 
on their affinity constants (Kaff). The difference between the Kaff value of the 
analyte and the competitor determines the preferential formation of the analyte-
antibody or competitor-antibody complex. Kaff-analyte much higher than Kaff-competitor 
means low amount of antibody binding the competitor and finally producing the 
measurable signal. For this reason, it is important to design and use competitors 
having Kaff similar to that of the analyte, in order to ensure a good competition 
between the Ag and the analyte, obtaining a significant signal.  
The representation of the logarithm of the analyte concentration in front of the 
signal gives the typical sigmoidal curve of a competitive assay, as reported in 
Figure 7.1-4. Fitting the curve with a four-parameters equation, the analytical 
features of the immunochemical assay are obtained. 
 
Figure 7.1-4: Inhibition curve typical of both direct and indirect competitive ELISA assays, 
measured by spectrophotometric (left side) or amperometric (right) techniques. In the curve fitting 
equation, the four parameters are IC50 (half maximal inhibitory concentration), Ymax (maximum 
value of absorbance or current), Ymin (minimum value of absorbance or current) and hillslope (slope 
of the linear part of the curve). 
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7.1.2.1 Immunochemical methods involving magnetic nanoparticles 
Nanotechnology can bring improvements in the analytical features of 
immunochemical methods and practical advantages in the correlated experimental 
protocols too. The introduction of nanotechnology in bioanalytical techniques, in 
fact, can be very helpful to improve the reliability and the selectivity of 
immunoassays in the detection of some analytes, particularly those characterized 
by low molecular weight.230 Using NPs, the performances of immunochemical 
devices can be enhanced thanks to the peculiar physicochemical features of 
nanomaterials. For instance, the high surface area can lead to the achievement of 
nanoplatforms with a high local quantity of biomolecules, such as antibodies, 
increasing the interactions with the analyte and facilitating the biorecognition 
process.  
Among nanosystems exploitable in immunochemical assays, MNPs have received 
great attentions.231 In fact, functionalizing MNPs with an antibody that 
specifically recognize an analyte might be a good idea to obtain a nanoplatform 
able to perform both the detection and the separation of the analyte from the 
matrix. The specific biorecognition element, as the antibody is, can be combined 
to the magnetic core of the nanosystems; after the analyte-antibody interaction, 
the application of the external magnetic field can lead to the separation and 
concentration of the target analyte. As reported in the literature, magnetic 
nanosystems have been used in immunochemical biosensors and assays for the 
detection of different kinds of analytes such as proteins, bacterial epitopes, viral 
antigens and small analytes like toxins, vitamins, biomarkers or drugs in complex 
matrices.65,228,232,233 
For the immunochemical methods based on MNPs for the detection of small 
analytes the direct competitive format is easier to perform. As shown in Figure 
7.1-5, the experimental procedure consists in mixing the MNPs functionalized 
with the appropriate specific Ab with the analyte and the enzymatic tracer. After 
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each step of the assay, the separation of the nanosystems can be achieved applying 
an external magnetic field. 
 
Figure 7.1-5: Scheme of the format of a direct competitive immunochemical assay based on 
antibody-functionalized magnetic nanoparticles. The nanosystems are separated after each step of 
the assay applying a permanent magnet. 
In a magneto-ELISA format, the spectrophotometric detection can be achieved 
measuring the colorimetric signal produced in each well of the plate after 30 min 
MNPs and substrate solution reacting, separating magnetically the nanosystems. 
Concerning an amperometric magneto-immunosensor, instead, the electric signal 
can be obtained in few minutes; in fact, after depositing the MNPs on an electrode 
and holding them by means of a permanent magnet, a constant voltage (V) can be 
applied and the reduction current at a fixed time for all the samples can be 
measured immediately after the addition of the substrate solution. The inhibition 
curves achieved in these methods involving MNPs are the same as in the ELISA 
standard configurations, previously reported in Figure 7.1-4. 
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7.1.2.2 Available immunoassays for EPI 
Immunochemical assays for the detection of EPI are not the most commonly used 
methods and are low discussed in the literature. Notwithstanding, many ELISA 
kits are commercially available for the determination of EPI alone or in 
combination with NorEPI. These competitive immunochemical assays are based 
on rabbit-antibodies recognizing the N-acyl derivative of EPI; therefore, the 
analyte needs to be first extracted using a cis-diol-specific affinity gel, then 
acylated to N-acyl adrenaline and finally enzymatically converted into N-acyl 
metanephrine. Although these assays are very sensitive, achieving for instance for 
Abnova EPI ELISA Kit (KA1882) LOD values < 1 ng/mL in urine and 0.01 
pg/mL in plasma, they require a complex sample treatment. 
Another example of commercially available ELISA kit (CatCombi ELISA – IBL 
International) is based on a sandwich format (rabbit anti-N-acyl metanephrine and 
alkaline phosphatase labelled antibody against biotin) able to detect both 
adrenaline and noradrenaline, after derivatization and biotinylating steps 
(sensitivity 0.3 ng/mL).234  
It is described in the literature a patent concerning an immunochemical assay for 
the detection of EPI and NorEPI; it is based on an oxidation procedure converting 
the analytes into compounds that are not bound by the antibody. Therefore, the 
quantification can be achieved performing the immunoassay before and after the 
oxidation reaction.235  
Immunochemical methods for EPI offer advantages compared to standard 
chromatographic techniques; they are easier to perform and more accessible to the 
laboratories since they required cheaper equipment. Moreover, they allow the 
simultaneous analysis of many samples or the contemporary detection of different 
kinds of analytes through multiplexed platforms.  
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 CHAPTER OBJECTIVES 
Considering the biological importance of the neurohormone EPI and its key role 
in many physiological and pathological conditions, the development of a 
sensitive, simple and rapid immunochemical method for its detection, avoiding 
sample pre-treatment and analyte derivatization, can be very useful. 
The combination of the magnetic properties of MNPs, with the recognition ability 
of an Ab and the advantages of an electrochemical sensor might lead to the 
development of powerful analytical tools for this diagnostic purpose. The 
presence of an Ab able to recognize the free analyte without performing any 
modification or treatment could ensure the capture and the selective binding of 
the analyte, while the magnetic core of the nanoparticles could facilitate the 
separation and concentration steps. Moreover, a readout technique based on 
electrochemical detection could bring rapidity, reliability and simplicity to this 
kind of diagnostic system. 
For all these reasons, the development of amperometric magneto-immunosensors 
for the detection of EPI is the aim of this research project. The diagnostic tools 
will be based on Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 MNPs functionalized 
with an antibody able to recognize and bind EPI. Rapidity, high simplicity and 
good sensitivity will represent the features of this analytical tool. 
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 RESULTS AND DISCUSSION 
In this section the experimental results concerning to the development of different 
kinds of immunochemical assays for the detection of EPI are presented and 
discussed. The evaluation of the immunoreagents, performed by standard ELISA 
configurations, was the starting point for the development of the MNPs-based 
amperometric immunosensors.  
7.3.1 Development of the indirect competitive ELISA 
7.3.1.1 Immunoreagents evaluation  
EPI is a low molecular weight compound not immunogenic by itself. Thus, the 
preparation of an immunizing hapten is required. This hapten must be 
conveniently attached to an immunogenic protein to stimulate the immune 
response and to produce the specific antibodies against the selected molecule. The 
specific antibodies against EPI had been produced in the Nb4D group. 
Particularly, the designed and synthesized immunizing hapten for EPI had a 
nucleophilic group (X) at the spacer arm which was conjugated to the 
immunogenic protein HCH using N-succinimidyl iodoacetate (SIA) as a 
heterobifunctional crosslinker agent. The resulting bioconjugate HCH-SIA-EPI, 
known as immunogen, was used for immunizing three female New Zealand 
rabbits obtaining three different antisera: As334, As335 and As336. These 
antisera contain the pool of polyclonal antibodies developed against all the 
epitopes present in the immunogen. 
In order to characterize the antisera produced against EPI, the preparation of 
competitor bioconjugates is required, as previously described.  These compounds 
consist in binding the immunizing hapten, or other chemical compounds 
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structurally related with the target analyte known as competitor haptens, to carrier 
proteins different to the one used for immunizing. In this case, the immunizing 
hapten of EPI and a competitor hapten derived from NorEPI, which was 
chemically modified in the same way, were covalently attached to Bovine Serum 
Albumin (BSA) instead of HCH. The conjugates containing the hapten of EPI 
were considered homologous competitor conjugates, while those incorporating 
the hapten of NorEPI were heterologous ones. The degree of homology or 
heterology depends, on one hand, on the structure of the competitor hapten, and 
on the other hand, on the crosslinker agent used for the preparation of the 
bioconjugates. For some conjugates, a different heterobifunctional crosslinker 
agent was used, the  N-succinimidyl 3-maleimidopropionate (N-SMP), increasing 
the structural differences between the immunogen and the corresponding 
competitor. Thus, four competitor conjugates, previously prepared in the Nb4D 
group, were selected for the development of the immunochemical assay for the 
detection of EPI. They were BSA-SIA-EPI, BSA-(N-SMP)-EPI, BSA-SIA-
NorEPI and BSA-(N-SMP)-NorEPI and their structure is reported in Figure 7.3-1. 
 
Figure 7.3-1: Structure of the homologous competitor conjugates BSA-SIA-EPI and BSA-(N-
SMP)-EPI and heterologous ones BSA-SIA-NorEPI and BSA-(N-SMP)-NorEPI. The general 
structures of the haptens for EPI and NorEPI, in which X corresponds to a nucleophilic functional 
group, are highlighted in blue. 
These conjugates were also previously characterized by spectrometric techniques, 
such as matrix assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF-MS). The hapten density of the bioconjugates varied 
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from 8 to 23 residues of hapten per protein molecule. In this context, it is known 
that conjugates with lower hapten densities could lead to assays with better IC50 
values 236; therefore, this parameter should be considered in order to modulate the 
binding affinity between the antibody and the competitor conjugate or antigen. 
The evaluation of the antisera raised against EPI was performed by different kinds 
of immunochemical assays. Firstly, two-dimensional (2D) ELISA assays were 
carried out for all the As-competitor combinations, varying the concentration of 
the Ag and the dilution of the As. The optimal As dilution and Ag concentration 
to be used subsequently in the competitive immunoassays were determined by 
performing the 2D checkerboard titration format. The typical curves obtained 
from a 2D ELISA are shown in Figure 7.3-2. The chosen combinations 
corresponded to those giving an A value close to 1 at 90% of the saturation curve. 
 
Figure 7.3-2: 2D-ELISA between As334 and the heterologous competitor BSA-(N-SMP)-NorEPI. 
All the optimal As-Ag combinations were tested in competitive assays in which 
the analyte EPI was added in serial dilutions with concentrations ranging from 0 
to 50 μM. The inhibition curves obtained in the competitive assays for As334, 
As335 and As336 with all the Ag are reported in Figure 7.3-3. 
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Figure 7.3-3: Sigmoidal inhibition curves achieved in the competitive ELISA assays performed 
among epinephrine, the four competitors - BSA-SIA-EPI, BSA-(N-SMP)-EPI, BSA-SIA-NorEPI 
and BSA-(N-SMP)-NorEPI - and As334, As335 or As336. At least three-well replicates were used 
for each assay. 
Analysing the experimental data, As334 and As335 showed inhibition curves with 
better detectability of the analyte compared to As336, which was therefore 
discarded. After further optimization of As dilution and Ag concentration, the best 
results in terms of detectability were achieved using the As334 (dilution 
1/256000) and the heterologous competitor conjugates BSA-SIA-NorEPI (40 
ng/mL) and BSA-(N-SMP)-NorEPI (20 ng/mL). The corresponding inhibition 
curves are shown in Figure 7.3-4: while the analytical parameters are reported in 
Table 7.3-1. The values of IC50 obtained were both in the nanomolar range, but 
far from the concentration of EPI in biological samples, like urine or plasma 206,208. 
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Figure 7.3-4: Inhibition curves obtained in the competitive indirect ELISAs among As334, 
epinephrine and BSA-SIA-NorEPI or BSA-(N-SMP)-NorEPI.  
Table 7.3-1: Analytical parameters for the best As-Ag combinations in competitive ELISAs: 
absorbance values, hillslope, R2 and IC50 are reported for the combinations As334 (dilution 
1/256000) and BSA-SIA-NorEPI (40 ng/mL) or BSA-(N-SMP)-NorEPI (20 ng/mL). 
 
BSA-SIA-NorEPI 40 ng/mL 
As334 1/256000 
BSA-(N-SMP)-NorEPI 20 ng/mL 
As334 1/256000 
Amax 0.895 ± 0.015 0.893 ± 0.008 
Amin -0.004 ± 0.022 -0.002 ± 0.012 
Hillslope -0.757 ± 0.079 -0.889 ± 0.054 
IC
50
 (nM) 72.5 ± 1.2 74.4 ± 1.1 
R2 0.991 0.997 
 
Several physicochemical parameters were assessed with the aim of optimizing the 
features of the assay to improve its sensitivity. 
7.3.1.2 Optimization of physicochemical parameters 
Indirect competitive ELISA assays using EPI (0-20 μM), As334 (dilution 
1/256000) and BSA-SIA-NorEPI (40 ng/mL) or BSA-(N-SMP)-NorEPI (20 
ng/mL) were performed varying only one parameter of the competition step each 
time. The addition of a preliminary incubation step between As334 and the analyte 
and the variation of the competition time were initially studied. Then, the 
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modification of the buffer composition, assessing tween concentration, ionic 
strength and pH, was considered. In Figure 7.3-5 are reported the experimental 
results obtained changing these parameters. 
 
Figure 7.3-5: Effect of the variation of physicochemical parameters on indirect competitive ELISA 
of epinephrine and As334/BSA-SIA-NorEPI (left side) or As334/BSA-(N-SMP)-NorEPI (right 
side). In each graph the left axis indicates the value of IC50 (blue) and the IC50/ΔA ratio (green) and 
the right axis the values of Amax (orange) and ΔA/IC50 (purple). Starting from the top the parameters 
are pre-incubation time, competition time, tween concentration, conductivity and pH.  
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The effect of the incorporation of a pre-incubation step of the As334 with EPI was 
evaluated from 5 min to overnight. According to the experimental results, the 
addition of a short pre-incubation step (10 min) improved the detectability of the 
immunoassay, comparing to the absence of pre-incubation (0 min). Overnight pre-
incubation resulted in analyte degradation and, consequently, in the worsening of 
the analytical parameters of the immunoassay.  
The competition time was assessed from 5 min to 60 min; short competition times 
caused a decrease in the maximum colorimetric signal, compared to long ones. 
Combining the 10 min preincubation step with competition, the best results were 
obtained maintaining the competition time at 30 min, as in the starting protocol. 
The effect of changing the tween concentration was evaluated, using PBS 
solutions containing Tween 20 from 0% to 0.1%. Tween caused some variations 
in the analytical parameters of the immunoassay; however, considering that IC50 
values were all in the nanomolar range, this parameter was maintained at 0.05%. 
Ionic strength was assessed using PBST solutions with a conductivity value 
ranging from 5 mS/cm to 95 mS/cm. At conductivity higher than the reference 
value of 16 mS/cm there was a loss of the colorimetric signal and for this reason, 
the lower conductivity range from 2 mS/cm to 19 mS/cm was assessed. Both the 
immunoassays showed high stability at low conductivity and good detectability, 
particularly working in the range 5-16 mS/cm. 
pH of the competition buffer was assessed using PBST solutions ranging from pH 
2.5 to pH 11.5 and performing the ELISA experiments without the pre-incubation 
step. pH altered dramatically the detectability of the immunoassays in terms of 
both IC50 and Amax, probably due to the degradation of the analyte.204 The stability 
of the immunoassays might be guaranteed working at almost neutral pH (6.5-7.5). 
According to all experimental results an improvement on the IC50 value was 
achieved introducing a short pre-incubation step (10 min) and maintaining all the 
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other parameters at the reference values: 30 min for the competition step and 
PBST as the competition buffer, characterized by 0.05% Tween 20, conductivity 
of 16 mS/cm and pH of 7.5. 
7.3.1.3 Optimized indirect competitive ELISA 
Indirect competitive ELISA assays for EPI were developed using the As334 and 
BSA-SIA-NorEPI or BSA-(N-SMP)-NorEPI, as shown in Figure 7.3-6. 
 
Figure 7.3-6: Scheme of the optimized indirect competitive ELISAs: the plate was coated with the 
heterologous competitor BSA-SIA-NorEPI or BSA-(N-SMP)-NorEPI (indicated as BSA-X-
NorEPI) and As334 and epinephrine were added for the competition step. AntiIgG-HRP was used 
as a secondary labelled-antibody for the achievement of the colorimetric signal.  
The features of the immunoassays are collected in Table 7.3-2 while the inhibition 
curves obtained from the optimized assays are shown in Figure 7.3-7. According 
to the experimental parameters both assays showed comparable detectability of 
EPI. After the optimization of the physicochemical parameters, that led to the 
introduction of a short pre-incubation step, the reached IC50 values were around 
47±6 nM and 35±5 nM for BSA-SIA-NorEPI and BSA-(N-SMP)-NorEPI, 
respectively.  
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Figure 7.3-7: Inhibition curves of the optimized indirect competitive ELISAs among As334, 
epinephrine and BSA-SIA-NorEPI or BSA-(N-SMP)-NorEPI. 
Table 7.3-2: Immunoassay features of the optimized indirect competitive ELISAs for epinephrine; 
information concerning immunoreagents, experimental parameters, Amax, Amin, R2, IC50, LOD and 
working range (WR) are summarized. 
Experimental 
parameters 
BSA-SIA-NorEPI BSA-(N-SMP)-NorEPI 
Ag concentration 
[ng/mL] 
40 20 
As334 dilution 1/256000 1/256000 
Preincubation time 10 min 10 min  
Competition time 30 min 30 min 
Tween concentration 0.05 % 0.05 % 
Conductivity [mS/cm] 5-16 5-12 
pH 6.5-7.5 6.5-7.5 
Amax 1.11 ± 0.04 1.07 ± 0.07 
Amin 0.05 ± 0.01 0.04 ± 0.01 
R2 0.998 0.996 
IC
50 [nM] 
IC
50 [μg/L] 
47 ± 6  
8.6 ± 1.0 
35 ± 5 
6.3 ± 0.7 
LOD [nM] 2.1 ± 0.6 1.5 ± 0.3  
WR [nM] 5-311 4-254 
Optimized Indirect Competitive ELISA
As334 vs EPI vs BSA-SIA-NorEPI or BSA-(N-SMP)-NorEPI
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7.3.2 Development of the direct competitive ELISA 
Once the immunoassay for the detection of EPI in an indirect competitive format 
was developed and optimized, the assay in a direct format was carried out, taking 
into account the immunoreagents and physicochemical conditions previously 
selected. 
The first step was to address the preparation, characterization and  
immunochemical evaluation of the required enzymatic tracer (ET), HRP-(N-
SMP)-NorEPI, which would be finally used for the immunoassays involving 
MNPs. As shown in Figure 7.3-8, the direct competitive ELISA assay was based 
on the competition between the analyte EPI and the conjugate HRP-(N-SMP)-
NorEPI for the binding site of As334, adsorbed on the assay plate. The oxidation 
of the substrate solution was catalysed by the ET, avoiding the addition of the 
labelled secondary antibody and thus shortening the assay time. 
 
Figure 7.3-8: Scheme of the direct competitive ELISA for epinephrine: EPI and HRP-(N-SMP)-
NorEPI competed for binding to As334, coating the plate. The oxidation of the substrate was 
catalysed by the enzymatic tracer that produced the colorimetric signal. 
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7.3.2.1 Enzymatic tracer HRP-(N-SMP)-NorEPI 
HRP-(N-SMP)-NorEPI was selected as the ET for the direct ELISA according to 
the results obtained in the indirect competitive immunoassay, in which the most 
heterologous competitor conjugate BSA-(N-SMP)-NorEPI showed the best 
performance.  
The ET was prepared in a two-step reaction, as shown in Figure 7.3-9. The first 
step consisted in the modification of the amino group of Lys residues with the 
linker N-SMP, forming amide bonds and introducing maleimide groups.237 
According to the structure of this enzyme, only two Lys residues are accessible 
enough to be derivatized. After the reaction, HRP-(N-SMP) conjugate was 
purified from the excess of linker by size exclusion chromatography on an ÄKTA 
prime system, eluting the sample through a Sephadex® G-25 column equilibrated 
with ultrapure H2O. The introduction of the maleimide group on the enzyme 
allowed to conjugate the hapten of NorEPI, already synthesized and characterized 
in the Nb4D group. The second step consisted in the Michael addition of the 
nucleophilic functional group of the hapten (X) to the electrophilic double bond 
of the maleimide moiety on the enzymatic conjugate, leading to the formation of 
covalent bonds. 
 
Figure 7.3-9: Reaction scheme for the preparation of HRP-(N-SMP)-NorEPI; activation of Lys 
residues with N-SMP (step 1) and Michael addition of the hapten of NorEPI (step 2). 
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After purification by dialysis with PBS and finally H2O, the ET was characterized 
by MALDI-TOF-MS analysis to determine its hapten density. The comparison 
among the mass spectra, reported in Figure 7.3-10, of the starting reagent HRP (in 
blue), the intermediate conjugate HRP-(N-SMP) (in red) and the final product 
HRP-(N-SMP)-NorEPI (in green) confirmed the derivatization of the enzyme 
with the linker and the conjugation of the NorEPI hapten. The densities of linker 
and hapten were, respectively, 2 and 1.5 for each enzyme macromolecule. 
 
Figure 7.3-10: MALDI-TOF-MS analysis of HRP (in blue), HRP-(N-SMP) (in red) and HRP-(N-
SMP)-NorEPI (in green) with the corresponding molecular weights. 
7.3.2.2 Direct competitive ELISA 
Once prepared the ET, 2D direct ELISA was performed both to assure the catalytic 
activity of HRP after conjugation process, and to optimize the As dilution and 
tracer concentration. The combination As334 1/12000 and HRP-(N-SMP)-
NorEPI with a concentration of 8 ng/mL was selected for the competitive assay 
with EPI (0-50 μM). 
In Figure 7.3-11 the competitive curve of the direct ELISA is compared to those 
obtained in the indirect formats while the experimental parameters of all these 
immunoassays are summarized in Table 7.3-3. The IC50 and LOD values and the 
working range of the direct ELISA were in the nanomolar range. The sensitivity 
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of this immunoassay, without optimization, was very similar to that of the indirect 
assay; however, the direct format could provide some advantages in terms of 
speed and simplicity of the immunochemical assay, being more attractive as 
diagnostic platform. 
 
Figure 7.3-11: Comparison between the direct and indirect competitive ELISAs for the detection of 
epinephrine using As334. The direct competitive format was performed using HRP-(N-SMP)-
NorEPI while the indirect ones using BSA-SIA-NorEPI and BSA-(N-SMP)-NorEPI. 
Table 7.3-3: Comparison among the immunochemical features of the direct and indirect competitive 
ELISAs between epinephrine, As334 and HRP-(N-SMP)-NorEPI, BSA-SIA-NorEPI or BSA-(N-
SMP)-NorEPI. IC50,Amax, Amin, R2, LOD, hillslope and working range values are reported. 
Experimental 
parameters 
HRP-(N-SMP)-
NorEPI 
BSA-SIA-
NorEPI 
BSA-(N-SMP)-
NorEPI 
Ag or ET 
concentration [ng/mL] 
8  40 20 
As334 dilution 1/12000 1/256000 1/256000 
Amax 1.10 ± 0.02 1.11 ± 0.04 1.07 ± 0.07 
Amin 0.04 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 
Hillslope -0.87 ± 0.04 -0.76 ± 0.03 -0.70 ± 0.05 
R2 0.994 0.998 0.996 
IC
50 [nM] 
IC
50 [μg/L] 
44 ± 1 
8.1 ± 0.8 
47 ± 6  
8.6 ± 1.0 
35 ± 5 
6.3 ± 0.7 
LOD [nM] 4.3 ± 1.3 2.1 ± 0.6 1.5 ± 0.3  
WR [nM] 2-70 5-311 4-254 
Comparison between Direct and Indirect ELISAs
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7.3.3 Synthesis and characterization of Ab-MNPs 
Since the levels of EPI in biological fluids are in the picomolar range, as reported 
in the literature, the introduction of sample preconcentration could be very 
useful.207 In this way, it could be possible to achieve a concentration of the analyte 
that might be measurable by direct or indirect immunochemical assays. The idea 
of preconcentrating the sample could be achieved by different methods, as 
explained in the introduction. In this context, one strategy might be using 
nanosystems able to recognize the analyte and then facilitate its separation from 
the mixture by a simple procedure.  
For this purpose, MNPs-Ab could be a good solution, providing in one single 
platform the recognition element, the antibody, and the separating feature, the 
magnetic core. For this reason, Fe3O4@SiO2 MNPs and Fe3O4@Cu@Au MNPs 
functionalized with the Ab - immunoglobulins G (IgGs) proteins - able to detect 
EPI were synthesized and characterized. 
7.3.3.1 Antibody purification 
The antiserum As334 was purified in order to obtain only the IgGs fraction for the 
functionalization of MNPs. The standard purification protocol for antibody 
consisted in few steps, as reported in the literature.238,239 The pre-purification step 
by ammonium sulphate precipitation was used to separate immunoglobulins from 
other serum proteins, while the affinity chromatographic purification was needed 
to achieve purified IgGs in buffer solution, eluting the solution of 
immunoglobulins through a Protein A column. The elution of the IgGs solution 
through a desalting column provided the purified antibody, named Ab334, that 
was finally lyophilized and used for the functionalization of the nanosystems.  
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7.3.3.2 Functionalization of Fe3O4@SiO2 MNPs 
In order to immobilize the antibody Ab334 on the nanosystems, the preliminary 
activation of their surface with heterobifunctional molecules was performed.  
The -OH groups present on silica shell of Fe3O4@SiO2 MNPs were exploited for 
the reaction with the epoxy-silane 3-(glycidyloxypropyl)trimethoxy silane 
(GPTMS) that allowed the further conjugation of macromolecules, as shown in 
Figure 7.3-12. The -OH groups were first deprotonated by treating the 
Fe3O4@SiO2 MNPs with 10% NaOH solution, increasing their nucleophilic 
power, and then used for the reaction with pure GPTMS (step 1). The MNPs-
GPTMS were then washed with absolute EtOH to eliminate the excess of GPTMS 
and desiccated before the biofunctionalization. The surface activation with epoxy 
groups enabled the covalent binding of the antibody Ab334 on Fe3O4@SiO2 
MNPs (step 2); in fact, the nucleophilic residues of the protein, particularly Lys, 
can easily react with the epoxy groups ensuring the formation of covalent bonds 
between the antibody and the nanosystems. After the conjugation reaction, a 
capping step with ethanolamine was performed to deactivate all the unreacted 
epoxy groups. After washings with PBS, Fe3O4@SiO2-Ab334 MNPs were stored 
at 4°C in the same buffer solution, characterized and then used for the 
immunochemical assays.  
 
Figure 7.3-12: Reaction scheme of the functionalization of Fe3O4@SiO2 MNPs with GPTMS (step 
1) and then with the purified Ab334 (step 2). 
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7.3.3.3 Functionalization of Fe3O4@Cu@Au MNPs 
To conjugate the antibody on Fe3O4@Cu@Au MNPs, a covalent approach 
involving heterobifunctional linkers was used instead of the easier but unstable 
protein absorption strategy.  
Exploiting the chemical affinity between Au and thiol groups, already described 
in section 3.1.1.3, the surface of this kind of magnetic nanoparticles was first 
activated with a mixed SAM based on heterobifunctional thiol-PEG molecules, 
that were finally used for the conjugation of the Ab334, as shown in Figure 7.3-13.  
A mixture of two kinds of linear PEG linkers, HS-PEG-COOH (average 
Mn=7500) and HS-PEG-OCH3 (average Mn=6000) was used to achieve the 
mixed SAM. The presence of the thiol groups ensured the stable anchorage on Au 
surface, while the -COOH groups were exploited for the further conjugation of 
biomolecules through amide bonds. The use of two kinds of linkers instead of one, 
in a relative molar ratio HS-PEG-COOH : HS-PEG-OCH3 of 1:3, decreased the 
negative charge density on the surface of nanoparticles, spacing them and 
promoting the biofunctionalization step. The anchorage of the linkers was 
performed under inert conditions in order to minimize the thiol-oxidation process, 
stirring the solution overnight at rt (step 1). Activated Fe3O4@Cu@Au-PEG 
MNPs were magnetically recovered, washed and then dried. 
For the biofunctionalization with Ab334, the well-known carbodiimide chemistry 
was used; the -COOH groups were activated by an EDC/NHS solution and used 
for the reaction with Lys residues of the antibody, allowing its covalent binding 
through amide bonds formation (step 2). After the capping reaction with 
ethanolamine to deactivate all the unreacted reagents, the Fe3O4@Cu@Au-Ab334 
MNPs were stored at 4°C in PBS. 
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Figure 7.3-13: Reaction scheme of the activation of Fe3O4@Cu@Au MNPs with mixed-SAM made 
of SH-PEG-COOH and SH-PEG-OCH3 (step 1) and their functionalization with Ab334 using 
EDC/NHS solution (step 2). 
7.3.3.4 Characterization of the antibody-functionalized MNPs 
The characterization of the two kinds of Ab334-MNPs was performed by different 
assays.  
The presence of IgGs on nanosystems was confirmed by an immunochemical 
assay using anti-IgG-HRP, which was performed directly on Ab-MNPs known as 
magneto-ELISA format. The recognition process between IgG and anti-IgG led 
to the binding of the secondary antibody on nanoparticles. Consequently, the 
colorimetric signal, derived from the HRP-catalysed oxidation of the substrate 
solution, proved the binding of IgGs to the nanosystems.  
The yields of the Ab conjugation reactions were determined by a quantitative 
Bradford protein assay.240 This assay was performed on the supernatants and the 
washings of the reactions between Ab334 and the MNPs, using Ab334 serial 
dilutions for the calibration curve. When the molecule of Coomassie Brilliant blue 
G-250 interacts with a protein, in this case an Ab, the absorption band at λ=595 
nm increases depending on protein concentration since it corresponds to the 
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protein-bound anionic form of the dye. As reported in Table 7.3-4, the conjugation 
of the Ab334 to nanosystems was successfully achieved, leading to reaction yields 
of 66.1% and 85.5% for Fe3O4@SiO2-Ab334 MNPs and Fe3O4@Cu@Au-Ab334 
MNPs, respectively.  
Table 7.3-4: Experimental results of Bradford protein assays on the solutions (supernatant + 
washings) corresponding to Ab334-conjugation reactions. For each nanosystem the concentration 
of Ab334 in solution (μg/mL), the amount of Ab334 bound to MNPs - expressed as concentration 
(μg/mL) or referred to a mg of MNPs (μg/mg) - and the conjugation yield (%) are reported. 
MNPs 
Free 
Ab334 
[μg/mL] 
Bound 
Ab334 
[μg/mL] 
Bound Ab334 
on MNPs mg 
[μg/mg] 
Reaction  
yield 
[%] 
Fe3O4@SiO2-Ab334 169.32 330.69 8.55 66.1 
Fe3O4@Cu@Au-Ab334 72.38 427.62 6.61 85.5 
 
According to these experimental data, immunochemical magneto-assays based on 
MNPs-Ab-334 were developed in order to assess the recognition activity of the 
conjugated antibody towards EPI and to produce new and sensitive MNPs-based 
immunoassays. 
7.3.4 Development of the direct competitive magneto-
ELISA 
Magneto-immunochemical assays were developed using the new synthesized and 
characterized Fe3O4@Cu@Au-Ab334 MNPs and Fe3O4@SiO2-Ab334 MNPs. 
The ability of Ab334 to recognize and interact with the analyte or its competitors 
could have been affected by the conjugation process; structural modification of 
the antibody, in fact, could have been occurred during the reaction with 
nanoparticles. For these reasons, preliminary 2D direct magneto-ELISA assays 
were carried out in order to confirm the recognition ability of the Ab and to select 
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the optimal combination of MNPs/ET for the further competitive assay. The 2D 
magneto-ELISA assays were performed varying the quantity of Ab-334 
functionalized magnetic nanoparticles, from 0 to 50 μg/well, and the 
concentration of HRP-(N-SMP)-NorEPI from 0 to 0.2 μg/mL. All the magneto-
ELISA experiments were carried out following the protocol of the direct ELISA 
format; however, after each step of the assay the MNPs were magnetically 
separated from the solution, placing the plate on a magnetic rack, and manually 
washed. After the stopping reaction, the supernatants were moved to another plate 
and the colorimetric signal was measured at λ=450 nm, excluding the MNPs to 
avoid possible interferences.  
The experimental evidences confirmed the activity of the Ab334 in detecting the 
ET, disproving the possible modification of the Ab due to the conjugation to 
MNPs. These assays allowed also the selection of the optimal combinations of 
MNPs quantity and ET concentration for the competitive assays, corresponding 
to 25 μg/well for Fe3O4@Cu@Au-Ab334 MNPs, 6 μg/well for Fe3O4@SiO2-
Ab334 MNPs and 60 ng/mL for HRP-(N-SMP)-NorEPI. 
According to the inhibition curves obtained in the competitive assays, shown in 
Figure 7.3-14, EPI was able to compete with the enzymatic tracer for the binding 
site of Ab334 anchored to the surface of the nanosystems. As reported in Table 
7.3-5, the detectability of the magnetic-immunoassays was comparable to that 
obtained using classic direct ELISA assays, especially in the case of 
Fe3O4@Cu@Au-Ab334 MNPs. The IC50 and LOD values, in fact, were in the 
nanomolar range. 
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Figure 7.3-14: Inhibition curves obtained in the competitive magneto-ELISAs among 
Fe3O4@Cu@Au-Ab334 or Fe3O4@SiO2-Ab334, epinephrine and HRP-(N-SMP)-NorEPI. 
Table 7.3-5: Analytical parameters of the competitive direct magneto-ELISAs. Absorbance 
(minimum and maximum values), hillslope, R2 and immunoassay features such as IC50, LOD and 
WR are reported for Fe3O4@Cu@Au-Ab334/HRP-(N-SMP-NorEPI) and Fe3O4@SiO2-
Ab334/HRP-(N-SMP)-NorEPI combinations.  
 
Fe
3
O
4
@Cu@Au-Ab334 
HRP-(N-SMP)-NorEPI 
Fe
3
O
4
@SiO
2
-Ab334 
HRP-(N-SMP)-NorEPI 
MNPs amount (μg/well) 25 6 
ET concentration (ng/mL) 60 60 
A 
min
 0.21 ± 0.07 0.42 ± 0.04 
A 
max
 1.49 ± 0.06 1.44 ± 0.03 
Hillslope -0.71 ±  0.18 -1.33 ± 0.36 
R2 0.969 0.977 
IC
50
 (nM) 
IC
50
 (μg/L) 
45.9 ± 1.5 
8.4 ± 0.3 
253.9 ± 1.2 
46.5 ± 0.3 
LOD (nM) 0.04 14.8 
WR (nM) 4-404 68-797 
 
The poor reproducibility of the assays derived from the intrinsic variability of the 
experiments limited the applicability of the magneto-ELISA immunoassays. 
However, starting from the encouraging experimental data achieved in those 
assays, the simplest and reliable electrochemical readout for the implementation 
of the magneto immunoassays was addressed. 
Direct competitive MagnetoELISA
MNPs-Ab334 vs EPI vs TE
10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5
0.0
0.5
1.0
1.5
2.0
Fe3O4@Cu@Au-Ab334 25 g/well;
HRP-(N-SMP)-NorEPI 0.06 g/mL
Fe3O4@SiO2-Ab334 6 g/well;
HRP-(N-SMP)-NorEPI 0.06 g/mL
EPI [nM]
A
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7.3.5 Development of the electrochemical magneto-
immunosensors 
Ab334-MNPs were used for the development of amperometric magneto-
immunosensors, as proofs of concept of diagnostics methods for the detection of 
EPI.  
As described previously in 7.1.2.1, MNPs could bring many advantages in 
electrochemical immunosensors; for instance, they could be easily manipulated, 
improving the washings and separation steps, and allow the possibility of 
renewing the surface of the electrode and shortening the time of the 
immunochemical assay. Moreover, the main advantage could derive from the 
possibility of using the Ab-MNPs for the recognition event of the analyte directly 
in the complex matrix, limiting the interferences due to different electroactive 
compounds present in the sample. 
For the development of the electrochemical magneto-immunosensors, 1D 
immunoassays were first performed for the evaluation of the best combination of 
MNPs amount and ET concentration; starting from the results obtained in 
magneto-ELISA formats, a constant amount of MNPs was treated with serial 
dilutions of HRP-(N-SMP)-NorEPI. In detail, 30 μg/sample of Fe3O4@SiO2-
Ab334 MNPs and 125 μg/sample of Fe3O4@Cu@Au-Ab334 MNPs were stirred 
with enzymatic tracer solutions with concentrations ranging from 0 to 2 μg/mL. 
After the recognition step, MNPs were washed and then deposited on a screen-
printed carbon electrode (SPCE) for the electrochemical detection. The negative 
current was measured separately for each sample after the addition of the substrate 
solution. As shown in the scheme of the electrochemical cell, reported in Figure 
7.3-15, applying the constant potential of -0.1 V, the substrate TMB oxidized by 
the HRP of the enzymatic tracer, was reduced; so, the experimental reduction 
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current was directly proportional to the concentration of HRP-(N-SMP)-NorEPI 
in the sample. 
 
Figure 7.3-15: Scheme of the electrochemical cell for the magneto-immunoassays using Ab334 
functionalized MNPs. Applying the constant V of -0.1 V to the SPCE containing the sample of Ab-
MNPs, the negative current derived from the reduction of the HRP-oxidized TMB was measured. 
From these electrochemical assays, the optimum concentrations of ET were 
selected, corresponding to 500 ng/mL and 250 ng/mL in combination with 
Fe3O4@SiO2-Ab334 MNPs and Fe3O4@Cu@Au-Ab334 MNPs, respectively; the 
final reduction currents were around -300 nA after 30 min of immunochemical 
reaction performed in absence of analyte.  
The competitive assays were carried out vigorously stirring standard solutions of 
EPI (0-50 μM) mixed with Ab-functionalized nanoparticles and ET solution. After 
magnetic separation and washings, the amperometric measurements of the 
concentration of the immunocomplexes MNPs/ET were performed in the 
electrochemical cell as previously described. The inhibitory effect of EPI was 
evident, according to the sigmoidal curves obtained from the electrochemical 
readout shown in Figure 7.3-16; the samples with high concentration of EPI, in 
fact, produced low reduction current. 
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Figure 7.3-16: Inhibition curves achieved in direct competitive amperometric magneto-
immunoassays among epinephrine, HRP-(N-SMP)-NorEPI and Fe3O4@SiO2-Ab334 MNPs (left) or 
Fe3O4@Cu@Au-Ab334 MNPs (right). 
Looking at the analytical parameters of these electrochemical immunoassays, 
summarized in Table 7.3-6, a slight but significant increment in the IC50 values 
was noted, comparing to the immunoassays performed without MNPs. However, 
despite the slight worsening of sensitivity of these assays, the use of MNPs could 
bring other advantages making the immunoassay quicker and easier to perform. 
Moreover, the optimization of some experimental parameters and the addition of 
a pre-incubation step might improve the sensitivity of this method.  
According to these preliminary results, the electrochemical magneto-
immunosensors based on Fe3O4@SiO2-Ab334 or Fe3O4@Cu@Au-Ab334 
nanosystems could be considered as promising diagnostics tools for the 
quantitative determination of EPI in biological samples. 
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Table 7.3-6: Analytical features of direct competitive amperometric magneto-immunoassays. The 
amount of Fe3O4@SiO2-Ab334 MNPs or Fe3O4@Cu@Au-Ab334 MNPs, HRP-(N-SMP)-NorEPI 
concentration, minimum and maximum values of amperometric signals, hillslope, IC50, LOD and 
WR values are reported in this table.  
 Fe
3
O
4
@SiO
2
-Ab334 Fe
3
O
4
@Cu@Au-Ab334 
MNPs amount 
(μg/sample) 
30 125 
HRP-(N-SMP)-NorEPI 
concentration (ng/mL) 
500 250 
Current bottom (nA) -3.1 ± 13.1 38.8 ± 18.0 
Current top (nA) 238.2 ± 9.7 323.7 ± 17.7 
Hillslope -0.35 ± 0.05 -0.64 ± 0.15 
R2 0.979 0.924 
IC
50
 (nM) 
IC
50
 (μg/L) 
162.3 ± 1.6 
29.7 ± 0.3 
149.5 ± 1.5 
27.4 ± 0.3 
LOD (nM) 0.6 19.5 
WR (nM) 4-5011 72-6310 
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 CHAPTER CONTRIBUTIONS 
- New immunochemical assays for the detection of EPI were developed. 
Indirect competitive ELISA assays demonstrated high sensitivity in the 
detection of the analyte achieving IC50 values in the nanomolar range (6-
9 μg/L), using As334 as antiserum and BSA-(N-SMP)-NorEPI  or BSA-
SIA-NorEPI as competitors. Comparable analytical parameters were 
obtained by the direct competitive ELISA format using the enzymatic 
tracer HRP-(N-SMP)-NorEPI (IC50 9-10 μg/L). 
- New MNPs-Ab based on Fe3O4@SiO2-Ab334 MNPs and 
Fe3O4@Cu@Au-Ab334 MNPs were synthesized and characterized. 
Different immunochemical assays were developed using these 
nanosystems, such as magneto-ELISAs and electrochemical magneto-
immunosensors, achieving good sensitivity and low detectability limits 
(IC50 27-30 μg/L), especially in the amperometric immunochemical 
assays. These nanosystems might be used both for the recognition and 
binding process of the analyte, due to the immobilized specific antibody, 
and for its separation and concentration from complex matrices, thanks to 
the properties of MNPs. The amperometric magneto-immunosensors 
might be considered promising diagnostics tools for the detection of EPI.  
7.4.1 Future perspectives 
- Optimize the experimental procedures of the amperometric magneto-
immunosensor assays including, for instance, a pre-incubation step 
between MNPs and EPI.  
- Evaluate the matrix effects of plasma and urine samples in the 
immunochemical assays and magneto-assays, and assess other analytical 
parameters (specificity, reproducibility and accuracy studies). 
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 MATERIALS AND METHODS 
Reagents, materials and equipment: The chemical reagents used were purchased 
by Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). ÄKTATM prime, 
provided with HiTrapTM Protein A HP column or HiTrapTM Desalting column (GE 
Helthcare, Uppsala, Sweden), was used for chromatographic purification with the 
corresponding software Prime View and Prime View Evaluation. OrDial D14 
dialysis membranes (molecular weight cut off 12000-14000 Da) were purchased 
from Orange Scientific (Braine-l’Alleud, Belgium). The matrix-assisted laser 
desorption ionization time-of-flight mass spectrometer (MALDI-TOF-MS) was a 
Bruker autoflex III Smartbeam spectrometer (Billerica, Massachusetts). The pH 
and the conductivity of all buffers and solutions were measured with a pH-meter 
pH 540 GLP and a conductimeter LF 340, respectively (WTW, Weilheim, 
Germany). Polystyrene microtiter plates were purchased from Nunc (Maxisorp, 
Roskilde, Denmark). Dilution plates were purchased from Nirco (Barberà del 
Vallés, Spain). Washing steps of the immunochemical assays were performed on 
a Biotek ELx465 (Biotek Inc.). 96-well plate magnetic separation rack (CORTEX 
Biochem, WI, USA) was used for magnetic separation steps. Absorbances were 
read on a SpectramaxPlus (Molecular Devices, Sunnyvale, CA, USA) using the 
software SoftmaxPro v4.7 (Molecular Devices). Screen Printed Carbon 
Electrodes DRP-C110 (DropSens, Asturias, Spain) were connected to the 
potentiostat COMPACTSTAT.e Mobile Electrochemistry controlled by 
IviumSoftTM Electrochemistry Software (IVIUM Technologies, Eindhoven, The 
Netherlands). All the experimental data were analysed using the software 
GraphPad Prism 5.03 (GraphPad Software Inc., San Diego, CA, USA) and 
competitive curves were fitted with a four-parameters logistic equation. 
Buffers: Unless otherwise indicated, phosphate buffer saline (PBS) is 0.01 M 
phosphate buffer in a 0.8% saline solution, pH 7.5. Coating buffer is a 0.05 M 
carbonate-bicarbonate buffer, pH 9.6. PBST is PBS with 0.05% Tween 20, pH 
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7.5.  Citrate buffer is 0.04 M sodium citrate, pH 5.5. The substrate solution 
contains 0.01% 3,3’,5,5’-tetramethylbenzidine (TMB) and 0.004% H2O2 in citrate 
buffer. Borate buffer is 0.2 M boric acid/sodium borate, pH 8.7. 
Non-competitive indirect ELISA: The recognition and binding abilities of the 
antisera (As334-336) with the different antigens (BSA-SIA-EPI, BSA-(N-SMP)-
EPI, BSA-SIA-NorEPI or BSA-(N-SMP)-NorEPI) were evaluated by two-
dimensional titration assays. 2D-assays were carried out based on the 
measurement of the binding of serial dilutions of the antisera (1/1000 to 
1/2048000, and zero) against different concentrations of the antigens (serial 1:2 
dilutions of 1 μg/mL solution, and zero). The microtiter plate was coated with Ag 
dilutions in coating buffer (100 μL/well) and incubated overnight at 4°C. The next 
day, the plate was washed four times with PBST (300 μL/well) and the As 
dilutions were added to the wells (100 μL/well). After incubating 30 min at 25°C, 
the plate was washed again and a solution of anti-IgG-HRP (1/6000 in PBST) was 
added to the plate (100 μL/well). After 30 min incubating at rt, the plate was 
washed again and incubated in the dark after the addition of substrate solution 
(100 μL/well). The colorimetric reaction was stopped after 30 min at rt with 4 N 
H2SO4 (50 μL/well), and the absorbance was read at λ=450 nm. From these 
experiments, optimum concentrations for coating antigens and antisera dilutions 
were chosen to generate around 0.7-1 units of absorbance.  
Competitive indirect ELISA: The microtiter plate was coated with the antigen, at 
the proper selected concentration in coating buffer (100 μL/well), and incubated 
overnight at 4 °C, covered with adhesive plate sealers. The next day, the plate was 
washed four times with PBST (300 μL/well), and the solutions of EPI (stock 
solution 10 mM in DMSO, serial dilutions from 50 μM to 0 nM in PBST) were 
added (50 μL/well), followed by the solution of antisera As334 (double 
concentration of the selected dilution in PBST, 50 μL/well). After 30 min at 25°C, 
the plate was washed four times with PBST (300 μL/well), and a solution of anti-
IgG-HRP (1/6000 in PBST) was added to the plate (100 μL/well) and incubated 
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for 30 min at rt. The plate was washed again and then incubated in dark after the 
addition of the substrate solution (100 μL/well). The colorimetric reaction was 
stopped after 30 min at rt with 4 N H2SO4 (50 μL/well), and the absorbance was 
read at λ=450 nm. The standard curves were fitted to a four-parameter equation 
according to the following formula: y = (A − B/[1 − (x/C)D] + B, where A is the 
maximal absorbance, B is the minimum absorbance, C is the concentration 
producing 50% of the maximal absorbance, and D is the slope at the inflection 
point of the sigmoid curve. Unless otherwise indicated, all the data presented for 
the immunochemical assays correspond to the average of at least three wells 
replicates. 
Physicochemical parameters optimization: Different physicochemical parameters 
were assessed in the indirect competitive ELISA assays; the study included the 
variation of pre-incubation time (overnight – 0 min), competition time (60 – 0 
min), Tween 20 concentration (0.1% - 0%), conductivity (96 – 2 mS/cm) and pH 
(11.5 – 2.5). 
HRP-(N-SMP)-NorEPI synthesis: HRP was dissolved in PBS 10 mM pH=7.5 
(5.04 mg in 474 μL) and N-SMP (0.65 mg in 30 μL DMF), ten-fold Lys 
equivalents, was added to the enzymatic solution, achieving a solution at 10 
mg/mL in HRP. The reaction mixture was stirred for 4 h at rt in dark and then 
purified by ÄKTATM chromatographic system eluting the solution through 
desalting columns by Milli-Q H2O. The intermediate product HRP-(N-SMP) was 
mixed with NorEPI hapten (10 eq in DMF) and the reaction was performed in 
PBS 10 mM stirring in dark for 90 min at rt and then overnight at 4°C. The protein 
conjugate was purified by dialysis against 0.5 mM PBS (4×5 L) and Milli-Q H2O 
(1×5 L) and was stored at 4°C. Working aliquots were prepared in 0.01 M PBS at 
1 mg/mL and stored at 4 °C.  
Hapten and linker densities of the bioconjugates were estimated by measuring the 
MW of the native protein and of the conjugates by MALDI-TOF-MS. BSA was 
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utilized as internal standard for calibrating the instrument, using the mixture 
HRP:BSA = 4:1 (40 μL HRP 10 mg/mL+10 μL BSA 10 mg/mL in H2O) as the 
reference protein sample. Each mass spectrum was obtained by crystallization of 
the matrix (sinapinic acid, 2 μL of 10 mg/mL in a 70:30 solution of ACN / H2O 
and 0.1% in HCOOH), followed by the addition of 2 μL of sample or 2 μL of the 
reference protein sample (diluted 1:2 with 0 ACN + 0.2% HCOOH). Finally, after 
evaporation of the solution deposited on the plate, 2 μL of the matrix were added 
again. The hapten densities (δ hapten) were calculated according to the following 
equation: [MWconjugate-MWHRP]/MWhapten or linker. 
2D Direct ELISA: The microtiter plate was coated with As334 dilutions in coating 
buffer (1/1000 to 1/1024000, and zero, 100 μL/well) and incubated overnight at 
4°C. The following day, the plate was washed four times with PBST (300 
μL/well), and serial 1:2 dilutions of HRP-(N-SMP)-NorEPI in PBST (starting 
solution 1 μg/mL in PBST, and zero) were added to the wells (100 μL/well). After 
stirring 30 min at rt in dark, the plate was washed again, and the substrate solution 
was added (100 μL/well). After stirring 30 min at rt in dark, the colorimetric 
reaction was stopped adding 4 N H2SO4 (50 μL/well), and the absorbance was 
read at λ=450 nm. From these experiments, optimum As334 dilution and 
enzymatic tracer concentration were chosen to generate around 0.7-1 units of 
absorbance.  
Competitive direct ELISA: The microtiter plate was coated with As334 dilutions 
(1/12000 and 1/16000) in coating buffer (100 μL/well), incubated overnight at 4 
°C. The next day, the plate was washed four times with PBST (300 μL/well), and 
the solutions of EPI (stock solution at 10 mM in DMSO, serial 1:5 dilutions from 
50 μM to 0 nM in PBST) were added (50 μL/well), followed by the solution of 
HRP-(N-SMP)-NorEPI in PBST (32 and 16 ng/mL; 50 μL/well). After stirring 30 
min at rt in dark, the plate was washed four times with PBST (300 μL/well) and 
the substrate solution was added (100 μL/well). The colorimetric reaction was 
stopped with 4 N H2SO4 (50 μL/well) after stirring 30 min at rt in dark, and the 
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absorbance was read at λ=450 nm. The inhibition curves were fitted as previously 
described. 
As334 purification: A saturated solution of (NH4)2SO4 was slowly added (50 μL 
each time) to three eppendorf containing 500 μL of As334 under stirring at 4°C, 
until reaching 45% of saturation. After stirring 4 h at 4°C, the solutions were 
centrifuged (10 min at 14000 rpm) and, once removed the supernatants, white 
precipitates were obtained. After solubilization with PBS 10 mM (300 μL/ 
sample), sample solutions were filtered on 0,2 μm filters and then purified by 
AKTATM, provided with Protein A column, eluting the solution with binding 
buffer (PBS 20 mM pH 7) and then with citrate buffer (0.1 M pH 4). The IgGs 
fraction of Ab334 was eluted with Milli-Q H2O through the desalting column and 
finally lyophilized.  
Synthesis of Fe3O4@SiO2-Ab334 MNPs: 100 mg of Fe3O4@SiO2 were stirred 30 
min at rt with 2.4 mL of NaOH 10%. After washing with MilliQ H2O (x3) and 
60% EtOH (x3), 1.2 mL of pure GPTMS was added to the MNPs. After stirring 
30 min at rt, the Fe3O4@SiO2-GPTMS MNPs were washed three times with 
absolute EtOH and finally dried under vacuum.  
1 mL of a stock solution of purified Ab334 (1 mg/mL in borate buffer 0.1 M pH 
8.5) was added to 50 mg of Fe3O4@SiO2-GPTMS MNPs dispersed in 1 mL of the 
same buffer solution and the reaction mixture was stirred 4 h at rt. Fe3O4@SiO2-
Ab334 were washed three times with the same buffer solution and then stirred 
with 1 mL of ethanolamine solution (0.1 M in PBS 10 mM). After 45 min, the 
Fe3O4@SiO2-Ab334 MNPs were washed with PBS 10 mM and stored at 4°C in 
the same buffer at a concentration of 50 mg/mL. 
Synthesis of Fe3O4@Cu@Au-Ab334 MNPs: 4 mL of an aqueous solution 
containing a mixture of HS-PEG-OCH3 15 mM (2 mL, average Mn 6000, linear) 
and HS-PEG-COOH 5 mM (2 mL, average Mn 7500, linear) were added to 100 
mg of Fe3O4@Cu@Au MNPs in 96 mL H2O under N2 flux.  The solution was 
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divided in ten fractions that were stirred overnight at rt. The PEG-activated 
nanoparticles were magnetically collected, washed several times with MilliQ H2O 
and dried.  
50 mg of Fe3O4@Cu@Au-PEG MNPs were dispersed in 1 mL of EDC/NHS 
solution in 0.1 M borate buffer pH 8.5 (500 μL EDC 0.5 M + 500 μL NHS 0.4 
M). After adding 1 mL of Ab334 stock solution (at 1 mg/mL in borate buffer), the 
mixture was stirred 4 h at rt. The Fe3O4@Cu@Au-Ab334 MNPs were 
magnetically collected, washed with the same buffer solution (1mL, x3) and 
dispersed  in 1 mL of ethanolamine solution (0.1 M in PBS 10 mM). After 45 min 
of capping step, MNPs were washed three times with PBS 10 mM and then stored 
at 4°C in the same buffer at a concentration of 50 mg/mL.  
Bradford protein assay: Serial 1:2 dilutions of Ab334 80 μg/mL in borate buffer 
were used for the calibration curve (160 μL/well) . The supernatants of the MNPs-
functionalization reactions were diluted in borate buffer to obtain a theoretical 
concentration of 40 μg/mL (160 μL/well) while the washings solutions were used 
without further dilutions (160 μL/well). Adding 40 μL/well of Coomassie Brilliant 
Blue solution, the UV-Vis analysis was performed after 10 min measuring the 
absorbance at λ=595 nm. Comparing the A values of the samples to the calibration 
curve, the quantification of the free Ab334 and consequently of MNPs-bound 
Ab334 was performed. 
Magneto-ELISA between MNPs and anti-IgG: MNPs-Ab334 dispersions in 
PBST, after 2 min sonicating, were added to the assay plate at serial 1:2 dilutions 
ranging from 50 μg/well to zero (100 μL/well). After magnetically separating the 
MNPs using the magnetic plate rack and removing the supernatants, 1/6000 
dilution of anti-IgG-HRP in PBST was added (100uL/well). The plate was stirred 
30 min at rt, MNPs were magnetically separated and three washings with PBST 
were performed. 100 μL/well of substrate solution were added to the plate and, 
after 30 min stirring at rt in dark, the colorimetric reaction was stopped adding 4 
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N H2SO4 (50 μL/well). MNPs were separated and the absorbance was read at 
λ=450 nm after moving the supernatants to a different dilution plate. 
Direct magneto-ELISA: MNPs-Ab334 dispersions in PBST, after 2 min 
sonicating, were added to the assay plate at 1:2 serial dilutions ranging from 50 
μg/well to zero (50 μL/well). 50 μL/well of HRP-(N-SMP)-NorEPI serial 
dilutions in PBST (from 0.4 μg/mL to zero) were added to the plate. After 30 min 
stirring at rt in dark, MNPs were magnetically collected using the magnetic plate 
rack and the assay plate was washed three times with PBST (100 μL/well). The 
substrate addition and the stopping reaction steps were performed as described in 
the previous protocol.  
Direct competitive magneto-ELISA: Fe3O4@Cu@Au-Ab334 MNPs in PBST, 
after 2 min sonicating, were added to the assay plate at 25 μg/well (50 μL/well)  
while Fe3O4@SiO2-Ab334 at 6 μg/well. 25 μL/well of EPI dilutions in PBST 
(from 50 μM to 0) and 25 μL/well of HRP-(N-SMP)-NorEPI 60 ng/mL in PBST 
were added to the plate. After 30 min stirring at rt in dark, MNPs were 
magnetically separated using the magnetic plate rack and the plate was washed 
three times with PBST (100 μL/well). The substrate addition and the stopping 
reaction steps were performed as previously described.  
Amperometric magneto immunosensor direct assay: 125 μg/sample of 
Fe3O4@Cu@Au-Ab334 MNPs or 30 μg/sample of Fe3O4@SiO2-Ab334 MNPs 
(100 μL/sample in PBST) were mixed with 1:2 serial dilutions of HRP-(N-SMP)-
NorEPI (from 2 μg/mL in PBST to zero, 100 μL/sample) in eppendorf tubes. After 
30 min stirring in dark at rt, MNPs were magnetically separated and washings 
with PBST were performed (3x100μL/sample). MNPs were dispersed in 160 μL 
of citrate buffer and 40 μL were put on the SPCE, holding them applying an 
external magnet, and used for each amperometric measurement. V=-0.1V was 
applied and, at t = 60 s, 10 μL of the substrate solution were added to the sample. 
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Current values measured at t=200 s, after resting the corresponding values at t=50 
s,  were plotted in front of [ET]. 
Amperometric magneto immunosensor direct competitive assay: 125 μg/sample 
of Fe3O4@Cu@Au-Ab334 MNPs (100 μL/sample in PBST) and 0.5 μg/mL of 
HRP-(N-SMP)-NorEPI (50 μL/sample in PBST) or 30 μg/sample of Fe3O4@SiO2-
Ab334 MNPs (100 μL/sample in PBST) and 1 μg/mL of HRP-(N-SMP)-NorEPI 
(50 μL/sample in PBST) were mixed in eppendorf tubes with 50 μL/sample of 
EPI serial dilutions in PBST (from 50 μM to zero). After 30 min stirring in dark 
at rt, MNPs were magnetically separated and washings with PBST were 
performed (3x100 μL/sample). The substrate addition and the amperometric 
detection were performed as previously described. Current values measured at 
t=200 s, after resting the corresponding values at t=50 s,  were plotted in front of 
[EPI].
  
8. ANNEX: NANOPARTICLES-
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 INTRODUCTION 
This annex deals with the proposal of using Fe3O4-based nanosystems as 
multifunctional nanoplatforms for the detection of EPI exploiting its MNPs-
mediated oxidation process. This research work was carried out in the Nb4D 
group. 
8.1.1 Oxidation mechanism of EPI 
The oxidation mechanism of EPI consists in two redox reactions separated by an 
intermediate cyclization reaction, as reported in Figure 8.1-1.213 The catechol 
moiety of EPI is oxidised into the corresponding orto-quinone compound. Then, 
an 1,4 Michael addition can occur, depending on the pH, transforming adrenaline 
o-quinone into leucoadrenochrome; at pH > 3, in fact, the secondary amine group 
is partially deprotonated, reacting as nucleophile group by an intramolecular 
cyclization and producing the stable corresponding five-membered ring. 
Leucoadrenochrome can therefore undergo to another oxidation of the catechol 
group, producing adrenochrome which can carry out a polymerization process, 
producing melanin molecules.212,241 
This mechanism can be catalyzed in the same way by using electrochemical 
techniques, oxidoreductase enzymes like HRP, and also some kinds of 
nanomaterials, such as SiO2 NPs.242,243 
Since the oxidation products show characteristic absorption bands, especially the 
red-colored final compound adrenochrome (λmax=490 nm), the UV-Vis 
spectroscopy can be used for monitoring this oxidation pathway.244 
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Figure 8.1-1: Oxidation pathway of epinephrine. The oxidation of the catechol moiety produces 
adrenaline o-quinone, that can undergo to an 1,4 Michael addition leading to leucoadrenochrome. 
Another oxidation produces adrenochrome which can polymerize into melanin molecules. 
 CHAPTER OBJECTIVES 
The combination of the well-known catalytic  properties of  MNPs with their 
surface functionalization with Ab able to recognize EPI might pave the way for 
the development of powerful multimodal diagnostic tools.  
For these reasons, the idea behind this annex is using MNPs-Ab for the 
recognition, separation and measurement of EPI using analytical techniques. The 
Fe3O4@Cu@Au-Ab334 MNPs and Fe3O4@SiO2-Ab334 MNPs might be very 
promising nanosystems for this purpose; in fact, they combine the antibody able 
to detect EPI, as demonstrated in the previous chapter, with the superparamagnetic 
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core sensitive to the application of an external magnetic field. However, their 
oxidative power towards EPI should already be demonstrated.  
The aim of this annex, as shown in Figure 8.2-1, is to evaluate the ability of 
Fe3O4@Cu@Au MNPs and Fe3O4@SiO2 MNPs, functionalized with the anti-EPI 
Ab334 to oxidize adrenaline to adrenochrome, performing also a comparative 
study with MNPs functionalized with the Ab186, a pre-immune not specific 
antibody. In this way it might be possible to demonstrate, as proof of concept, the 
powerful potential applicability of MNPs-Ab334 as multitasking diagnostic tools 
for the recognition, separation and quantification of EPI. 
 
Figure 8.2-1: Scheme of the aim of the annex: a study of the oxidative ability of Fe3O4@Cu@Au 
and Fe3O4@SiO2 nanosystems, functionalized with Ab334 (anti-EPI Ab) towards epinephrine, 
compared to other nanosystems functionalized with Ab186 (not specific Ab).  
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 RESULTS AND DISCUSSION 
In this section the experimental results concerning the study of the oxidative 
ability of Fe3O4@Cu@Au-PEG-Ab334 MNPs and Fe3O4@SiO2-GPTMS-Ab334 
MNPs towards EPI are presented. The evaluation of the selectivity of these 
nanosystems is also reported by a comparative study with the same nanoparticles 
functionalized with the pre-immune not specific antibody Ab186.  
 
8.3.1 Evaluation of the oxidative ability of Ab334-MNPs 
The study of the oxidative ability towards EPI of the MNPs-Ab334, previously 
synthesized and characterized as reported in chapter 7, was first assessed. 
Fe3O4@Cu@Au-Ab334 MNPs or Fe3O4@SiO2-Ab334 MNPs were dispersed in 
EPI solutions in citrate buffer and H2O2 was added to trigger the oxidation 
reaction. The same samples of MNPs and EPI without adding H2O2 were used as 
negative controls, together with the blank of EPI and H2O2 without the MNPs. 
After stirring the samples for 20 min in dark, a significant and clearly visible 
increase in red colour was observed only in the solutions containing both MNPs 
and H2O2, as qualitatively shown in Figure 8.3-1. The same experiment was 
performed mixing MNPs with only H2O2, without achieving any colour variation 
in the samples. The change in the solutions from colourless to red was a strong 
proof that EPI (colourless) was oxidized to adrenochrome (red). These evidences 
were also an interesting signal of the key role of the MNPs as reaction promoters. 
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Figure 8.3-1: Qualitative proof of the MNPs-mediated oxidation of epinephrine (colorless) to 
adrenochrome (red). As reported in the legend, samples consisted in epinephrine solutions with or 
without nanosystems (Fe3O4@Cu@Au-Ab334 or Fe3O4@SiO2-Ab334 MNPs) and H2O2 solution. 
8.3.1.1 Kinetic evaluation 
Since adrenochrome is the final product of the oxidation of EPI and is 
characterized by an absorption band in the visible region, kinetic studies by 
monitoring and measuring it were performed using UV-Vis spectroscopy to better 
understand the process. MNPs and EPI were stirred in the presence and in the 
absence of H2O2, recording UV-Vis spectra at times ranging from 0 min (before 
adding H2O2) to 360 min. Analysing the data reported in Figure 8.3-2, the increase 
of an absorption band corresponding to adrenochrome (λmax=490nm) was evident 
only in the samples containing MNPs and H2O2, corresponding to green and blue 
lines. Any absorption band in the visible region was observed in the samples 
without H2O2 (red and orange lines) used as negative control neither in the EPI + 
H2O2 blank (purple line). In these experimental conditions – MNPs 1 mg, EPI 1 
mM and H2O2 1% - the phenomenon was observed already after few minutes 
reacting and regardless of the kind of nanosystem used. The formation of the 
adrenochrome reached a maximum after 30 min stirring, according to the intensity 
of its corresponding absorption band, and then it probably reacted through 
polymerization mechanism to melanin since the solutions became colourless again 
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and the absorption band decreased. These experimental evidences validated the 
hypothesis of the MNPs-mediated oxidation of EPI, triggered by the formation of 
free radicals on the activated surface, which were able to oxidize the hydrogen 
donor substrate – here EPI.  
 
Figure 8.3-2: Top: UV-Vis kinetic study at λ=490 nm of the MNPs-mediated oxidation of 
epinephrine from 0 min to 360 min. Epinephrine solutions were stirred with Fe3O4@SiO2 MNPs, in 
presence and in absence of H2O2 (blue and orange lines respectively) or with Fe3O4@Cu@Au-
Ab334 MNPs in presence and in absence of H2O2 (green and red lines respectively). Purple line 
corresponds to negative control of EPI and H2O2. Bottom: Comparison among the same samples 
after 30 min reacting. 
8.3.1.2 Changing of concentrations: MNPs, H2O2 and EPI  
To achieve experimental evidences measurable by UV-Vis spectroscopy, high 
amounts of MNPs, H2O2 and EPI were used. First, the effects of changing the 
concentrations of each reagent was evaluated. MNPs concentration was assessed 
from 1 mg/sample to 1 μg/sample. The decrease in MNPs quantity from 1 
mg/sample to 100 μg/sample led to a significant reduction of the maximum 
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intensity of the colorimetric signal, which was reached after long reaction time 
(40-60 min). Lower quantities of MNPs than 100 μg/sample did not produce 
measurable UV-Vis signals. H2O2 concentration was assessed from 3% to 0.01 %; 
the increase in H2O2 concentration from 1% to 3% had not a significant effect 
since it could be considered already in excess. Below 1%, the signal was not 
measurable. EPI solutions at a concentration ranging from 1 nM to 1 mM were 
analysed. The use of μM and nM EPI solutions produced an amount of 
adrenochrome too low for UV-Vis detection. For this reason, other analytical 
techniques, for instance electrochemical ones, should be probably used in order to 
detect samples with low concentrations of analyte (EPI < 1mM). 
8.3.2 Evaluation of the selectivity of Ab334-MNPs 
In order to evaluate the possibility to carry out a selective oxidative process, a pre-
incubation step between MNPs and EPI was introduced. For this purpose, 
different kinds of MNPs-Ab were selected; MNPs loading Ab334 and MNPs 
functionalized with Ab186 were used. Fe3O4@Cu@Au-Ab186 MNPs and 
Fe3O4@SiO2-Ab186 MNPs were synthesized in the same way as the 
corresponding MNPs-Ab334, as reported in 7.3.3, conjugating the purified pre-
immune Ab186 already available in the Nb4D group. This antibody did not show 
specificity and for this reason it was selected, in opposition to the specific Ab334.  
The four kinds of nanosystems at 1 mg/sample, Fe3O4@Cu@Au-Ab (334 or 186) 
MNPs and Fe3O4@SiO2-Ab (334 or 186) MNPs were stirred with 1 mM EPI 
solution in citrate buffer for 15 min. This pre-incubation step was performed to 
promote the binding of EPI to the Ab-MNPs without triggering its oxidation. 
MNPs were then washed several times with citrate buffer to remove the unbound 
EPI and finally H2O2 1% solution was added to each sample. A solution containing 
only EPI and H2O2 was used as negative control. After 20 min stirring, the UV-
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Vis spectra reported in Figure 8.3-3 were recorded. Analysing the experimental 
data, an increase in the absorption bands corresponding to EPI-oxidation products, 
especially adrenochrome (λmax=490nm), was observed only in the samples 
containing MNPs functionalized with Ab334 (red and blue lines). Since the 
samples containing MNPs-Ab186 (green and purple lines) did not show any 
difference compared to the blank (EPI + H2O2; orange line), the oxidation of EPI 
was not occurred. Therefore, the UV-Vis absorption bands derived from the 
oxidation of the amount of EPI loaded to the MNPs only due to the specific 
recognition between Ab334 and the analyte, which took place during the pre-
incubation step. 
 
Figure 8.3-3: UV-Vis spectra concerning the selectivity experiment recorded after 20 min. 
Fe3O4@Cu@Au-Ab (334 or 186) and Fe3O4@SiO2-Ab (334 or 186) were preincubated with 
epinephrine and, after magnetic separation and washings, H2O2 was added to the samples. 
These experimental evidences can pave the way to the development of a 
diagnostic system for detecting EPI by a two-step procedure. The pre-incubation 
step between MNPs-Ab334 and the analyte into the sample ensures the specificity, 
promoting the recognition and binding events. The following addition of H2O2, 
after the magnetic separation of the nanosystems from the solution, triggers the 
oxidation process of the analyte, producing the signal measurable with sensitive 
analytical techniques.  
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 CHAPTER CONTRIBUTIONS 
- The nanosystems based on Fe3O4@Cu@Au and Fe3O4@SiO2 MNPs were 
able to promote the oxidation of the catecholamine EPI mediated by H2O2,  
- Using MNPs functionalized with a specific antibody raised against EPI, 
like Ab334, it was possible to achieve a selective method for binding, 
magnetically separating and detecting the analyte. Through a two-step 
procedure, consisting in a pre-incubation between MNPs-Ab334 and EPI 
followed by the addition of H2O2, the selective oxidation of EPI bound to 
MNPs-Ab334 could be achieved. 
8.4.1 Future perspectives 
- Study the MNPs-mediated oxidation of EPI using more sensitive 
analytical techniques, such as electrochemical ones, evaluating also the 
activity of bare MNPs. Optimize some physicochemical parameters such 
as the incubation time, buffer solution or concentration of MNPs. 
- Validate the two-step procedure in standard complex solutions and 
biological matrices, such as plasma or urine. 
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 MATERIALS AND METHODS 
Reagents, materials and equipment: The chemical reagents used were purchased 
by Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The pre-immune 
antiserum As186 was already present in Nb4D group and ÄKTATM prime, 
provided with HiTrapTM Protein A HP column or HiTrapTM Desalting column (GE 
Helthcare, Uppsala, Sweden), was used for its purification with the corresponding 
software Prime View and Prime View Evaluation. The pH and the conductivity 
of all buffers and solutions were measured with a pH-meter pH 540 GLP and a 
conductometer LF 340, respectively (WTW, Weilheim, Germany). UV-Vis 
spectra were recorded from 200 to 1000 nm by means of SpectramaxPlus 
(Molecular Devices, Sunnyvale, CA, USA) with the software SoftmaxPro v4.7 
(Molecular Devices) using dilution plates as sample holders, purchased from 
Nirco (Barberà del Vallés, Spain). All the experimental data were analysed using 
the software GraphPad Prism 5.03 (GraphPad Software Inc., San Diego, USA). 
Kinetic evaluation: two samples of Fe3O4@Cu@Au-Ab334 (1 mg/sample) and 2 
samples of Fe3O4@SiO2-Ab334 MNPs (1 mg/sample) were stirred at 25°C in 
Eppendorf tube with 1 mM EPI solution (180 μL/sample) in citrate buffer (0.04 
M pH 5.5). UV-Vis spectra were recorded in a dilution plate before and after the 
addition of H2O2 10 % solution in citrate buffer (20 μL/sample) or only citrate 
buffer (20 μL/sample) from 5 min to 360 min. A solution of EPI 1 mM and H2O2 
10 % without MNPs was used as blank. 
Changing of concentrations: MNPs  
90 μL/sample of EPI 1mM solution in citrate buffer were stirred with MNPs-
Ab334 (Fe3O4@Cu@Au-Ab334 or Fe3O4@SiO2-Ab334 MNPs) at concentrations 
of 1000, 100, 10 or 1 μg/sample. After adding 10 μL of H2O2 10 % in citrate buffer 
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UV-Vis spectra were recorded in a dilution plate at 20, 40 and 90 min. Samples 
of EPI/H2O2 and MNPs-Ab334/EPI/citrate buffer were used as blank. 
Changing of concentrations: H2O2 
90 μL/sample of EPI 1mM solution in citrate buffer were stirred with 100 
μg/sample of MNPs-Ab334 (Fe3O4@Cu@Au-Ab334 or Fe3O4@SiO2-Ab334 
MNPs). After adding 10 μL of H2O2 solution in citrate buffer (at concentrations 
of 30%, 10%, 1% or 0.1%) UV-Vis spectra were recorded in a dilution plate after 
20, 40 and 60 min. Samples of EPI/H2O2 30% and MNPs-Ab334/EPI/citrate 
buffer were used as blank. 
Changing of concentrations: EPI 
90 μL/sample of EPI solutions in citrate buffer, at concentrations ranging from 1 
mM to 1 nM, were stirred with 100 μg/sample of MNPs-Ab334 (Fe3O4@Cu@Au-
Ab334 or Fe3O4@SiO2-Ab334 MNPs). After adding 10 μL of H2O2 10 % solution 
in citrate buffer, UV-Vis spectra were recorded in a dilution plate after 20 and 60 
min. Samples of EPI 1 mM/ H2O2 10% and MNPs-Ab334/citrate buffer/H2O2 10% 
were used as blank. 
Selectivity evaluation: 1 mg of Fe3O4@Cu@Au or Fe3O4@SiO2 MNPs 
functionalized with Ab334 or Ab186 were stirred for 15 min with 100 μL/sample 
of EPI 0.9 mM in citrate buffer (0.04 M, pH 5.5). After magnetic separation, 
MNPs were washed twice with citrate buffer and then dispersed in H2O2 1% (100 
μL/sample). A solution of EPI 1 mM (90 μL) and H2O2 10% (10μL), added after 
15 min, was used as blank. After 20 min stirring, UV-Vis spectra of the samples 
were recorded in a dilution plate (100 μL sample/well). 
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 Conclusions 
Among the superparamagnetic nanoparticles suitable for biomedical applications, 
new engineered nanosystems have been developed in this research work.  
- Two basic core-shell structures made of Fe3O4@Cu@Au or Fe3O4@SiO2 
MNPs have been designed, synthesized and characterized by means of 
different physicochemical techniques, proving their nanometric size and 
core-shell structure.  
- The surface activation exploiting the physicochemical features of the 
external inorganic shell, and the functionalization with polymers, proteins 
or bioactive molecules have been carried out according to the planned 
biomedical end use. 
- The internalization of differently coated MNPs into monocyte-
differentiated macrophages have been achieved, preferentially for the 
nanosystems loading Tf. These results, together with the possibility of 
further functionalization with drugs and combined with the ability of Tf 
in targeting cancer cells, make these nanosystems favourable for using in 
the Trojan Horse approach. 
- The lipodepsipeptides SRE and SP22A have been loaded, for the first 
time, on nanoparticles without losing their biological activities. The 
confirmation of the in vitro antimicrobial activity on the yeast R. 
pilimanae and the uptake by monocyte-differentiated macrophages make 
the MNPs-SRE and MNPs-SP22A promising tools for a new-generation 
strategy for monitoring and treating infectious diseases. 
- The development of the direct and indirect competitive ELISA 
immunoassays for the in vitro detection of EPI has been firstly addressed, 
reaching good sensitivity and detectability parameters. Amperometric 
magneto-immunosensors involving antibody-functionalized MNPs have 
been developed, avoiding analyte modification, reaching IC50 and LOD 
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values in the nanomolar range. These diagnostic platforms, including 
those based on the engineered nanosystems, could prove to be efficient 
and sensitive alternatives to the standard analytical methods used for 
detecting EPI in biological samples. 
- The ability of antibody-functionalized MNPs to detect EPI and promote 
its H2O2-mediated oxidation have been demonstrated, opening the 
possibility to use them as diagnostic tools for the recognition, separation 
and analysis of EPI.  
The scientific results achieved during this research work using the nanosystems 
based on Fe3O4@Cu@Au and Fe3O4@SiO2 MNPs might contribute to know and 
develop new diagnostic tools and/or therapeutic strategies. 
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10.1 ACRONYMS AND ABBREVIATIONS 
A Absorbance 
AA Amino Acid 
Ab Antibody 
Ab186 Antibody 186 after purification 
Ab334 Antibody 334 after purification 
ACN Acetonitrile 
AFM Atomic Force Microscopy 
Ag Antigen 
APTES (3-AminoPropyl)TriethoxySilane 
As Antiserum 
As334, As335, As336 Antiserum 334, 335, 336  
Au NPs Gold nanoparticles 
BSA Bovine Serum Albumin 
CD Circular dichroism 
CSIC Spanish National Research Council 
CT Computer Tomography 
Da Dalton 
Dab 2,4-diaminobutyric acid 
DCC N,N’-dicyclohexylcarbodiimide 
DHFR DiHydroFolate Reductase 
DMEM Dulbecco's Modified Eagle's medium 
DMF N,N-dimethylformamide 
DOSY Diffusion Ordered SpectroscopY 
EDC-HCl 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
ELISA Enzyme-Linked Immunosorbent Assay 
EPI (-)-EPInephrine 
EPR Enhanced Permeability and Retention Effect 
ET Enzymatic Tracer 
FA Folic Acid 
FBS Fetal Bovine Serum 
FRs Folate Receptors 
FT-IR Fourier-Transform Infrared Spectroscopy 
GPTMS (3-Glycidyloxypropyl)trimethoxysilane 
Hc Coercivity 
HCH Horseshoe Crab Hemocyanin 
HRP Horseradish Peroxidise 
IC10 Concentration in which the signal is 90 % inhibited 
IC20 Concentration in which the signal is 80 % inhibited 
IC50 Concentration in which the signal is 50 % inhibited 
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IC80 Concentration in which the signal is 20 % inhibited 
IC90 Concentration in which the signal is 10 % inhibited 
IgG Immunoglobulin G 
IQAC Institute of Advanced Chemistry of Catalonia 
LA Lipoic Acid 
LOD Limit Of Detection 
LSPR Localized Surface Plasmon Resonance 
MALDI-TOF-MS Matrix Assisted Laser Desorption Ionization - Time of Flight 
Mass Spectrometry 
MIC Minimum Inhibitory Concentration 
MNPs Magnetic NanoParticles 
MNPs-Ab186 Fe3O4@Cu@Au-PEG-Ab186 or Fe3O4@SiO2-GPTMS-Ab186 
MNPs-Ab334 Fe3O4@Cu@Au-PEG-Ab334 or Fe3O4@SiO2-GPTMS-Ab334 
MNPs-APTES Fe3O4@SiO2-APTES MNPs 
MNPs-GPTMS Fe3O4@SiO2-GPTMS 
MNPs-LA-NHS Fe3O4@Cu@Au-LA-NHS MNPs 
MNPs-PEG Fe3O4@Cu@Au-PEG 
MNPs-PLA Fe3O4@SiO2-APTES-PLA MNPs 
MNPs-PLA-SP22A-TR Fe3O4@SiO2-APTES-PLA-cadaverineTR-SP22A MNPs 
MNPs-PLA-TR Fe3O4@SiO2-APTES-PLA-cadaverineTR MNPs 
MNPs-PLL Fe3O4@Cu@Au-LA-PLL 
MNPs-PLL-FA Fe3O4@Cu@Au-LA-PLL-FA 
MNPs-PLL-MTX Fe3O4@Cu@Au-LA-PLL-MTX 
MNPs-PLL-TR Fe3O4@Cu@Au-LA-PLL-TR MNPs 
MNPs-SP22A Fe3O4@SiO2-APTES-PLA-SP22A MNPs 
MNPs-SRE Fe3O4@SiO2-APTES-PLA-SRE MNPs 
MNPs-Stv-TR Fe3O4@Cu@Au-LA-Stv-TR 
MNPs-Tf Fe3O4@Cu@Au-LA-Tf 
MNPs-Tf-TR Fe3O4@Cu@Au-LA-Tf-TR 
Mr Remanence 
MRI Magnetic Resonance Imaging 
Msat Saturation Magnetization 
MTX Methotrexate 
MW Molecular weight 
Nb4D Nanobiotechnology for Diagnostics Group 
NHS N-HydroxySuccinimide 
NOESY Nuclear Overhauser Effect Spectroscopy 
NorEPI (-)-NorEPIneprhine 
NPs Nanoparticles 
N-SMP N-succinimidyl 3-maleimidopropionate 
P.s. pv. syringae Pseudomonas syringae pv. syringae 
PAb Polyclonal Antibody 
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PABA p-AminoBenzoic Acid 
PBS Phosphate Buffered Saline solution 
PBST Phosphate Buffered Saline Tween-20 solution 
PEG PolyEthylene Glycol 
PEG-SH Thiolated poly(ethylene)glycol 
PET Positron Emission Tomography 
PhR Phenol Red 
PLA Poly-L-Aspartic acid 
PLA-TR Poly-L-Aspartic acid-Texas Red cadaverine conjugate 
PLL Poly-L-Lysine 
PLL-TR Poly-L-Lysine-Texas Red conjugate 
PMA Phorbol 12-Myristate 13-Acetate 
PVP PolyVinylPyrrolidone 
R. pilimanae Rhodotorula pilimanae 
RFC Reduced Folate Carriers 
RPMI Roswell Park Memorial Institute medium 
rt Room temperature 
SAM Self-Assembled Monolayer 
SIA N-Succinimidyl IodoAcetate 
SP22A Syringopeptin 22A 
SPCE Screen Printed Carbon Electrode 
SPION SuperParamagnetic Iron Oxide Nanoparticles 
SPs Syringopeptins 
SPR Surface Plasmon Resonance 
SRE Syringomycin E 
SRs Syringomycins 
Stv Streptavidin 
TEM Transmission Electron Microscopy 
TEOS TetraEthyl Orthosilicate 
Tf Transferrin 
TFA Trifluoroacetic acid 
TfRs Transferrin Receptors 
Tf-TR Transferrin-Texas Red conjugate 
THF TetraHydroFolate 
TMB 3,3’,5,5’-TetraMethylBenzidine 
TOCSY TOtal Correlated SpectroscopY 
TR Texas Red 
TSP Trimethylsilyl propionate 
V Voltage 
VSM Vibrating Sample Magnetometer 
XRPD X-Ray Powder Diffraction 
α-FR α isoform of the Folate Receptor 
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